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Abstract
Despite advancements in cancer therapy, certain indications continue to have a poor
prognosis, including cancers of the thorax. Existing methods for treating moving tumors with
carbon ions have shown promise, but require technologically complex facilities and still have
inherent limitations to mitigating tumor motion. The goal of this dissertation was to develop
and test a safe, portable and modular motion-synchronized dose delivery system (M-DDS)
and its peripheral components as a framework for studying motion mitigation with ion beams.
We designed and integrated a motion-synchronized radiotherapy approach, called multiphase 4D delivery (MP4D), as modular units of a clinical dose delivery system. The MP4D
approach was integrated into a research facility and the facility was redesigned for
developing and testing new cancer therapy technologies. We performed a comprehensive risk
assessment for the M-DDS and validated the performance of the MP4D approach
experimentally. Finally, we compared MP4D to other delivery strategies in terms of
dosimetric quality and projected therapeutic outcomes.
The prototype system was implemented and characterized at GSI and CNAO. The
functionality and performance was confirmed through a series of tests. Validations revealed
that MP4D produces quantitatively superior dosimetric quality and projected therapeutic
outcomes. Additionally, we determined that the MP4D dose delivery strategy compensated
for heterogeneous anatomical motion with minimal dose distribution degradations. Our safety
analysis revealed several risks that are unique to MP4D; appropriate solutions were
implemented and tested.
The major findings of this study are that the MP4D approach delivered conformal,
motion-synchronized beams with acceptable performance, dosimetric quality, safety and
projected therapeutic outcomes. We demonstrated that MP4D may become a suitable strategy

xi

for conformal, motion mitigation in clinical radiotherapy. The modular design of the M-DDS
allows for integration into a variety of facilities, and the MP4D methods presented can be
utilized at any ion therapy center that operates with a similar delivery system. The
generalized and modular design of the M-DDS provides a framework for testing a variety of
motion mitigation and other therapy approaches. This work, taken together, provides a
comprehensive pre-clinical study on the modular, motion-synchronized dose delivery system
for delivering conformal dose distributions to moving targets.

xii

Chapter 1. Introduction
1.1.

Background and Motivation
Cancer continues to be a major health care problem globally: 1 in 6 deaths worldwide

are due to cancer alone [1]. In the United States, almost 1.8 million people were diagnosed
with cancer in 2019 [2]. In the last 20 years, overall cancer survival rates have increased by
over 10 %, as new treatment methods have expanded to wide scale use [3]. These methods
include radiotherapy technologies, such as IMRT, image guidance, and active scanning ion
therapy [4-6]. Ion therapy has proven to be advantageous in treating a wide array of tumor
sites, including salvage radiotherapies that were considered incurable [7, 8]. Despite these
successes, certain indications continue to have a poor prognosis, such as cancers of the
thorax. For these cancers, including lung, liver and pancreatic cancer, the poor outcomes can
be attributed, in part, to tumor motion during radiotherapy. Some promise has been shown for
applying ion therapy to treating moving tumors [9], but assessing the efficacy of ion therapy
methods has been slow due to the diversity of treatment methods, including fractionation
schemes and accelerator types [10].
Research in developing new methods for therapy often does not successfully translate
to new medical devices [11]. Barriers to implementation of new medical technologies into the
clinic exist at several stages: development, safety testing, commercialization and clinical
trials. In some cases, as many as 90 % of projects do not translate to human use. During
development, technologies created without feedback from clinical experts may not
adequately suit the needs of the clinic [12]. Additionally, without feedback on safety and
regulatory requirements, developing technologies may require to be redesigned. Finally, the
limited number of ion therapy testing and research facilities can make the efficacy of new
This chapter was previously published as “Lis M, et al. (2020) A modular dose delivery system for
treating moving targets with scanned ion beams: Performance and safety characteristics, and
preliminary tests Physica Medica 76 307-16”. Reprinted by permission of Elsevier.
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modalities hard to quantify, slowing down the process of verifying the safety of new devices,
and commercializing the devices at multiple institutions.
In particular, large-scale scientific testing is limited by the diversity of ion therapy
systems. Clinical trials are slow, and limited in their impact, as, in contrast to photon therapy,
few ion therapy facilities exist. Further, exisitng facilities differ in accelerator types,
treatment planning systems, fractionation schemes, delivery control systems and motion
maanagement, making comparisons between clinics challenging. More harmonized systems,
including similar delivery control systems at more centers and standardized treatment
protocols, including at therapy research centers, would allow for performing pre-clinical
research and clinical trials at multiple institutes, accelerating the transition of these
technologies. So far, we do not have a portable, modular modality for development and
preclinical testing of emerging technologies.
One pervasive issue that is yet to be solved due is mitigating tumor motion during
treatment. The benefits of ion therapy cannot be fully exploited with current motion
mitigation strategies, and new methods must be developed. Current approaches for motion
handling rely on external components to control and direct delivery (i.e., beam gating,
abdominal compression or ITV based methods). One method has been to use beam gating to
limit the amount of motion during active beam delivery. However, this strategy assumes no
changes to the tumor motion motion, and requires larger dose volumes to account for delivery
uncertainties. A more recent strategy is to use a combination of two common motion
handling methods: phase-controlled rescanning and gating [13]. This approach utilizes fast
delivery methods and image guidance to limit the extent of postion motion changes during
active delivery, while repeating delivery of dose volumes multiple times to “blur out” the
remaining inhomogeneities from residual tumor motion. More accurate delivery and smaller
safety margins are possible with this approach; however, several limitations still remain,
2

including difficulty to adjust for changes in tumor motion patterns, long delivery times, and a
dependence on accelerator capabilities, making them suboptimal solutions for most ion
therapy facilities. Relatively less is known about the efficacy of delivery methods that
synchronize beam delivery to the detected motion, such as beam tracking. Some studies have
attempted to implement 3D beam tracking solutions [14-16]. So far, no clinically viable,
adaptive motion tracking solution has been developed.
1.2.

Statement of the Problem
We lack a framework for developing and testingcertain aspects of new radiotherapy

modalities for solving persistent problems in cancer therapy, such as treating radioresistant
and moving tumors. Further, we lack a dedicated facility for developing and testing the
efficacy of a variety of motion mitigation approaches, such as a radiation research facility
that contains the infrastructure for testing strategies in conditions similar to those in the
clinic, to facilitiate translation into clincial use. Additionally, this necessitates developing
programs for performing comprehensive risk analysis and safety testing to facilitiate
translation into the clinic. Development of solutions for one such persistant problem, treating
moving tumors, has been hindered by the slow progress in implementing new delivery
strategies and integrating them into the clinic. No such facility is in existence, therefore, the
feasibility of developing such a platform was unknown.
1.3.

Objective
The goal of this dissertation was to develop and validate a safe, portable and modular

dose delivery system and its peripheral components as a framework for research in novel ion
therapy approaches for motion mitigation. We have achieved this by adapting a clinical ion
therapy dose delivery system into the ion therapy research room at GSI (Cave M) and
implementing motion-synchronization capabilities as modular units (Chapter 2). We then
redesigned the research facility at GSI as a platform on which novel delivery methods can be
3

tested for clinical use, including comparing several motion mitigation solutions with light ion
beams (Chapter 3). To do this, we updated the peripheral components and interfaces of beam
nozzle components to the M-DDS. We then performed a comprehensive risk analysis to
confirm the safety of our implementation of the motion-synchronized DDS (Chapter 4). This
analysis allowed for identifying potential safety risks, implementing solutions and suggesting
regular safety tests. This strategy can be applied and adapted to any clinical environment that
is in the pre-clinical testing phases of adopting the M-DDS hardware and software. Finally,
we validated that the M-DDS can mitigate for anatomical motion in heterogenous phantoms
(Chapter 5), and demonstrated that the multi-phase 4D dose delivery approach can deliver 4D
patient treatment plans with more favorable treatment quality and projected therapeutic
outcomes compared to other motion compensation strategies with scanned carbon and proton
ion beams (Chapter 6).

4

Chapter 2. A Modular Dose Delivery System for Treating Moving Targets
with Scanned Ion Beams: Performance and Safety Characteristics, and
Preliminary Tests
2.1.

Introduction
Longstanding impediments to performing clinical trials on the efficacy of proton and

heavier ion beam therapies include treatment systems that are technologically diverse. These
impediments make it difficult to accrue sufficient numbers of patients in clinical trials to
elucidate the role of ion beam therapy in oncology. Technological diversity of treatment
systems may further introduce confounding factors that limit the power and utility of studies
that are sensitive to details of the treatment techniques. A prominent open question pertains to
the potential role of ion beams for treating moving tumors in the lung, a prevalent cancer with
a poor prognosis for survival. In particular, contemporary ion beam centers utilize distinct
and markedly different technical strategies to mitigate respiratory motion. These differences
derive from a variety of factors, including the performance characteristics of beam delivery
hardware systems, treatment planning systems, systems to monitor respiratory motion, and
treatment control systems. Thus, to increase patient accrual rates and reduce confounding
factors, modular technologies offer an attractive way to increase the similarity of treatments
delivered by multiple institutions that use treatment systems of different designs.
Additionally, a modular approach allows the majority of research and development of a
prototype system to be performed in a research facility. It also facilitates translation of the
prototype system from a research laboratory to a clinical facility for pre-clinical testing. In
commercial systems, due to safety and regulatory considerations, the concepts and approach
to modularity are typically implemented by device manufacturers in proprietary form,

This chapter was previously published as “Lis M et al. (2020) A modular dose delivery system for
treating moving targets with scanned ion beams: Performance and safety characteristics, and
preliminary tests Physica Medica 76 307-16”. Reprinted by permission of Elsevier.
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complicating research on new functionalities. A more modular control system, developed
within an open research platform with a direct link to the clinical environment, may
overcome this limitation. For example, this would allow a variety of beam transport system
conditions and motion mitigation strategies to be researched and evaluated at a single center,
thus accelerating the translation of nascent motion management technologies to clinic
implementation.
Many particle therapy centers have implemented motion handling techniques into
clinical practice [17]. However, a majority of these techniques consist of auxiliary
components for minimizing tumor motion during active beam delivery [18-21].
Comparatively few of these systems have motion mitigation techniques integrated into the
dose delivery system design [22]. Additionally, though the feasibility of conformal treatments
through beam tracking has been established at GSI Helmholtzzentrum für
Schwerionenforschung GmbH [18, 23], pre-clinical testing revealed irreconcilable problems
with the design [24]. To our knowledge, there is no charged-particle dose delivery system,
which contains a designated motion synchronization unit integrated into the dose delivery
system architecture. Thus, existing strategies cannot deliver conformal plans while
dynamically adapting the delivery in real time to anatomic movement.
The objective of this study was to design, implement, and test a prototype of a
modular motion-synchronized dose delivery system (M-DDS) which can mitigate against
target motion. We implemented a modular system, developed from a CE labeled system,
which functioned at two markedly different carbon beam centers. The dosimetric
performance of the system was characterized with treatment planning calculations and
measurements of dose distributions in moving phantoms. Safety was characterized through a
series of errors verification tests.
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2.2.

Methods and Materials

2.2.1 Design of Modular Motion-synchronized Dose Delivery System
This section describes the system we have developed which synchronizes the delivery
of scanned ion beam to tumor motion. The fast control portion of the dose delivery system
(DDS) at the Centro Nazionale di Adroterapia Oncologica (CNAO) has been updated and
adapted to the therapy research beam line at GSI. The fast control system monitors and
guides the ion beams to deliver 3D dose volumes. The fast control system interfaces with
peripheral components, including the interlock, scanning magnet, beam chopper, beam
detector, accelerator control system and timing systems, as well as the treatment control room
(LCR) [25], as seen in Figure 2.1. The fast control system hardware is comprised of FPGAs,
which serve as the controls of each of these peripheral components, as seen in Figure 2.2. The
DDS hardware and associated software have been updated and the memory handling
functionalities have been repackaged into a single subunit in preparation for implementing
motion mitigation functionalities. Finally, motion monitoring and mitigation capabilities were
designed and integrated into the DDS. In the following sections, we describe the design and
implementation of the modular motion-synchronized dose delivery system (M-DDS).
Additionally, we provide illustrative examples of the performance of the M-DDS.
2.2.1.1.

Modular Motion-Synchronized Dose Delivery System

The M-DDS is dedicated to all controls during treatment delivery. It is comprised of a
peripheral component interconnect (PCI) eXtensions express (PXIe) crate (National
Instruments, Austin, Texas, USA). The crate houses a controller (PXIe-8840 Quad Core
controller) and nine PXIe field programmable gate array (FPGA) modules, as seen in Figure
2.2. The FPGA modules control each subsystem during treatment delivery through distinct
tasks: the particle count readout and treatment progression is controlled through intFPGA; the
beam spot position readout is controlled through pos1FPGA; the beam spot scanning is
7

controlled through the scanFPGA; the spill and treatment timing synchronization is
controlled through timingFPGA; interfacing with the beam request system and creation of
simulated timing events (for offline testing) is controlled through GSItimingFPGA; the
treatment plan loading, storage and beam spot progression order is controlled and determined
through memoFPGA; the safety functionalities and interlocks are controlled through
interlockFPGA; the motion detection and motion phase discrimination is determined through
motionFPGA. Each FPGA works as a standalone module for maximum speed, versatility,
and reliability, as well as portability.

Figure 2.1. CNAO treatment control system layout and connections of the DDS to the
treatment controls and accelerator. The intensity detection subunit is indicated in orange (a);
the position detection subunit is indicated in red (b); the scanning magnet subunit is indicated
in violet (c); the motion mitigation subunit is indicated in blue (d); the safety and monitoring
subunits, are indicated in shades of green, including gating system (e) and interlock system
which are indicated in teal (f) and the control room monitoring system (LCR) in bright green;
the timing subunit is indicated in green-yellow (g), which connects to the accelerator
communication system, indicated in yellow (h).
The FPGAs have been updated from the PXI-7813R FPGAs used at CNAO to PXIe7821R FPGAs. The PXIe cards utilize a faster, backplane communication and
synchronization, via a differential reference clock, and contain 512 MB of on-board memory.
Output signals and connectors for each PXIe FPGA were modified to account for the
reduction from 40 to 32 outputs per front connector. Additionally, memory loading protocols
8

in each FPGA were modified to direct memory access protocols (DMA), allowing for direct
data exchange between the controller and each FPGA without heavy use of processing
resources.

Figure 2.2. Schematic layout of the FPGA cards in the fast control system of the M-DDS.
The fast control system is comprised of 9 PXIe FPGA cards, including the (a)
interlockFPGA, (b) an ADC readout card, (c) intFPGA, (d) pos1FPGA, (e) memoFPGA, (f)
motionFPGA, (g) scanFPGA, (h) timingFPGA, and (i) and optional GSItimingFPGA. Each
FPGA card serves as a control unit for their associated DDS subsystem.
The fast control system has been integrated into the GSI therapy research beamline
and installed into the CNAO research room. Both facilities are synchrotron based particle
accelerators. Integration into the GSI environment was possible with the addition of a layer of
interfaces and with minimal modifications to the fast control system software. Modifications
included network communication with the beam request software and simulation of timing
system events that are not used in the GSI DDS. Motion monitoring and mitigation
capabilities were integrated into the fast control system as well.
2.2.1.2.

Memory and Treatment Plan Handling

Modifications were made to the treatment plan handling protocols in preparation for
motion mitigation functionalities. First, the treatment plan structure has been changed from a
single plan to a library of sub-plans which contain motion compensation. Plan libraries were
created using the research treatment planning system at GSI, TRiP4D [26]. TRiP4D is an
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extension of TRiP98 [27, 28] that considers temporal changes to patient anatomy during
treatment plan creation. During treatment planning, conformal 4D-optimization is utilized to
create a library of treatment plans. Each plan in the library is a separate 3D optimization,
planned [29] on a geometrical PTV, created on the tumor volume found in each motion phase
from the 4DCT. The 3D optimization is a cost function that minimizes the difference between
prescription and planned dose for each beam spot. The particle intensities of every beam spot
in each plan is then scaled down, weighted by the length of the motion phase [30], so that the
total dose of the entire plan library is the prescription dose. The library of plans was then
converted to a modified version of the CNAO treatment plan format that includes motion
phase information for each beam spot. Additionally, each slice in each plan was padded to be
the same size.
Second, four memory modules (NI PXI 6534 FPGAs), each designated to store
delivery information for one iso-energy slice (IES), were replaced with one memoFPGA,
designated to loading and storing the entire treatment plan before delivery begins. Before
treatment, the plans are sent via a TCP-IP connection to the M-DDS and converted to
synchrotron beam parameter codes for each IES (containing information on beam spot
FWHM, energy, particle, particle rate) and FPGA IES files (SLD files), which are grids of
raster points that are to be irradiated sequentially. The entire array of SLD files is then loaded
onto the memoFPGA dynamic random access memory (DRAM) at the beginning of
treatment. This allows for sending beam spots both sequentially and out of order to the other
FPGAs without increases in spot switching time. Additionally, minimum IES switching time
was reduced to 100 ms, allowing for the possibility of using the DDS with a cyclotron. The
memoFPGA receives motion phase information from the motionFPGA, and has a central role
in motion mitigation, as described below.
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During treatment, the memoFPGA sends delivery information, spot by spot, to the
other FPGAs. Additionally, delivery data is logged in two binary files: dose delivery data
(DDD) files and motion mitigation data (MMD) files. Delivery data from the beamline
detectors and scanning system is written into a new DDD file at the completion of delivering
the IES, whereas previously, this data was written out into a new DDD file during each spill
pause. In parallel, the MMS writes motion information every 50 ms and for each spot during
delivery. At the conclusion of treatment, the motion signal, timing information, and motion
phases are written into an MMD file.
2.2.1.3.

Motion Mitigation Upgrades

The motion mitigation system (MMS) is an independent, optional component of the
DDS that contains all functionalities for adapting the treatment delivery to the tumor motion.
The flexibility of the MMS allows for adapting several motion mitigation strategies. The
MMS is comprised of the motionFPGA (a NI PXIe-7857R FPGA), a motion detection
device, the gating system and a portion of the memoFPGA. The MMS determines the realtime respiratory motion phase from the detected analog motion signal and controls treatment
delivery sequence and progression. Existing treatment synchronization signals are used to
synchronize the motion mitigation actions with the treatment delivery.
Upon plan loading, the number of motion phases and mitigation method are extracted
from the treatment plan, and the MMS is set accordingly. Both amplitude-based and phasebased motion phase discrimination are available. The amplitude-based method involves
discrimination of motion phases into fractions of the total detected motion amplitude, while
the phase-based method discriminates motion phases into fractions of the total detected
respiratory cycle duration. A ‘threshold gating’ mode is also available, where the delivery of
beam spots is interrupted when detected respiratory motion is outside of a specified tumor
position window. An analog motion amplitude signal is continuously acquired at 1000 Hz
11

and averaged to 50 ms for noise reduction. After the treatment plan is loaded and during a
stable motion cycle, the motion signal is calibrated to the detected motion amplitude. For the
phase-based method, the duration of a motion cycle is also measured. The motion phases are
subsequently delineated. Additionally, lateral beam spot coordinates can be sent to the
memoFPGA to make adjustments to the beam spot position for position corrections or for the
beam tracking motion compensation strategy. During treatment, the motion phase is sent to
the memoFPGA to redirect treatment progression.
The general motion-synchronized delivery concept implemented here was described
by Graeff et al. [31] and modified to enhance the treatment-progression logic. Here, the
motion phase is continuously sent from the motionFPGA to the memoFPGA. The beam spots
within the plan corresponding to the identified motion phase are delivered sequentially until a
motion phase change occurs. When the motion phase changes, the delivery is directed to the
plan within the plan library corresponding to the new motion phase. The distribution of
motion phases is represented in Figure 2.3. The beam spot that is closest to the current beam
position is selected and the spot delivery progresses in sequence until a different motion
phase is detected and the delivery is redirected again (Figure 2.4). Each delivered spot is
masked and when the delivery is returned back to a partially delivered plan, the masked spots
are skipped. For completely delivered sub-plan slices, the beam is gated until a new motion
phase is detected. When the number of delivered spots matches the number of spots within
the plan library for the current IES, the delivery progresses to the next IES. The same system
also delivered static treatments, i.e., which were 4-D plans with only one motion phase. In
the DDS, the motion phase was set to one, and, by default, the beam spots were delivered in
their as-planned sequence. For testing purposes, an uncompensated delivery mode is
available, where a static (one phase) plan is delivered to a moving target.
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Figure 2.3. A schematic depiction of the treatment plan library for an amplitude-based
motion. Each individual plan is optimized on the motion phase-specific PTV, in an
independent 3D-optimization. The beam spots in all of those plans are then scaled down, such
that their total dose is the prescription dose.

The MMS is structured as a state machine, running independently and in parallel with
the main DDS. The transition between states is synchronized with DDS loading, treatment
plan sending, treatment delivery and recording of delivery data, but the MMS remains
independent from the DDS. At the completion of a treatment, the motion data, including the
motion amplitude, phase beam spot count and timing information, is written into a motion
mitigation data file (MMD), and the MMS transitions back to an idling state until the next
treatment begins or until the MMS is signaled to shut down.
Additional gating capabilities were implemented for motion mitigation. This includes
triggering delivery interruption under unexpected motion behaviour such as lateral shifts that
are out of the amplitude range determined during calibration or sudden loss of motion signal.
Rapid gating was also utilized in partially or fully delivered sub-plans and when ‘jumping’ to
13

the next undelivered beam spot. When gating, each FPGA enters and ‘idling’ state, where no
beam spot information is sent and treatment information is logged every 50 ms. The gating
functionalities have been experimentally verified at GSI and CNAO.

Figure 2.4. MMS logic schematic. The motion information directs selection of the plan from
the library. Beam spots in the library are delivered in sequence until a different motion phase
is detected and the delivery is redirected to another plan in the library. Delivered spots are
masked and the delivery is gated when directed to a delivered portion of the slice. The plan
progresses to the next energy layer when the number of delivered spots matches the number
of spots within the plan library for the current IES.
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2.2.2 M-DDS Verification Tests
The modularity and the functionality of the motion mitigation system was
characterized and verified for functionality and performance through a series of offline
(without beam) and online tests at CNAO. The purpose of these tests was to determine the
feasibility of using the implemented M-DDS for 4D therapy in future clinical systems.
Offline and online tests were performed during several stages of development to test
the functionality of the motion mitigation system. Specifically, we tested motion detection,
motion phase transmission to the memoFPGA and motion-related gating. Experiments were
performed by delivering simple spot patterns to radiochromic film (Gafchromic EBT3 ISP,
Wayne, New Jersey, USA) (Table 2.1). Additionally, the capability to progress through
multiple IES was verified online by delivering treatment plans with vertical lines each in
separate IES for each motion phase. In addition to these verification tests, the motion
mitigation capabilities were also studied experimentally.
Simple 2D and 3D geometries, such as squares and cubes, were designed for static
deliveries and for 3, 6 and 10 amplitude-based motion phases. 2D plans were generated from
a script, while 3D geometries were created with TRiP4D. The plan libraries were designed
with 4D-optimization to target volumes [32, 33] which results in a conformal treatment plan
for each motion phase. The degree to which the M-DDS can compensate for motion was
investigated by delivering 2D geometries to single films and to the ionization chamber array
detector behind 2 cm of water-equivalent (TE) plastic (RW3, LAP GmbH, Lüneburg,
Germany) and 3D geometries behind 10 cm water-equivalent plastic to measure a 2D cross
section through the center of each delivered volume.
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Table 2.1. Summary of offline and online verification tests and relevant analysis tools for
verifying implemented motion mitigation system functionalities.
Offline functionality tests
Subunit

Test

Analysis tool

Motion
mitigation
system

Connection with moving platform

Observation of sinusoidal motion
signal from OD laser in MMS

Detection of motion

Observation of motion phases in fast
control

Sending of motion phases

Receiving phases in log files

Treatment plan Loads entire plan libraries
handling
Sends single spots

SLD file analysis
DDD file analysis

Sub-plan switching from motion
phase changes

DDD file analysis

Online subunit tests: Delivery of ‘6 lines, each in 6 slices’ treatment plan
Motion
mitigation
system

Motion phase changes

DDD file analysis

Motion mitigation

Film analysis

Gating related to motion handling

Film and log file analysis

Treatment plan Plan loading
handling
Non-sequential delivery

2.2.2.1.

Plan accepted into DDS

Data Analysis

The quality of the delivered doses was assessed through gamma index analysis,
homogeneity index and conformity number.
First, dose reconstructions were performed in order to compare the planned and
delivered dose distributions. In order to do this, the ionization chamber array detector readout
data was correlated with the delivered beamline detector data from DDD log files by
matching the 100 ms frames of the ionization chamber array detector to the timestamps of the
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delivery data. The correlated DDD data was converted to the TRiP4D treatment file format
and the doses were reconstructed from these created treatment files. Reconstructed data was
compared with the original treatment plans using an in-house developed tool to compute the
gamma index [34] with a 3 %/ 3 mm criteria. Pass rates of > 90 % were considered
acceptable.

Figure 2.5. Experimental set-up used during measurements of dose distributions at CNAO. A
a) 2-dimensional array of ionization chamber detectors is seen here, mounted vertically on
top of b) a platform exhibiting 1-dimensional periodic motion. The motion is monitored with
c) an optical distance sensor.
Second, radiochromic films were assessed to determine homogeneity index. All
irradiated films were scanned in landscape orientation with a scanning digitizer
(DosimetryPro, VIDAR System Corporation, Herndon, VA, USA) using 16 bit sampling and
300 dpi resolution. Calibration films were acquired at the beginning of each measurement
period for eight particle fluences, from 2 x 105 to 4 x 107 particles/mm. Calibration curves
were acquired from the calibration films and applied to all films using image analysis
software (ImageJ version 1.52a, National Institute of Health, Bethesda, MD, USA). The
homogeneity of the film deliveries was evaluated by measuring the dose distribution flatness
within 70 % of the field size, using the equation HI = 100 × (Dmax ‐ Dmin)/(Dmax + Dmin),
where Dmin and Dmax are the minimum and maximum doses, respectively [35]. The dose
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distribution homogeneity was assessed in 60 x 60 mm2 uniform squares, delivered with
238.63 MeV/u carbon ions. HI of > 90 % were considered to have acceptable homogeneity.
Finally, the conformity of the homogeneous squares to the target area was assessed with the
conformity number (CN), as described by van’t Riet et al [36]. The CN was calculated from
data for static and compensated measurements with the ionization chamber array detector.
CN of > 60 % were considered conformal.
2.2.3 Critical Safety Testing
We performed critical safety tests at GSI and CNAO to verify that the motion
mitigation strategy does not introduce safety risks to the DDS. Failure mode and effects
analysis (FMEA) was performed to determine the highest risk safety errors [37]. Errors with
a Risk Priority Number (RPN) above 100 were considered most critical. These high-risk
errors included the failure to disrupt the beam during treatment errors and improper treatment
verification. Potential causes of each error were identified through a fault tree analysis [37].
Treatment plan verification processes were altered with permanent corrective actions to
prevent user errors, such as setting incorrect motion conditions, from occurring. Treatment
plan verification was also tested for incorrect file format. Treatment plans that contained
errors in formatting were loaded onto the DDS. For each error scenario, the DDS was
expected to transition into a ‘Setup Error’ state upon plan loading, disabling progression to
treatment.
Additionally, beam disruption error scenarios were investigated. First, delivery
disruption triggered by loss of the motion amplitude signal was tested. For this test, a virtual
switch was used to disable receiving motion phase signals from the motion detection unit in
the MMS. The time delay in treatment interruption was measured and error recognition was
confirmed. Phase shifts and changes in motion period are inherently handled by the M-DDS,
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so only beam disruption when motion amplitude goes out of the expected range was tested.
For this test, the motion amplitude was increased after the amplitude calibration was
performed. The gating behaviour, when outside of the expected amplitude bounds, was then
assessed.
2.3.

Results

2.3.1 Results for Modular Motion-synchronized Dose Delivery System Design
The hardware and software design and motion mitigation functionalities were
integrated into the M-DDS found at the GSI experimental therapy line and the CNAO
research room according to the tests described in section 2.2. Memory and motion mitigation
systems were confirmed to run as independent modules. A layer of interfaces between the
FPGAs and peripheral components was developed that achieved interoperability with the
system at CNAO. Interoperability and functionality with two extraction types were confirmed
through experiments with the same dose delivery system at both GSI and CNAO. Following
integration, the M-DDS performance was characterized.
2.3.2 Results for Motion-synchronized Dose Delivery System Performance Verification
2.3.2.1.

Motion Mitigation System Verification Tests

The functionality of the motion mitigation was characterized in a series of offline and
online signal transmission tests at CNAO and GSI. The MMS components of the M-DDS
functioned at both centers without modification. The MMS was confirmed to measure motion
amplitude, discriminate motion phases, and send motion phases for directing treatment
delivery. The M-DDS was also confirmed to signal delivery interruption due to out-of-range
motion. In addition to sub-system testing, separate integration tests were performed.

19

2.3.2.2.

Integration Testing

The M-DDS delivered treatment plan libraries to moving and non-moving targets at
both CNAO and GSI without modification, confirming the portability of the M-DDS between
these centers. The FPGA for handling treatment plans (memoFPGA) was confirmed to
properly handle up to 1 million beam spot plans of up to 300 IES per plan. The plan library
format was accepted into the treatment control room at CNAO and loaded without error.
MMD files were created and stored for all plans. DDD file analysis confirmed the
functionality of the M-DDS, with and without the optional motion mitigation unit. No
compromise to performance or significant increases in CPU consumption have been
observed. Delivery efficiency was analyzed by assessing the beam spot progression
efficiency for motion compensated plans compared to uncompensated plans (Figure 2.6).
Duty cycles relative to static plans were determined to be between 80-95 % for all plans and
total increases to treatment time were a factor 1.29 – 1.61 larger than for the static deliveries
of squares, cubes and ellipses. Following integration testing, delivered dose quality was
assessed.

Figure 2.6. A comparison of particle counts delivered through time (s) for the delivery of an
uncompensated static square, and 3, 6 and 10 motion phase compensation squares with
dimensions of 60 x 60 mm2. Plateaus in particle counts indicate spill pauses and delivered
motion phases.
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Figure 2.7. Cross-sections of dose distributions measured with EBT3 Gafchromic films at 10
cm depth for 60 x 60 x 60 mm3 cubes delivered with 20 mm amplitude 1D motion, for a)
static deliveries, b) uncompensated deliveries, c) 3 phase, d) 6 phase and e) 10 phase motion
compensated deliveries.

2.3.2.3.

Online Motion Compensation Tests

We assessed the extent of motion compensation by assessing the delivered dose
quality for motion synchronized deliveries. The homogeneity of the motion compensated 60
x 60 mm2 squares and 60 x 60 x 40 mm3 cubes was calculated with EBT3 films using the
homogeneity index. The HI was > 95 % for 6 and 10 motion phase squares delivered with
238.63 MeV/u carbon ions. The HI for 10 motion phase cubes was 95.2 % and the HI was
98.1 % for static cubes. HI, gamma index analysis and CN results are summarized in Table
2.2. For both the 60 x 60 mm2 squares and 60 x 60 x 40 mm3 cubes, the gamma index
analysis resulted in pass rates of > 90 % for both 6 and 10 motion phase compensation. The
dose distributions for static, uncompensated, 3 phase, 6 phase and 10 phase square profiles
can also be seen in Figure 2.7. The CN indicated a high level of conformity for 6 and 10
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motion phase plans. Low detector numbers in the IC detector array resulted in particularly
high CNs for the cube deliveries. A comparison of measured IC detector array doses and
planned doses for static, uncompensated, 3 phase and 6 phase compensation can be seen in
Figure 2.8. In addition to assessing the degree of motion compensation, the functionality of
critical safety features was also confirmed.
Table 2.2. Summary of gamma index pass rates, CN and HI from 3D and 4D treatments,
delivered to simple phantoms. The gamma index analysis compared planned dose
distributions to delivered doses with a criterion of 3 % / 3 mm. The HI measured particle
fluence homogeneity within 70 % of the area of the delivered profiles on radiochromic films.
The CN was calculated from the IC array detector. The gamma index analysis, CN, and HI
were performed on 238.63 MeV/u 60 x 60 mm2 squares at 20 mm amplitude of horizontal
motion behind 2 cm of PMMA, and for 60 x 60 x 40 mm3 cubes behind 10 cm of water
equivalent plastic (RW3).
60 × 60 mm2 square 238.63 MeV/u behind 2 cm RW3
Gamma pass rate

Conformity number Homogeneity index

Static

100.0%

67.1%

95.1%

Uncompensated

44.0%

4.0%

47.6%

3 phase

80.0%

57.3%

88.5%

6 phase

94.0%

68.3%

95.8%

10 phase

96.0%

62.7%

97.5%

60 × 60 × 40 mm3 cube behind 10 cm RW3
Static

98.6%

98.8%

98.1%

Uncompensated

43.1%

24.7%

43.1%

3 phase

75.0%

49.6%

90.9%

6 phase

96.3%

85.2%

96.0%

10 phase

99%

100%

95.2%
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Figure 2.8. Cross-sections of dose distributions measured with the PTW Octavius IC array
detector for 60 × 60 × 60 mm3 cubes, delivered with a 20 mm amplitude of 1D motion (here
represented in the squares) compared to planned dose distributions for a) static deliveries, b)
uncompensated deliveries, c) 3 phases and d) 6 phases of motion compensation deliveries.

2.3.3 Initial Safety Assessment
We performed safety tests for high-risk safety errors at GSI and CNAO. Results of the
safety tests are summarized in Table 2.3. During treatment plan verification error tests, the
DDS identified the plan format errors and transitioned into a ‘Setup Error’ state, disabling
progression to treatment.
Additionally, safety errors due to failure to disrupt beam delivery during treatment
were also tested. A virtual switch, which manually disables receiving motion phase signals
from the motion sensor in the MMS, was used, and the treatment plan progression was
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interrupted. Beam disruption from movement outside of the expected amplitude bounds was
automatically triggered from the MMS.
Table 2.3. Summary of critical safety tests performed at CNAO and the DDS response to the
error conditions. These tests confirmed the safety of the motion mitigation additions to the
dose delivery system.
Safety Test Description

DDS response to error condition

Idling during gating

No beam spots sent

Beam gate from out of range motion

Sets gate

Manual beam gate from MMS

Sets gate

Match motion phase in plan and MMS

Matched automatically from treatment plan

Phase or amp. based motion incorrect

Matched automatically from treatment plan

Load corrupt treatment file

Goes to error state

Motion not being monitored

Delivery gates until motion signal acquired

Baseline drift detection

Sets gate when out of amplitude range

Incomplete slice delivered

Aborts and stops treat

2.4.

Discussion
We developed a modular motion-synchronized dose delivery system (M-DDS) for

delivering motion mitigated ion-beam treatments with the raster scanning technique.
Specifically, we developed the M-DDS, as an extension of the DDS, which is in clinical use
at CNAO for static treatments. The major finding of this study is that the M-DDS
demonstrated acceptable dosimetric performance and portability between two ion therapy
centers, GSI and CNAO.
The implication of this finding is that the fast control portion of the M-DDS is a
portable and modular design, which could be utilized at multiple centers with a similar
treatment control system. This, in turn, could facilitate future research on motion mitigation,
including sharing of technical methods and pooling of data from multi-institution clinical
24

Figure 2.9. Homogeneity profiles comparing 60 × 60 mm2 a static cube (green) delivery to a)
an uncompensated cube delivery, b) 3 motion phase delivery, and c) 6 motion phase delivery.
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trials. The presented design is not a singular solution to motion mitigation, but can be used in
conjunction with other mitigation strategies, such as beam tracking or rescanning, to provide
a more comprehensive solution to conformal lung cancer therapy. With further study, this
design can be expanded to include real-time corrective beam tumor tracking with optical
motion sensors [24].
This is the first implementation of a dose delivery system for conformal, motionsynchronized delivery of scanned ion beam plans. The results of this study are coherent with
previous works in developing motion-synchronized dose delivery at GSI and comparable to
the system at the National Institute of Radiological Science (NIRS) [31, 38]. At GSI, sectored
target delivery and multi-gating with tumor tracking were employed to motion-synchronized
conformal deliveries [31, 39]. In these studies, single IES plans could be delivered with
gamma index analysis results from 79.6 % to 94.6 % compared to static delivery. For a
similar experiment in this study, gamma index analysis resulted in 96.0% pass rates. In all
cases, a criteria of 3% / 3mm was used. The implementation of the motion mitigation
strategies was spread throughout the entire treatment control system, resulted in timing and
delivery complications and was not deemed a clinically viable solution. At NIRS, phasecontrolled rescanning is utilized to adapt the rescanning duration to the gating duration [13].
This strategy is combined with online tumor location measurements via x-ray fluoroscopy,
resulting in homogeneous irradiations [38]. The NIRS strategy uses a single motion state,
larger beam-gating window and utilizes motion-synchronization only for more effective
rescanning of statically planned (3D) treatments. Thus, because the present approach
considers multiple motion states, in theory it can provide superior dosimetric performance.
Our study has several notable strengths. A key strength is that the FPGA hardware
and software structure is commercially available, and is based on a clinically certified
(LabVIEW) software. The use of commercial products allows for hardware and software
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updates and maintenance with replacement of standard parts. Additionally, the architecture of
the M-DDS is highly modular and expandable, which allows for straightforward
implementation of additional motion mitigation capabilities: all motion mitigation
capabilities will continue to be contained within the motionFPGA to maintain a modular
design.
An additional strength of this study is that we validated our work experimentally
using a scanned carbon ion beam, a moving phantom and several detectors, including a timeresolved ionization chamber array detector and films. Our experimental results have indicated
that the M-DDS can deliver conformal treatments by synchronizing real-time tumor motion
to the ion beam scan path. Effective motion compensation was possible with 6 motion phase
plans for an amplitude of 20 mm. Gamma index analysis revealed acceptable dose
distributions for 6 and 10 phase geometries which had > 90 % pass rates. Similarly, the CN
were within clinically acceptable standards of > 60% for 6 and 10 phase plans and the HI
produced similar homogeneity for static and 10 phase deliveries. Further, the safety of the
motion mitigation additions to the DDS were confirmed through critical safety tests. Results
of verification tests have indicated that the proposed motion synchronized treatment strategy
can deliver treatments to clinically acceptable accuracy.
A final strength of this study was that 3D dose distribution data was collected with
radiochromic film stacks and the ionization chamber array. The films exhibited quenching
which is typical for carbon ions and, therefore, could be compensated for during analysis.
Additionally, though the longitudinal film spacing reduced resolution to 1 cm in depth, the
direction of motion was in the horizontal lateral direction, so distribution with depth were less
critical for this study and 1 cm resolution was deemed acceptable. In further studies, higher
resolution 3D dose distributions could be acquired with a 3D dosimetry system.
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One limitation of our study is that the current method assumes that respiration patterns
and tumor position do not differ significantly from those seen during 4DCT scans used for
creating treatment plans. Deviations from expected tumor locations are to be expected and
must be compensated by an enlarged treatment field, counteracting the desired conformity
[40]. In further studies, deviations from expected tumor motion will be studied and
appropriate compensation, including corrective tracking, will be introduced [41]. The updated
M-DDS and continued collaboration with CNAO will allow for integration of further motion
mitigation into the M-DDS and, eventually, integration of the M-DDS into the clinic.
Another limitation was that a comparatively simple experimental setup, with only onedimensional regular motion patterns was used. In further studies, more complex experiments
will include irregular, 3D breathing traces. More precise, 3D dose measurements will be
acquired using a 3D dosimetry system with a higher resolution IC detector array or with gel
dosimeters [42]. Finally, compensation for tissue heterogeneities have not been considered
yet and the delivery results in lung and bone equivalent materials has, therefore not been
determined. Studies are under-way at GSI and CNAO to address additional layers of
complexity in respiratory motion mitigation, such as baseline drifts, irregular motion and
position corrections. Additionally, the DDS will be assessed for motion compensation
through heterogeneous density phantoms and through multiple depths. Additional motion
handling techniques will be implemented into the DDS and compared.
2.5.

Conclusions
We developed a motion-synchronized dose delivery system for scanned ion beam

radiotherapy. This work has demonstrated that it is possible to deliver conformal, motion
compensated dose distributions to moving targets. The M-DDS provides dose distributions of
> 90 % gamma index pass rates. Importantly, the M-DDS provides a solution for motion
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mitigation studies at both a research and a clinical center, providing the possibility for testing
a broad variety of motion mitigation strategies while maintaining clinical safety standards.
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Chapter 3. A Facility for the Research, Development, and Translation of
Advanced Technologies for Ion-beam Therapies
3.1.

Introduction
External-beam radiation therapy is a safe and non-invasive treatment for a wide

variety of malignant diseases. The objective is to sterilize the tumor while sparing
surrounding healthy tissue. Most treatments utilize photon beams, yet beams of protons and
heavier charged particles are of increasing interest to treat radiation resistant tumors and in
sites where radiation damage to healthy tissues is of concern [43-45]. Synchrotrons and
cyclotrons produce narrow ion beams that are magnetically scanned laterally and modulated
in penetration range to deliver highly conformal dose distributions [46, 47]. Research with
ion beams for therapy includes advanced technologies, such as Flash [48], radioactive ion
beams (RIB) [49], mixed species of ion beams [50], and advanced motion mitigation
strategies [14, 51]. Most research on these technologies have higher technical demands than
those of conventional ion therapy treatments, and, in some cases, go beyond the capabilities
of current medical accelerators. Therefore, research on these topics is commonly conducted at
dedicated accelerator research laboratories that can provide dedicated beamtime for
experiments, specialized technical support teams, and the possibility to modify beamlines and
safety systems. Typically, this type of research is more difficult, or even impossible, to
conduct at a clinical facility that is mainly utilized to treat patients. Currently, the pace of
progress of research is constrained by the scarcity of accelerator research facilities, as well as
limitations in their capabilities and capacities to support certain research activities.
Currently, there are 92 proton therapy centers and 14 heavy ion therapy centers

This chapter was previously published as “Lis M, Newhauser W, Donetti M, Durante M, Weber U,
Zipfel B, Hartmann-Sauter C, Wolf M and Graeff C 2021 A facility for the research, development,
and translation of advanced technologies for ion-beam therapies Journal of Instrumentation 16
T03004.” Reprinted with permission of IOP Publishing.
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worldwide [52], with only a few capable of supporting research that relies on the delivery
ofbeams with characteristics that are radically different from those currently used in clinical
practice. Thus, beams with potentially paradigm-shifting characteristics are scarce, which
constitutes a gap in the needed research infrastructure. For these reasons, as well as the
difficulty of translating new treatment paradigms to clinical practice, it is imperative to have
research facilities that support research, development, and clinical translation efficiently.
Ideally, such facilities can mimic the characteristics of current clinical treatment systems
[53], but also offers enhanced characteristics, additional capabilities for experimentation, and
allows for rapid system modifications. In practice, several facilities approach this ideal [5458]. One of these, the radiotherapy research facility at GSI (frequently denoted as Cave M), is
the focus of this report. Construction of a predecessor therapy beamline was completed in
1996 [59]. In 2008, after the successful technology transfer and commercialization of the GSI
therapy systems, patient treatments at GSI ceased and were resumed at a replacement facility
in Heidelberg [58]. Currently, GSI is modernizing and upgrading several of its research
facilities within the Facility for Antiproton and Ion Research (FAIR) [60, 61] project. This
includes significant upgrades of the SIS-18 synchrotron, including increased beam intensity,
faster ramping and improved beam extraction. The modernization of Cave M [46, 62], which
began in 2016 and is ongoing, is reported for the first time in this manuscript. The facility
opened in 2020 for users within the Biophysics Programme Advisory Committee (BioPAC)
and the European Space Agency (ESA).
The objective of this work is to describe the general design, features, and selected
preliminary performance characteristics of the modernized Cave M. This includes beam
monitoring and delivery systems, peripheral components of the beam delivery system, and
corresponding software to facilitate research, testing, and translation of new devices and
technologies. We provide readers with an update on the performance specifications and
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general characteristics of the beamline, as Cave M is now available for users. The
performance of the treatment control system (TCS) components was characterized through
beamline component tests and end-to-end tests.
3.2.

Methods
In the following sections, we describe the layout, general specifications, and

performance of beamline components in Cave M. The accelerator and beamlines are briefly
reviewed here for the convenience of the reader. This includes relevant upgrades to the
synchrotron, beamline components (such as the beam line detectors, power supplies for
scanning magnets, interfaces to the timing system, beam request and scanning magnets, and
the gating system) and the hardware and software of the dose delivery system (DDS).
Additionally, we report selected preliminary performance characteristics of the beam delivery
system for radiotherapy research.
3.2.1 SIS-18 Accelerator and Beamlines
Ions entering Cave M are accelerated in the synchrotron (Figure 3.1). The SIS-18 can
accelerate ions ranging from hydrogen to uranium, with energies from 0.1 to 2 GeV/u for
light ions and up to 4.7 GeV/u for protons [63]. It alternates between accelerating and spilling
the beam, where each spill is the extraction phase for one bunch of accelerated ions. During
the GSI pilot project, carbon beams of up to 2 × 108 ions per spill were available and slow
extraction was utilized to deliver beams with 2.2 s spill durations and 2.2 s pauses between
spills. In addition to the slow extraction method [54], fast resonance extraction is also
available, which allows for delivering high intensity particle beams, accumulated in several
beam bunches, in a single burst, usually on the order of 1 μs spill length [64]. The beamline
was previously commissioned during the pilot project to deliver 80 to 430 MeV/u carbon ions
to clinical safety standards [54].
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Figure 3.1. The layout of the accelerators and beamlines at GSI [63], including the ion
sources, the universal linear accelerator (UNILAC), the synchrotron, the FRagment Separator
(FRS), and the radiotherapy research facility (Cave M).
As part of FAIR Phase-0, the synchrotron has undergone several modifications. Spill
pauses have been decreased to < 1 s, and spill duration can vary between 0.5 s and more than
10 s, with full cycle times of up to 20 s. Beam intensities of up to 1011 ions/spill have been
achieved for proton and carbon ion beams. The acceleration and spill cycle patterns currently
must be fixed during the beam tuning process, although we anticipate variable capability will
become available in the future. Additionally, radio-frequency knockout extraction was added
to the synchrotron extraction line and tuned, allowing for fast beam gating. Beam
specifications and limitations, including radioprotection limitations are summarized in Table
3.1 [63]. For experiments requiring other ions, beam intensities or energies, the high-energy
beamline (Cave A) and the Atomic Plasma Physics and Application (APPA) beamline are
available. The main control system for this accelerator monitors and operates the major beam
delivery components and the tuning of beam optics [61]. The spill cycle and beam parameters
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are tuned from a beamline model and optimized manually via the main accelerator control
system (ACS) [65] before beam delivery begins.
The original, Versa Module Eurocard (VME) based dose delivery system hardware of
the ACS has been replaced with a control system with modern architecture. This architecture
is also used at the Large Hadron Collider (LHC) and includes the LHC Software Architecture
(LSA) based settings management system and a new timing system based on the White
Rabbit framework [66].
Table 3.1. Summary of the current SIS-18 accelerator specifications for the ion-beam therapy
research facility (Cave M), after FAIR Phase-0 upgrades.
Ion species
Ion energies
Spill duration (slow
extraction)
Emittance
Intensity variation
Maximum rigidity in SIS-18
Maximum rigidity to reach
Cave M isocenter
Beam diameter

H – Fe*
100 MeV/u - 2 GeV/u for light ions*
1 - 20 s
1π - 20π mm mrad
103 to 1011 ions / spill for p+ and C6+*
18.5 Tm
11.8 Tm
Typically 2 – 10 mm FWHM in air at isocenter

*Stated ranges conform to the radioprotection limits due room shielding in Cave M as well as beam scanning
capabilities.

3.2.2 Beamline Components
One branch at the SIS-18 synchrotron facility is the Cave M beamline. This is a
horizontal beamline that is equipped with components for directing the beam and magnets for
focusing the beam, as well as the radiofrequency knockout (RFKO) system. An alternative
beam path is also available, which traverses the FRagment Separator (FRS) and branches into
Cave M, can be used to deliver radioactive ion beams. Figure 3.2 shows the layout of both of
these beamlines, from the synchrotron to the nozzle, located within the therapy room.
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Figure 3.2. Layout of the beamline from the SIS-18 accelerator to the ion-beam therapy
research facility (Cave M). Two beamlines branch out from the SIS-18, including the main
line (indicated in red) and a secondary line that traverses the FRagment Separator (FRS) to
deliver radioactive ion beams. Other notable beamlines include the cryogenic storage ring
(Cryring), the heavy ion storage ring (ESR), and the high-energy beamline (Cave A).
3.2.3 Treatment Delivery Elements
Several major beam delivery components are used to monitor and control the delivery
of treatment beams. These include orthogonally oriented two dipole magnets for pencil beam
scanning, three beam-position monitoring detectors, two transmission-type ionization
chambers to monitor the beam current, and a ripple filter [67], each located in the beam
nozzle (Figure 3.3). These components are controlled by a DDS implemented with field
programmable gate arrays (FPGA). To preserve the sharp lateral penumbra of the beam, the
material through which the beam traverses in the nozzle was minimized. Specifically, the
total water-equivalent path length (WEPL) of the components in the beam, excluding the
ripple filter, is only 1.71 mm.
During beam delivery, these components are controlled and read out by a TCS. The
real-time VME treatment control system (composed of control and readout module (SAM)
digital signal processors) used previously [62], was no longer compatible with the accelerator
and was replaced. The replacement TCS was adapted from the clinical DDS at the National
Center for Oncological Hadrontherapy (CNAO), as described by Giordanengo et al. [25]. A
research version of the TCS is found at both GSI and CNAO, and consists of a peripheral
component interconnect (PCI) eXtensions express (PXIe) crate (National Instruments,
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Austin, Texas) and FPGA cards. A description of the DDS used in this work was reported by
Lis et al. [51]. Figure 3.4 shows components located at the end of the beamline.

Figure 3.3. The radiotherapy research facility (Cave M) beam nozzle. Beam nozzle elements
include the exit window to the vacuum chamber, five beamline monitors and positron
emission photography (PET) camera. The PET camera has been removed and will be replace
with other online beam monitoring technologies. The dose delivery system is located behind
the beam nozzle (not shown).
All beam deliveries are made with their centroid location relative to the beamline’s
isocenter, which is localized with five positioning lasers mounted in the irradiation room.
The maximum field size at isocenter is 20 × 20 cm2. The coordinate systems were based on
the recommendations of the International Electrotechnical Commission (IEC) (IEC 61217,
1996).
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Figure 3.4. A) A schematic of the beam nozzle for ion-beam therapy research at GSI. The
nozzle contains several beamline elements, including a) horizontal and b) vertical scanning
magnets, c) the vacuum tube, d-i) five beam monitors and a ripple filter. All distances are
relative to the isocenter position (indicated with a red dot). The patient couch is movable and
found past the isocenter position. B) A schematic representation (not to scale) of the exit
window design. The exit window contains a double layer of polyester film and support mesh.
C) A close up of the exit window, beam monitors, including two position detectors ( d)
MWPC1 and h) MWPC2), and three transmission-type ionization chambers ( e) IC2, f) IC1
and g) IC3), and i) a ripple filter, including distances from isocenter (in mm). The isocenter
location is marked with a red ‘×’.
3.2.3.1.

Treatment Control System

The current TCS runs on the Windows operating system (version 7; Microsoft,
Redmond, Washington) and is based on real-time software (LabVIEW version 16.0; National
Instruments, Austin, Texas). The TCS can also run on another commercial, real-time
operating system (NXG Real-time Module LabVIEW; National Instruments, Austin, Texas),
which is used in clinics. The architecture of the TCS closely resembles the version reported
by Giordanengo et al. [25]. The delivery control crate comprises eight PXIe field
programmable gate array (FPGA) modules: six PXIe-7821R cards, which we labeled
memoFPGA, intFPGA, scanFPGA, pos1FPGA, pos2FPGA, and GSItimingFPGA and one
PXIe-7820R card, which we labeled timingFPGA. These are dedicated to controlling
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treatment slice loading and voxel sending, measuring the number of particles delivered,
directing the beam spot, measuring beam spot position, acting as a timing system interface
and synchronizing DDS operations with synchrotron operations, respectively. Additionally,
there is one PXIe-7857R card, which serves as the motion control module, which will be
referred to as motionFPGA. Detailed descriptions of the TCS can be found in the work by Lis
et al. [51] and Giordanengo et al. [25].
3.2.3.2.

Beam-abort and Beam-gating Systems

Beam delivery can be stopped for two reasons. During the course of a treatment, the
beam is temporarily stopped at the end of an iso-energy slice (IES) or the end of treatment,
once all beam spots have been delivered. Additionally, if abnormal conditions arise, the
delivery may need to be prematurely and irreversibly terminated. Cave M has a beam abort
system to perform these “treatment control” and “safety” operations.
During normal irradiations, the TCS uses the beam abort system for both of these
operations. At the end of an IES, the beam is temporarily aborted, enabling the TCS to
prepare delivery for the next IES. At the end of a treatment, the beam is permanently stopped.
Additionally, the beam abort system is activated during abnormal and unsafe conditions, such
as steering magnet failure. In this case, an interlock is set and the beam is also permanently
and irreversibly aborted.
The beam abort system utilizes a fast quadrupole magnet, located at the SIS-18
extraction channel (Figure 3.2). The magnet rapidly shifts the beam tune towards resonance,
destabilizing the particles and pushing them out of the beam path. The beam is then dumped
in the synchrotron, so that recovery of the spill is not possible. Cave M also contains a beam
gating system. The beam gating system is used for rapid, temporary beam interruption during
the course of a spill. One example is beam gating synchronously with organ motion.
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Beam gating is performed using RFKO extraction which is now utilized for rapid
beam interruption and recovery and can also be used for beam abort functionality. In order to
rapidly gate beam delivery, RFKO extraction is momentarily interrupted by switching the
RFKO exciter off and then on again to resume the extraction. In addition, a frequency shift is
introduced on a synchrotron cavity, moving the beam out of tune and effectively preventing
extraction. This allows for beam gating and recovery multiple times during a spill, without
requiring a fast kicker magnet in the beam extraction junction, as present in most clinical
facilities. In contrast to fast kicker magnets, frequent and rapid gating with RFKO does not
pose a risk of gating failure due to overheated power supplies for the magnets. On the other
hand, RFKO beam pauses cannot fully block the beam and a small number of particles will
leak through (as seen in Figure 3.8). During normal operation, the DDS triggers both systems
automatically, as described in section 3.2.7.1. The abort system can also be triggered
manually to gate the beam and pause the delivery.
3.2.3.3.

Scanning Magnets

The scanning magnets in Cave M function by steering a pencil beam to each spot
position via the raster scan technique, as described by Haberer et al. [46]. The center of the
horizontal (X) and vertical (Y) magnets are located 8 826 mm and 7 800 mm from the
isocenter, respectively, as seen in Figure 3.4. The scanning magnet power supplies and
calibration were retained without alteration as originally installed in 1995. Table 3.2 lists
selected characteristics of the scanning magnets and power supplies.
The communication interface for the scanning magnet power supplies was also
redesigned. The scanning magnet power supply set values are communicated via a digital
serial optical fiber cable and are sent at 20 Mbit/s with 20-bits per set value. The conversion
of the spot position from lateral position (mm), from treatment plans, to power supply set
values (current) for the scanning magnets are calculated using an analytical calibration
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formula. Parameters used in the conversion formulas are stored in files that are loaded during
DDS configuration and transmitted to the power supplies through the scanFPGA module of
the TCS. The equations for this conversion are as follows:
X(mm) =

Ix − I0x
+ X0
Fx (E)

Y(mm) =

Iy − I0y
+ Y0
Fy (E)

where Ix and Iy are deflection currents, I0x and I0y are energy dependent correction factors, Fx
and Fy are energy dependent rigidity correction factors, and X0 and Y0 are magnet offset
correction factors. The GSI scanning magnet power supplies are unidirectional, with currents
of up to 400 A. The nominal horizontal beam scanning velocity in the isocenter plane is 27.5
mm/ms for 430 MeV/u carbon beams. The beamline is vertically inclined by -2.203° and
horizontally by 0.649°, accommodating the unipolar scanning magnets. This was designed as
a safety feature for therapy, so that the beam will pass 300 mm above the isocenter and thus
miss the location of a patient in the event of a scanning magnet failure. The vertical magnet
strength limits the beam rigidity that can hit the isocenter to Bᵨ < 11.8 Tm, and to Bᵨ < 8.9
Tm for the maximum scan field of 200 × 200 mm2 at isocenter.
Table 3.2. Specifications of the scanning magnets and their power supplies used in the GSI
radiotherapy research facility (Cave M).
Characteristic
Magnet gap
Magnet effective length
Overall length
Max deflection angle
Maximum field strength
Coil resistance
Coil inductance
Maximum current
Maximum voltage
Current ramp rate
Scan speed for 280 MeV/u for C6+
Power supply polarity

Unit
Mm
Mm
Mm
°
T
mΩ
mH
A
V
kA/s
m/s
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X magnet
130
531
600
1.45
0.38
63
9.2
400
± 368
± 40
35
Unipolar

Y magnet
170
1209
1290
3.30
0.38
154
33
400
± 330
± 10
17
Unipolar

3.2.3.4.

Exit Window

The exit window (Figure 3.4c) is found at the end of the evacuated segment of the
beamline, which encloses a vacuum, typically at 10-8 mBar. The usable area of the exit
window measures 210 × 210 mm2, as required to create large enough lateral area for therapy.
The inner layer of the vacuum window is composed of 100 µm, 14 g/m2 polyester film
(HOSTAPHAN RN 100; Mitsubishi Polyester film GmbH, Wiesbaden, Germany) that is
supported by a 120 µm thick, 58 g/m2 high-strength synthetic fiber mesh (Kevlar 49 Style
120; Fa. Cramer & Co, Heek, Germany), as seen in Figure 3.4b. Behind these materials, there
is a second layer of polyester film and high-strength synthetic fiber, with the same properties,
which is spaced at a few mm apart from the first layer, and contains pre-vacuum. The second
layer serves as a therapy safety feature and creates a tighter vacuum. The front face of the exit
window is located 1050 mm from isocenter.
3.2.3.5.

Nozzle Detectors and Readout Algorithms

Five detectors are mounted in the nozzle (Figure 3.3). Three of these detectors are
parallel plate ionization chambers – IC1, IC2, and IC3 – and are found 880, 925, and 835 mm
from the isocenter, respectively. The ICs are ArCO2 gas filled (80 % Ar and 20 % CO2 by
mass) ICs, which provide the beam intensity signal (a current that is proportional to particle
rate). The remaining two detectors are position sensitive multi-wire proportional chambers
(MWPC), which provide beam spot position information. The two MWPC detectors, denoted
by MWPC1 and MWPC2, are located 970 mm and 790 mm from isocenter, respectively.
Three of these detectors (IC1, IC2, and MWPC1) are currently used for beam monitoring.
IC3 is used by the ACS for beam diagnostics and its signal is digitized independently of the
DDS by a current to frequency converter. These detectors have been retained without
modification from the original Cave M facility, where redundant dose and beam position
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monitors were installed to fulfill the safety requirements for patient therapy; however, the
electronic readout systems for these instruments were replaced.
The ICs have 210 × 210 mm2 large area anodes and cathodes of 54 µm thick nickel
coated polyester mesh. The two cathode planes are symmetrically arranged around the anode,
with 10 mm gaps in between. The ICs are housed in an aluminum frame with 25 µm
metallized plastic windows. Both ICs operate at a potential of 1.8 kV.
The IC1 current is read out by a fast current-to-voltage amplifier (DLPCA-200;
FEMTO, Berlin, Germany) and the output voltage (-10 V to 10 V) is sampled by a 14 bit
analog to digital converter (ADC) card (NI PXIe-5172 FPGA). The ADC card digitizes at
125 MHz rates, which is down-sampled to 1 MHz. The current from IC2 is read out with an
application-specific integrated circuit (ASIC) chip (TERA09; DE.TEC.TOR Srl, Torino,
Italy). This chip based on the TERA06 and TERA08 [68] chips, developed at the University
of Torino, which are used at CNAO and MedAustron [69] respectively. As is done at CNAO,
the second IC detector’s counts are scaled down by a factor (Grel) of 1.1: without this scaling
factor, both ICs would alternate in signaling beam spot progression. Additionally, IC2 serves
as a redundant detector in the case of IC1 failure.
The ASIC chip contains 64 charge-to-frequency converter channels [70]. The charge
collected in the second ionization chamber (IC2) is accumulated by one of the 64 channels of
the ASIC chip and converted to counts. The 32-bit charge counter of these channels is read
out with 1 MHz rate by the intFPGA, at the same rate as for the ADC card from IC1.
The currents from all of the wires of each the MWPC position detectors are read out with
four ASIC chips. A modular board has been designed for the position detector readout,
containing up to 4 TERA09 chips. This board reads out the signals from the MWPC, which
contains 224 wires in the X-plane and 224 wires in the Y-plane. Each wire is electronically
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connected to a neighboring wire for noise reduction. The wires within the MWPC are each 50
µm diameter with 1 mm spacing between wires.
A gas electron multiplier (GEM) strip chamber detector [71, 72] is under development
as the new, primary position detector. MWPC2 has been previously used as a redundant
position readout for safety purposes during radiotherapy. For diverse and redundant readouts,
one MWPC will be maintained. It is anticipated that the GEM detector will be considerably
faster than the MWPC as it amplifies the fast electron signal by a factor of 10 to 100 through
the gas amplification at the GEM layers while suppressing the slowly drifting positive ions.
The GEM design has 256 strips per plane with a 1 mm pitch and requires one readout board
per plane. Comprehensive tests on this detector are planned for 2021.
The IC counts are read out by the intFPGA, and when the set number of counts is
reached, a signal is sent to the DDS controller to progress to the next beam spot. Particles
numbers for each beam spot (extracted from the treatment plan) are converted to IC counts
through the following equation:
Counts =

P × GRel × F(Xb, Yb)
k(E) × k TP (T, P) × k QAfit

where P is the number of particles, GRel is a ratio of the relative gain between the two ICs,
F(Xb, Yb) is a spatial uniformity correction lookup table, k(E) is an energy-dependent
conversion factor, kTP is the temperature and pressure correction and kQAfit is a correction
factor derived from daily quality assurance measurements.
The MWPC detector is read out by the pos1FPGA, which analyses the signal
distribution from all wires and determines the relative lateral beam position and spot size of
each beam spot by calculating the center-of-mass and standard deviation [33] with the
following equations:
KxPos × Xb − X0Pos NchXPos − 1
) 100
XPos (FPGA units) = (
+
pchPos
2
43

KyPos × Yb − Y0Pos NchYPos − 1
) 100
YPos (FPGA units) = (
+
pchPos
2
where KxPos and KyPos are constant conversion factors for converting between mm and
relative units used internally by the FPGA, X0Pos and Y0Pos are the offset of the position
detector in the X and Y directions, respectively, pchPos is the pitch of the detector, NchXPos
and NchYPos are the number of channels of the position detector, XPos and YPos are the X and
Y coordinates (in detector units) of the position detector, and Xb and Yb are the IEC
coordinate X and Y positions (in mm) of the isocenter, respectively. The first term in the
parentheses of the two equations converts the isocenter position into detector units, and the
second term shifts the value to the expected multi-wire number. These values are scaled by
× 100 for sub-millimeter position sensitivity. The pos1FPGA also provides position feedback
to the scanning system for lateral position control of the beam.
3.2.3.6.

Ripple Filter

A ripple filter is placed within the beamline, located 600 mm from the isocenter, to
broaden the Bragg peak maximum region of ions to more than 2 mm. Two ripple filters are
available, which are composed of 2 mm thick and 3 mm thick polymethyl methacrylate
(PMMA) plates with a periodic structure of fine grooves with a well-defined ridge shape. The
3 mm ripple filter is mainly used during carbon ion therapy experiments. The design of the
ripple filters was reported by Weber and Kraft [67].
3.2.3.7.

Range Shifters

A portable binary range shifter is available to shift the beam penetration range.
Following the upgrade of the SIS-18 ACS, treatment directed energy variation, performed by
the synchrotron, was eliminated. This lost functionality provided 250 beam energy steps. In
future phases of the FAIR upgrades, this capability will be restored; however, in the interim,
the binary range shifter is available to shift the particle range and deliver dose volumes. The
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range shifter is composed of 10 precisely cut polyethylene (PE) plates, each roughly doubling
in size, to vary the WEPL delivery depth up to 100.2 mm. The plates are 0.063, 0.125, 0.235,
0.474, 0.951, 1.90, 3.80, 7.69, 15.46, and 30.91 mm water-equivalent thickness (WET). An
additional 38.6 mm WET block can be added for additional depth. The range shifter is placed
behind the ripple filter, with the thickest plate as close to isocenter as possible. Further details
were reported by Simeonov et al. [73].
3.2.4 Motion Mitigation System
The motion mitigation system is an optional unit, used for motion mitigation studies.
The motion mitigation capabilities are produced by two FPGAs, motionFPGA (PXIe-7857R,
National Instruments, Austin Texas), and memoFPGA (PXIe-7821R, National Instruments,
Austin Texas), which monitor target motion and redirect delivery to the measured motion
position, respectively. The motionFPGA contains both analog and digital I/O and can be
adapted to a variety of detection systems that deliver diverse forms of data, such as position
in space, 1D motion traces, or externally pre-computed motion state information.
Implemented motion mitigation strategies include conformal motion-synchronized dose
delivery, gated delivery, and internal tumor volume [74] rescanning treatments. Tumor
tracking, as described by Saito et al. [75], will be implemented for further motion mitigation
studies. More information on the motion mitigation system was reported by Lis et al. [51].
3.2.5 Timing System and Beam Request Processor
The timing system is used to synchronize beam delivery to the accelerator spills.
Timing signals are sent from the timing system interface (timingFPGA) and used within the
other FPGAs to synchronize beam delivery signals between the FPGAs. An additional
software layer has been added to the timing system interface to allow for communication
between the beam request processor of the synchrotron and the DDS while maintaining the
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timing events from the implemented DDS. This layer is located in the GSItimingFPGA and
serves as a compatibility layer to allow the rest of the DDS to be used at multiple centers
without modification. Spill patterns are pre-set by the ACS during machine tuning, along
with other machine parameters, such as focal spot size and particle intensity, and only signals
for the start and end of treatment are sent to the central accelerator during delivery.
The developed beam request software communicates beam progression signals with
the ACS. Signals are sent via a transmission control protocol (TCP) to the ACS, which
triggers the beginning and end of beam delivery with the ‘Start Treat’ and ‘End Treat’
signals. Spill patterns from pre-set beam parameters (spot size, energy, particle flux) are
delivered until the ‘End of Treatment’ signal is received. For each spill, synchrotron timing
events trigger the stop and start of a spill through the ‘Begin Extraction’ and ‘End Extraction’
signals. These external signals trigger ‘BeamOn’ and ‘BeamOff’ signals internally to
synchronize the DDS FPGAs during delivery. ‘NextCycle’ and ‘RepeatCycle’ signals are
generated from the DDS to signal the accelerator to repeat a spill or transition to the next
energy, respectively. At the end of an IES and in between spills, the fast-extraction-stop
quadrupole magnet is activated until the end of that spill, as seen in Figure 3.5. Additionally,
in physics mode (beam delivery without a treatment plan) the beam request system interface
can request one beam spill, ‘Trigger Request’, or a repeating pattern of spills, ‘Continuous
request’. During plan delivery, these modes are disabled and the beam request begins
automatically once a treatment plan is loaded and sent. As described in section 3.2.3.7, only
single energies could be pre-set with the current ACS. However, the existing CNAO beam
parameter code protocols (so-called CycleCodes) are still maintained, anticipating for future
multi-energy switching capabilities at GSI. These CycleCodes [25] are hexadecimal codes
that represent accelerator energy settings for each IES. To deliver 3D volumes at GSI, the
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CycleCodes were converted to settings for the binary range shifter, allowing range
modulation.

Figure 3.5. Timing events from the accelerator, where ‘Begin Extraction’ triggers the
beginning of a spill, ‘End Extraction’ triggers the end of a spill, and both ‘End Extraction’
and ‘End of Slice’ signals turn on the ‘Beam Abort’ signal until a spill is completed or at the
end of a treatment. These signals are recorded along with motion phase changes and can be
used to reconstruct delivered doses from delivery log files.
3.2.6 Pre- and Post-treatment
Treatment plans are created through two methods: simple, mono-energetic rectangular
plans with homogenous fluences are generated from a plan creation tool, while 3D
geometries are created with the research treatment planning system at GSI, TRiP4D [26].
TRiP4D is an extension of TRiP98 [76, 77] that considers temporal changes to patient
anatomy during treatment plan creation. The plans and, in the case of motion-compensation
deliveries, plan libraries were designed with 4D-optimization to target volumes [29], which
results in a conformal treatment plan. Robustness has also been incorporated, allowing for
minimizing the effects of delivery degradation due to range uncertainties, patient set-up
errors and uncertainties in anatomy changes due to respiratory motion [78]. TRiP4D has been
optimized for carbon, oxygen and helium ion beams, but can be extended to include
additional ions. Additionally, the DDS has been designed to accept Digital Imaging and
Communications in Medicine (DICOM) standard and VOXELPLAN format [79] treatment
plans and can easily be modified for additional plan format options.
During delivery, the data from the beam monitors and scanning magnets for each
delivered spot is logged into binary dose delivery data (DDD) log files. For motion47

synchronized deliveries, detected motion is logged into binary motion monitoring data
(MMD) files. These files can be fed back into TRiP4D for 3D and 4D dose reconstructions.
3.2.7 Description of Verification Tests
Online and offline tests were performed during several stages of development to
verify the functionality of each subsystem. The offline subunit tests are summarized in Table
3.3. Signal transmitting and receiving, as well as the correct calibration of the scanning
magnets and beam line detectors was confirmed through measurements with dedicated testing
software. Timing events, treatment progression and beam request functionality were
confirmed on a digital oscilloscope (R&S RTB2004; Rohde & Schwarz, Munich, Germany)
and through timing system log file analysis. Subsequently, the integrated functionality of
each sub-system was also confirmed offline by delivering treatments to completion with
simulated beam signals and then assessing accuracy in DDD files and treatment logs.
Online subunit tests were performed to visualize the performance of each beamline
component and end-to-end tests were performed to test the entire TCS during delivery (Table
4). The beam output, or the absorbed dose to water at isocenter, was measured with a farmer
type ionization chamber and an electrometer (Unidos E, PTW, Freiburg, Germany).
Additionally, each batch of radiochromic films (Gafchromic EBT3; ISP, Wayne, New Jersey)
was calibrated by delivering a pattern of eight squares of increasing particle fluence to a film
placed behind 2 cm of PMMA plastic [80]. A calibration curve, converting optical density
values to particle fluence was then applied to each film, using an image analysis software,
(ImageJ version 1.52a; National Institute of Health, Bethesda, Maryland). A 60 × 60 cm2
square profile was delivered three times to a 2D ionization chamber array detector (Octavius
VDR 1500; PTW, Freiburg, Germany) to measure the absolute dose and delivery constancy
(calculated with standard deviation of the absolute dose measurements). Experiments were
performed by delivering simple geometries and spot patterns to the detectors. Additionally,
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cubes and ellipsoids were delivered to confirm the performance of the range shifter and the
capability to deliver multiple depth plans uniformly. In addition to online performance
verification tests, the performance of individual beamline components was also studied
experimentally.
End-to-end tests were performed, including field homogeneity, beam reproducibility,
dosimetric precision and delivery speed. Field homogeneity tests were performed by
delivering a uniform 60 × 60 mm2 square field to radiochromic films, placed behind 2 cm of
PMMA plastic. The homogeneity was calculated with the homogeneity index (HI), using the
equation HI = (Hmax - Hmin) / (Hmax + Hmin) × 100 [25]. Reproducibility measurements were
performed by delivering the same square field multiple times to a farmer type IC chamber.
Additionally, 3D dosimetry was performed to measure doses across a uniform square volume.
The HI was measured across several depths. Treatment delivery speed was assessed by
delivering a square shaped plan with ramped particle intensities for each line, starting at 500
000 particles per beam spot and decreasing to 100 000 particles per beam spot. The 2D
ionization chamber array detector was used for several measurements, including uniformity
measurements, and is a standard tool for experiments in Cave M.
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Table 3.3. Summary of offline subunit verification tests and the relevant analysis tool for
each portion of the dose delivery system and integration tests to the beamline components.
SLD refers to slice file data and DDD refers to the dose delivery data.
Subunit

Test

Analysis tool

Beam request

Triggers a single spill

Virtual beam spill visualized on
oscilloscope

Continuous beam request sent A series of spills visualized on
oscilloscope
Triggers start and end of
treatment

A series of spills visualized on
oscilloscope

Timing system

Timing events sent to other
Timing log file analysis
FPGAs
Range shifter
Triggers correct change total Set manually and confirm total
thickness
thickness
Delivers simple plan of several Confirm CycleCodes and depths
depths
correspond
Beam abort
Boolean trigger from
Visualized on oscilloscope
application
Scanning magnets Communication with power
Visualized on hall probes
supplies
Coordinates correct
Set values with an application
Power supply calibration - spot Set values with an application
position correct
Ionization chambers Simulates signal to amplifier Observe signals
Signal counts calibration
Treatment log file analysis
Signals spot and spill
Observation in DDD files
progression
IC1 as dominant detector
Observation in DDD files
Motion mitigation Connection to external motion Observation of motion signal from
system
signal
motion sensor in the motion monitoring
system
Detection of motion
Observation of motion phases in the
DDS
Sends of motion phases
Receiving phases treatment in log files
Multi-wire position Spot position as expected
Set values with an application
chamber readout
Treatment plan
Loads entire plan libraries
SLD file analysis
handling
Sends single spots
DDD file analysis
Sub-plan switching when
DDD file analysis
motion phase changes
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Table 3.4. Summary of verification tests performed at GSI. The described treatment plans
were designed to test individual functionalities.
Plan

Subsystem/system

Test

8 spots in 1
slice

Beam request

Delivery completion

Scanning

Spot position in correct location

Scanning, position detectors

Correct orientation

Detectors

Multiple spots delivery

Gating system

End-of-treatment beam abort

Scanning magnets

Spot position accuracy

Timing system

Synchronized delivery of multiple spills

Beam request

Slice change when triggered

Gating system

End-of-spill beam abort

6 lines, each
in 6 slices

Gating system

Gating related to motion handling

Treatment plan handling

Capability to deliver plan non-sequentially

25 spots plan
at various
depths
Uniform
squares

Range shifter

Beam spot size and shape at different depths

End-to-end

Beam reproducibility

End-to-end

Uniformity at several depths

Ramp square

Scanning magnets

Scanning magnet speed limits and accuracy

5 spots in 5
slices

3.2.7.1.

Beamline Component Tests

The effect of the range shifter on the beam spot profile was characterized by
delivering 25 beam spots, each to a different range shifter depth, varying from 0 to 100.18
mm. To perform this, a 25 beam spot grid plan was delivered to a radiochromic film. The
film was calibrated in the image analysis software, by applying a gray-value to particle
fluence correction, and corrected for the linear energy transfer (LET) dependence response
for C6+ . To determine the beam spot sizes, the full width half maximum (FWHM) was
determined and the beam spot profiles were fit to double Gaussian functions. This data was
used to update TRiP4D for deliveries using the range shifter.
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The functionality of the MWPC was tested by delivering single beam spots and
correlating the positions and fluence profiles measured in the detector with spot positions
found in the DDD files and the profiles measured with a digital oscilloscope card (PXIe5172; National Instruments, Austin, Texas), respectively. Additionally, the speed of the beam
spot position readout was characterized by calculating the internal deadtime and comparing
the determined position with the delivery duration.
The readout for IC1 was tested by delivering a 2.5 Gy square-shaped plan to a
calibrated farmer chamber (PTW 30010; PTW, Freiburg, Germany). The calibration of the
beamline IC chambers was calculated and confirmed using an in-house developed software.
The functionality of the redundant readouts of IC1 (ADC) and IC2 (TERA09) was confirmed
with C6+ beams by evaluating the difference in electric charge between measured beam spot
counts and planned beam spot counts matched for both ICs. Additional validation testing
studies are ongoing.
Tests were also performed to determine the maximum delivery speed. Delivery speed
is limited by scan speed and position-detector-readout speed, which dictates the minimum
particle number when creating treatment plans. Two square fields, each with increasing
particle numbers for each row of the treatment plan in either the horizontal or the vertical
direction, were delivered with carbon ion beams. The actual beam spot positions in the DDD
log files were compared to expected positions in the slice delivery (SLD) files. Position
accuracy was calculated by calculating the distance to agreement for each spot.
The performance of the fast (RFKO) gating system and the beam abort system was
benchmarked. Two types of tests were performed manually to characterize the DDS response
to anomalous losses of beam. First, the functionality of both the quadrupole beam abort and
the RFKO gating system was tested by connecting the trigger line of the quadrupole magnet
extraction and, respectively, the RFKO system, to the timingFPGA and manually triggering
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beam disruption with a virtual Boolean switch. Subsequently, the speed of both modes of
beam disruption and recovery were assessed to determine the rapid gating performance
capabilities of the gating system during treatment deliveries. These tests were performed by
manually triggering the RFKO extraction off and on in the same manner, while measuring the
particle fluence (in µs) for single spills. The digital oscilloscope card was used to measure the
particle intensity at 1.25 MHz.
3.3.

Results
Tests to confirm the functionality and reliability of Cave M were performed and are

reported here. Preliminary tests for each beamline component were performed offline
(without beam) and online, using the available ion beams (Ar+18 and C6+). Successful signal
transmission, reception and proper calibration were confirmed for each sub-system through
the analysis tools described in Table 3.3. The hardware and software to the beamline
components have been successfully integrated into the experimental therapy beamline at GSI.
The pass/fail tests described in Table 3.4 all passed. Further results for tests on beam spot size
and shape at different depths, beam reproducibility and uniformity, spot position accuracy,
gating and beam abort tests are presented below.
Beamline component functionality tests (see section 3.3.2.7.1) were performed
successfully and test case plan libraries were delivered to completion. Timing system events,
including ‘Start Treat’, ‘End Treat’, ‘Start Extraction’, and ‘End Extraction’ were confirmed
to be transmitted to the beam request processor. The scanning system and detector systems
were found to be properly calibrated and in the correct orientation. At the time of writing,
signal degradation due to noise has limited the position detector readout speed, and the ASIC
readout cards are being redesigned.
The beam spreading when using the range shifter was characterized for C6+ and p+
beams by delivering 25 spots at 25 different range shifter settings (Figure 3.6). The beam spot
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FWHM for each range shifter depth varied from 3.15 to 7.15 mm for C6+ and 8.0 to 19.4 mm
for p+, corresponding to the range of 0 to 100.8 mm in water. FWHM for each energy step
was interpolated with a linear fit curve and resulting beam spot sizes for each energy step
were used during log file based dose reconstructions. The base data of TRiP98 will be
updated accordingly.

Figure 3.6. Beam spot sizes for 25 range shifter settings, delivered with carbon ion beams.
The calibration of the beamline IC chambers and redundant readout functionality was
confirmed. Beam position detection accuracy was assessed by comparing measured beam
spot positions on a radiochromic film with planned positions. Accuracy was found to be
within 1 mm in the horizontal and vertical directions. High noise due to the design of the
position detector readout remain, and portions of the board are being redesigned.
The scanning direction and calibration was confirmed by manually setting the magnet
set values to various positions. Without position feedback, the scanning magnet set values
were found to be accurate within 1 mm, and maximum deviations were found to be
0.99 mm ± 0.1 % and 0.99 mm ± 0.06 % for the vertical and horizontal scan directions,
respectively, as seen in Figure 3.7. The scanning magnet accuracy was 0.5 mm for the ramp
square delivery. The accuracy of delivery is expected to increase once position feedback from
54

the position detections to the scanning magnets is in place. Minimum detector counts are
currently set to 20 000 particles per spot for faster delivery: lower-weighted beam spots can
create a bottle-neck in irradiation speed due to limitations in measurement precision.
The usable maximum energy is limited by ion species and by scanning magnet
strength. The maximum energy to deliver ions to isocenter and across a 10 × 10 cm2 scan
field were calculated for various ion species and are summarized in Table 3.5.

Figure 3.7. Beam spot position accuracy for a cube plan delivery, delivered with 240 MeV/u
carbon ions, using the range shifter. The difference between planned and recorded current
values in the X (orange) and Y (blue) directions are indicated.
Table 3.5. Maximum energies for various ions, with respect to scanning magnet limitations.
Ion
P+
Fe26+
C6+

Delivery across 10 × 10 cm2 scan field
1 850 MeV
575 MeV/u
680 MeV/u

Delivery to isocenter
2 000 MeV
950 MeV/u
1 100 MeV/u

The functionality and performance of the beam abort and beam gating systems was
confirmed. The beam abort system was activated when triggered, including at the end of each
slice and until the completion of each spill, as expected. RFKO gating tests for multi-gating
capabilities determined that reduction to 5 % of the full beam intensity was achievable within
2 ms, and full beam disruption, to 1 % intensity, was achievable within 20 ms, as seen in
Figure 3.8. The minimum gate duration was determined to be 10 ms. Further RFKO tuning
will be performed to improve beam gating speeds. The beam ramping was optimized to
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achieve these results. These rates were sufficient to conduct motion-synchronized
irradiations. Comparable clinical fast gating systems, such as that at CNAO, are capable of
complete beam disruption within 150 µs.

Figure 3.8. Beam gating by halting the radiofrequency knockout extraction. The beam
intensity was measured at 1.25 MHz using the beam nozzle IC (red) and readout by an
amplitude to digital converter (ADC) oscilloscope card. Particle intensity is shown before and
after activating the beam gate signal (blue).
Dosimetry was performed prior to performing other beam deliveries. Absolute
dosimetry measurements with a farmer chamber resulted in a dose reproducibility of
± 1.07 % for 2.5 Gy deliveries, where standard deviations of < 3 % are considered acceptable.
Field homogeneity of a square, delivered to a depth of 20 mm into PMMA was within 4.9 %
in the horizontal direction and 4.7 % in the vertical direction (Figure 3.9a). Gamma index
analysis pass rates for cube deliveries, comparing measurements with the 2D IC array
detector to log file dose reconstructions, were found to be 100 %. Time to deliver the cube
was 423 s. The slight misalignment between the two data sets in Figure 11b may be due to
limitations to the resolution of the 2D IC array detector and imperfect tuning of the beam spot
prior to experiments.
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Figure 3.9. Uniformity measurements of a 60 × 60 mm2 square, placed behind 20 mm of
PMMA plastic, measured with a (a) radiochromic film and the horizontal uniformity profile;
b) measurements of a 60 × 60 × 60 mm3 cube, reconstructed from delivery log files and
overlaid with the respective 2D ionization chamber array detector measurement (white
boxes).
3.4.

Discussion
We have re-designed and upgraded the GSI radiotherapy research facility (Cave M)

during the FAIR shutdown period from 2016 to 2018. We designed the beamline to maintain
clinical specifications and have adapted and extended a clinical dose delivery system (DDS)
from CNAO, for 4D capabilities, to allow for experiments in clinical-like conditions. Tests
have been performed to confirm functionality and consistent performance of the beamline
elements and the DDS. The presented information is also intended as a reference for external
users to determine the possibility of conducting research at GSI and applying for beam time
through the GSI BioPAC [81]. The major finding of this study is that the updated Cave M has
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been successfully characterized and is now available for users. The new DDS was used to
perform the first experiments on biological samples, including uniform spread-out Bragg
peak irradiations of culture flasks with protons and carbon ion beams, and online microscopy
experiments with protons, carbon and iron ions.
The implication is that researchers may exploit this new research infrastructure to
pursue new avenues of research. Cave M has been developed in such a matter that continuous
upgrades will allow for performing innovative clinical research, beyond the capabilities of
current medical accelerators. This will allow for testing innovative new therapy methods in
conditions beyond the limitations of clinical lines, but is not limited to therapy research. GSI
offers multiple modes of beam extraction, including fast extraction, slow extraction and
radiofrequency knockout extraction, and a broad range of beam energies, which allows for
testing novel delivery methods. High dose rates and a broad range of particle energies will
allow for studying Flash therapy [48]; multiple ion sources allow for mixed beam irradiations
[82]; the alternative beam path, through the FRS allows for radioactive ion irradiation [49];
rapid gating and position feedback will allow for testing motion mitigation strategies,
including tracking and conformal, motion-synchronized delivery [31, 51, 83]. The Cave M
layout is not the final design, but the current stage in the continuous upgrades as part of
FAIR-GSI phase-0. With further upgrades, additional capabilities will be possible, including
dynamic intensity control [84] and fast beam energy switching.
This work presents, for the first time, on the upgrades to the original Cave M design,
including a comprehensive description of the updated beamline and the TCS for delivering
arbitrary dose volumes. The results of this study are comparable to performance
specifications of clinical accelerators, such as CNAO [35, 85] and NIRS [86]. At CNAO,
commissioning results revealed that all beam spots could be delivered within < 1.5 mm of the
expected positions (without position feedback) and with particle fluence accuracies of
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< 2.5 %. The resulting dose distributions were 100 % gamma index pass rates for 3 %/3 mm
criteria when delivering a representative patient plan [35]. The time to deliver a 60 mm
diameter sphere, with carbon ion beams, at CNAO was found to be 223 s, excluding the time
required to prepare the accelerator before treatment. At NIRS, commissioning results found
that the difference between measured and expected beam spot positions was < ± 0.3 mm.
Measured doses were within ± 2 % of the expected dose [87]. Typical delivery times are not
noted in the literature, however particle intensity and scan speed limits suggest around × 10
faster deliveries [88]. Our results reveal a particle position accuracy of < 1 mm, a particle
fluence accuracy of < 1.07 %. The time to deliver a 60 × 60 × 40 mm3 cuboid was found to
be 423 s. By increasing particle fluences during delivery, delivery speeds at Cave M can be
theoretically increased by a factor of 10. In order to perform Flash experiments with proton
and carbon ion beams, particle rates of 1013 s-1 and 1010 s-1, respectively, will be required
[48]. With the continued FAIR upgrades to the SIS-18, these rates will be achievable. Beam
nozzle intensity and position monitors are in principle compatible with Flash dose rates, but
research into optimal dosimetry is ongoing.
This work has several strengths. First, a majority of the features of Cave M that were
developed for clinical use during the pilot project are maintained, and the DDS has been
adapted from the clinical ion therapy facility CNAO. This is a major advantage because the
beamline components were designed to clinical standards [25, 54], and the beamline is
structured so that beam monitoring components can be inserted. Further, a majority of the
safety interlocks are already in place, so as each upgraded element was implemented, and as
new therapy methods are developed, the safety and beam monitoring strategies can be
directly developed as well. Another strength is that a broad variety of tests were performed to
validate that we have met design specifications in these upgrades. This study was performed
on multiple ions, at multiple particle intensities, and each component was tested extensively
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offline before performing online and end-to-end tests. Though the tests described here are not
exhaustive, they represent many tests that are required to confirm the performance of the
facility for radiotherapy research studies. Finally, several of the updated components,
including the DDS and the ASIC readout chips, are commercial components. This ensures the
reliability of these components, allows for straightforward updates and modifications, as well
as documentation on the hardware and underlying software and technical support.
One limitation of this work is that we do not give an in-depth description of each
component of the beam delivery system. Here, we provide only brief summaries and example
test results. This is not a major limitation because detailed accounts and exhaustive tests will
be provided in other studies. Another limitation is that this study has been written at a time
when some beamline components are in the preliminary stages of testing or are still being
developed. The readouts for the MWPCs and GEM detectors have not been fully
implemented, so online beam position was not available, and the RFKO gating system has
not been fully tuned. These components are expected to be available in the next couple of
years. This is not a major limitation, as the accuracy of the scanning magnets allowed for
delivering beam spots within ± 1 mm of the planned position without positions detector
feedback. Further, the beamline detectors have been confirmed to deliver accurate
irradiations, as the beamline detectors have been previously used for therapy and only their
readouts have been modified. Additionally, only single energies are available for experiments
and a range shifter is used to deliver tumor volumes. The range shifter produces significant
particle scattering, due to the air gaps between each plate. Multiple energy deliveries are not
anticipated at this time, but a new range shifter will be developed to reduce beam scattering.
However, this is not a major limitation, as delivering dose volumes is still possible, and
increases to the beam spot size for each range shifter setting has been measured and
implemented into the treatment planning system. Finally, the delivery system also can already
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deliver full treatments to the requirements of most users, and updates on the status of
development can be provided.
Cave M is now available for pre-clinical research experiments. Prospective users
should be aware of the current status, limitations, and the planned future upgrades. The online
positron emission tomography (PET) camera that was used during the GSI pilot project is
currently not functional. The entire system for the online PET system [89] has been removed
and the PET imaging components have become outdated. The PET system will be replaced
for the study of radioactive beams within the ERC Advanced Grant – BARB [90]. In the
future, a hybrid monitor for prompt gamma ray imaging and PET will be used for online
beam monitoring of the secondary particles of four beta emitters (C-10, C-11, O-14, and O15). These aspects may be potential obstacles for users in the near term and should be
available in the coming years. Interested users should contact the Biophysics department at
GSI for the beamline status.
In the future, the beamline components will undergo several more updates to increase
delivery speed. New power supplies for the scanning system will be implemented, which can
double the scan speeds. Additionally, the two scanning magnets will be updated to three
smaller and faster ones. The current magnet system, a very large vertical scanner, will be
divided into one dipole, responsible for tilting the beam into the isocenter, and one scanning
magnet, responsible for directing the beam during treatment. The scanning magnet will be
considerably smaller due to the smaller scanning angle. Both scanning magnets will be
controlled by bipolar power supplies, and will be designed for a smaller inductivity, allowing
for faster operation. The new system can be used later for the scanning system at the FAIR
BIOMAT beamline [74], as the size of the magnet allows for scanning higher energy ions.
The intensity control loop will be characterized and calibrated to achieve a stable and
constant extracted intensity. Additionally, new detectors, including the GEM position
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detector, will enhance precision and beam intensity and position measurement speed. Finally,
ongoing updates to the SIS-18, in preparation for the FAIR project, aim to increase the
maximum beam intensity for all ions.
The adapted DDS has also been updated, as described by Lis et al. [51]. Modifications
have been made from the original DDS design [25] to repackage the system as a fully
modular design, with integrated motion detection and motion-synchronized delivery
capabilities. This upgrade, including several significant changes and upgrades to the
hardware and software of the DDS, is an example of how we envision the future use of Cave
M: as a testing facility for pre-clinical research on delivery strategies that require intervention
with the accelerator line and would provide undue risk if performed in clinical environment,
but are posed to produce major advances in radiation therapy if thoroughly investigated and
vetted before being implemented to clinic practice.
3.5.

Conclusion
The ion-beam therapy research facility described in this study has been updated for

performing experiments under clinic-like conditions. Cave M has re-opened in 2020 to
external users. The layout and specifications for each beamline component have been
described. The performance testing results confirm that each component performs to clinical
specifications. Cave M will provide for a near-ideal infrastructure and environment for
research on novel radiation therapies with heavy ion beams.
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Chapter 4. A Modular System for Treating Moving Anatomical Targets
with Scanned Ion Beams at Multiple Facilities; Pre-clinical Testing for
Quality and Safety of Beam Delivery
4.1.

Introduction
Quality, safety and radioprotection are integral parts of radiotherapy facilities [91].

Radioprotection and area monitoring systems are designed to protect staff under the
principles of justification, optimization and limitation [92]. During regular operation, the
critical safety operations of each accelerator are regulated by the main treatment control room
and, for redundancy, by independent safety interlock systems [93]. Medical systems used for
radiotherapy, including accelerators, treatment control systems, and safety systems, typically
take into account safety considerations during the design, construction, preclinical, and
clinical phases. In addition, safety is considered in regulatory processes, e.g., in the USA, the
510k premarket clearance by the Food and Drug Administration (FDA) (21 C.F.R. § 807.81807.97). Once in clinical use, exhaustive safety and quality assurance testing must be
periodically performed. Quality management has been an integral part of modern
radiotherapy and is essential for safe and effective treatments. Organizations such as the
American Association of Physicists in Medicine (AAPM), American College of Radiology
(ACR), the American Society for Radiation Oncology (ASTRO), the International Atomic
Energy Agency (IAEA), and the European Society for Radiology and Oncology (ESTRO)
[94] have established safety standards and guidelines [95]. Radiotherapy device
manufacturers and therapy centers typically agree upon test procedures as part of the
acceptance testing process and guidelines are published for verifying the performance and
safety of radiotherapy equipment during commissioning and periodic quality assurance
testing [96-100]. Beam commissioning and QA standards have been established for proton

This chapter was previously published as “Lis M et al. (2021) A Modular System for Treating Moving
Anatomical Targets with Scanned Ion Beams at Multiple Facilities: Pre-Clinical Testing for Quality
and Safety of Beam Delivery Frontiers in Oncology 11” Reprinted by permission of Frontiers.
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beams in the AAPM Task Group 224 report [101] and are being established for ion beam
therapies through the PAR-13-371 National Cancer Institute (NCI) grant [102]. As the
complexity of modern treatment planning and delivery technologies, such as scanned ion
beam therapy, has increased, additional consideration of safety is necessary. There is
typically a lag between implementing modern therapies into the clinic and developing
consensus safety guidelines for these therapies. The AAPM’s Task Group 100 (TG-100)
wrote a report [103] on an analysis methodology that aims to reduce this lag. The report is a
framework to prospectively assess all aspects of workflow for possible critical safety errors in
existing and new therapy methods [103, 104].
Broadly, the methods of safety analysis and risk mitigation are mature, rich, and
generally applicable. Several major analysis strategies have been applied to clinical
radiotherapy. For example, the AAPM and the Joint Commission on Accreditation of
Healthcare Organizations (JCAHO) recommended the failure modes and effects analysis
(FMEA), adapted from aviation safety to radiotherapy, as a general guidance for performing
safety analyses [105]. Additionally, guidelines have been developed by groups such as the
‘Accidental and unintended exposures in radiotherapy’ (ACCIRAD) project of the European
Commission (EC), the Radiation Oncology Incident Learning System (RO-ILS; ASTRO,
Arlington, VA), which are based on pooled data on reported adverse events [106, 107]. Many
photon therapy clinics have adopted these methods [108, 109], while others have developed
their own variations [110]. However, knowledge of the safety of emerging radiation therapy
technologies is inherently incomplete. Furthermore, emerging technologies have been
identified as a common source of delivery errors [111]. It is not yet clear how best to address
the safety of emerging technologies, particularly for systems that treat moving tumors. It has
been suggested that developing and simultaneously performing quality assurance during
clinical trials of emerging technologies decreases safety errors [112]. Prospective analyses,
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such as FMEA, could be a useful tool for emerging technologies [113], including conformal
ion therapy for treating moving tumors [29]. Though several motion handling strategies with
ion beams exist [114-117], few of these motion handling strategies are integrated into their
beam delivery systems [38]. Relatively less is known about the safety risks of a modular
motion-synchronized dose delivery system (M-DDS) for ion beam therapy [51], and no
comprehensive assessment of the safety of a dose delivery system with integrated motion
compensation has been reported in the scientific literature.
The purpose of this study was to apply an established method to analyze safety risks
from a novel, modular, motion-synchronized dose delivery system for scanned ion beams.
The system is in the late stages of preclinical development and testing. Here, we focused on
the beam delivery process, identified potential motion-related errors, and implemented
corresponding solutions. The performance of the M-DDS has been previously described by
Lis et al. (2020). Where relevant, we developed and performed sample commissioning-style
tests and quality assurance (QA) tests. These results provide information for subsequent
clinical safety assessments of a novel, modular motion-synchronized dose delivery system in
development.
4.2.

Materials and Methods
This work describes a safety assessment of a dose delivery system (DDS) that is

undergoing pre-clinical testing at two ion therapy centers. The M-DDS is an extended version
of a clinical products used at the National Center for Oncological Hadrontherapy (CNAO)
and MedAustron that have undergone full safety certification. The two most important
extensions to the DDS were to make it portable and to allow for motion mitigation by
synchronizing beam delivery to anatomical motion. The performance of the prototype
motion-mitigation DDS was previously demonstrated, including preliminary tests such as the
delivery of conformal, motion-synchronized beams [51]. These results focused on proof of
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concept and the preliminary characterization of performance, but not safety. However,
failures in the functionality of the M-DDS components could theoretically compromise
patient safety. To minimize this risk, safety was integrated into each stage of development, in
an effort to maintain the existing safety system for reintegration of the M-DDS into CNAO.
The assessment strategy described in this work applies an established methodology
from AAPM Task Group 100 [103]. This strategy is a prospective risk analysis method that
has been widely used in the medical and other industries. With this strategy, we first defined
each step of the treatment process, in detail, with a process map. We then identified possible
errors that could occur at each step and quantified the effect on patient treatment with an
FMEA. Finally, we identified the causes of errors with a fault tree analysis (FTA). After
determining the potential safety risks, we developed and tested solutions for these errors
[103].
The prospective risk analysis was performed on a DDS, with integrated capabilities
for target motion compensation [51]. For convenience, the general characteristics of the MDDS are summarized here. The DDS was adapted from the DDS found at CNAO to function
with the therapy research line (Cave M) at GSI Helmholtz Center for Heavy Ion Research
(GSI). The DDS is composed of commercial field programmable gate arrays (FPGAs) (PXIe1085; National Instruments, Austin, TX), which control each beam delivery component,
including the scanning magnets, beam monitoring detectors, timing system, and interlock
system. The DDS has been modified to synchronize the delivery of 4D-optimized plan
libraries [29, 51] to detected target motion.
Motion mitigation features are integrated into the M-DDS. The first step of motion
synchronized dose delivery is creating 4D treatment plan libraries from 4DCTs, where each
plan in the library contains delivery information for a motion phase within the 4DCT. During
beam delivery, a motion-monitoring device continuously monitors the tumor position, from
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which the M-DDS determines the current motion phase [118, 119]. The delivery progresses
in sequence until the tumor position has entered into another motion phase and delivery is
redirected to the plan from the plan library that corresponds to the detected motion phase.
Further information on the M-DDS is described by Lis et al. [51].
Good manufacturing practices were followed through the development of the M-DDS.
Critical processes in the M-DDS were maintained from the clinical M-DDS design and all
changes were evaluated experimentally in the clinical environment. The implemented
software design choices were based on the existing software structure, so most uncovered
sources of error were found to be related to unclear workflow and limitations to memory or
signal speed. All changes and additions were documented. In the following sections, we
describe a safety assessment strategy for the M-DDS. Additionally, we provide example
safety and quality assurance tests for the M-DDS.
4.2.1 Process Steps
The first step of the prospective risk analysis was to identify the sub-processes that
occur through the course of treatment with a process map. A process map is a visual
representation of a process that demonstrates the flow of each step from start to end. We
divided the process of treating a patient with scanned ion beams into 10 main stages, based
on the guidelines proposed by the World Health Organization [120]. In this study, we focused
on six of these stages - planning, simulation, patient setup, treatment delivery, treatment
verification and monitoring - as these were the most relevant to treating moving targets. For
each of these stages, we identified the sub-processes that occur at an ion beam therapy center
[111], such as delivery of an iso-energy slice (IES) during the course of treatment. We then
amended each stage to include any additional sub-processes when delivering motionsynchronized ion beams with the M-DDS, such as redirecting the plan delivery to compensate
for detected motion. Modes of failure were then identified for each of these sub-processes.
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4.2.2 Failure Modes and Effects Analysis
The FMEA assesses the likelihood and impact of failures from each step of a process.
An FMEA was applied to each of the identified process steps and potential modes of failure
at each step were described. Each of the failures were assigned a rank value on a numerical
scale of 1 to 10 for each of three safety indices: the severity index (S) is the extent of harm of
the failure on the patient, the occurrence index (O) is the likelihood that a cause will result in
a failure, and the detection index (D) is the likelihood that a failure will not be detected. All
three of these indices are estimated under the assumption that there was no safety check in
place for that failure. The corresponding definitions for the rankings of each of these values
are summarized in Table 4.1. This data has been adapted from the TG-100 [103]. The failures
were then ranked by calculating the risk priority numbers (RPN), which is the product of
these three indices (RPN = S × O × D). RPN values of above 125 were considered high risk,
and any S score above 5 was also considered high risk. One example error is the gradual drift
of the scanning magnet throughout the course of delivering an IES. This could potentially
cause limited toxicities or overdose, as the drift may be on the scale of a few mm, and would
potentially occur for every delivery in the absence of position feedback. Such an error would
be difficult to detect without monitoring. The resulting RPN would then be 6 × 10 × 7 = 420.
Selected FMEA indices were agreed on by a consensus group of experts, including the
authors on this work.
4.2.3 Fault Tree Analysis
Causes of each identified failure were mapped out with a fault tree analysis (FTA). The
FTA allows for visualizing potential points to perform quality management procedures and to
minimize the propagation of errors [121]. Each failure mode was traced back to its potential
causes using a logic tree. Possible failure modes include user errors, such as selecting the
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wrong delivery setting or incorrect patient setup, software errors, equipment failures, and
patient non-compliance. For the example of an error in delivery of an IES, the cause could be
traced back to a faulty position feedback from the beamline monitors to correct the scanning
magnet power supplies. Other causes of the error could also be postulated, including slow
scan speeds and incorrect magnet calibration. Once causes for each failure were identified,
methods to eliminate the cause or to detect the possibility of each failure were developed.
Table 4.1. Numerical scale used to assign rank values to Severity Index, Occurrence Index,
and Detectability Index for each failure. This data has been adapted from the TG-100 report
on FMEA. For each case, a rank of 1 was considered harmless, and a rank of 10 was
catastrophic. Chosen rank values were based on observed or estimated.
Rank
Value
1
2

Severity Index

Occurrence Index
(Mean Time Between
Failure)
+ 4 years
2 years

Detectability Index

3

No effect on patient care
Inconvenience or delay in
care
“

4
5
6

Minor dosimetric error
“
Limited toxicity or overdose

6 months
1 month
2 weeks

7

Potentially serious under- or
overdose or toxicity
“
Very serious under- or
overdose or toxicity
Patient death

1 week

Highly likely to
notice
Easy to detect
Fairly easy to detect
Fairly difficult to
detect
“

3 days
1 day

Nearly undetectable
“

1 hour

Undetectable

8
9
10

1

Impossible to miss
“

4.2.4 Solutions and Tests
After identifying the potential solutions for the safety risks, appropriate solutions were
implemented and error-handling tests were designed and performed. Solutions for failure
modes can be classified into several categories: permanent corrective actions, error states and
interlocks, commissioning and quality assurance tests, and plan verifications. Permanent
69

corrective actions are changes in the workflow of the planning or delivery software or user
protocols in order to eliminate the possibility of that failure mode occurring. This can include
implementing redundancies, such as redundant devices and communication protocols. Passfail tests were performed by simulating error states and checking that the delivery system
entered an error state or triggered an interlock. Tests for proper exception or error handling
are pass-fail safety checks that ensure error signals are sent to enter an error state, or to set an
interlock when a runtime error occurs. Commissioning and QA tests are tests that verify that
the system consistently works according to manufacturer specifications and within acceptable
fault tolerances. Plan verification tests verify the accuracy of patient plans. For example, scan
magnet position errors can be prevented in several redundant ways. Two position-monitoring
chambers are used during delivery to monitor the accurate delivery of beam spots within an
IES. Additionally, interlocks are in place in the case of failure of one of the monitoring or
scanning magnets. Finally, daily QA is performed to confirm the functionality of the entire
delivery system. Whenever possible, permanent corrective actions were implemented.
4.2.4.1.

Description of Error Handling Tests

Error handling tests were created for each of the failures identified in the FTA. Passfail test cases were written for each of these failures. Corresponding software tests were then
created that inject error scenarios into the delivery process to confirm that the DDS can
respond to the respective error. In the case that an error-handling test failed, the underlying
delivery software was modified to prevent the error from occurring. In other cases, an
interlock was also implemented to trigger the interruption or termination of treatment in the
presence of a motion synchronization error. The implemented interlocks were also tested by
injecting error scenarios into the delivery process.
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4.2.4.2.

Daily, Weekly and Annual QA

The performance of the accelerator and beam delivery components was characterized
through a series of quality assurance measurements. While existing QA protocols [101] will
confirm the functionality of most aspects of motion-synchronized dose delivery, additional
tests must still be performed to ensure the performance of additional features, including the
motion monitoring system and 4D plan library. QA tests were designed that prioritized a
simple set up, are multi-purpose, are fast and use well-characterized phantoms. A QA concept
was designed to test the safety and reproducibility of motion-deliveries. Where possible, the
current clinical protocols at ion therapy centers, such as those used at CNAO [35] were
extended to include motion scenarios. Each test was verified experimentally in a clinical
setting at CNAO.
Daily QA tests were designed and performed for measuring field uniformity, beam
spot positions, and beam reproducibility. Set-ups with water-equivalent plastics (RW3 slab
phantom; PTW, Freiburg, Germany) and radiochromic films (EBT3 Gafchromic;
International Specialty Products, Wayne, NJ) were selected, as their assembly time is fast and
they are both well-characterized systems. The daily QA procedures found at CNAO were
modified and applied to test the delivery quality of motion compensation with the M-DDS.
This allowed faster delivery that was not dependent on additional custom made software for
analysis. The daily QA setup, a radiochromic film, mounted behind 2 cm of water-equivalent
plastic, was mounted on top of a linear stage with programmable motion patterns (M414.2PD; Physik Instrumente GmbH, Karlsruhe, Germany). Motion amplitudes, detected
from an optical laser distance sensor (OD100 − 35P840; SICK, Waldkirch, Germany), were
converted into motion states [51]. For each test, the clinical (non-moving) procedure was
performed first, followed by the motion-compensation variant. For these beam deliveries, the
linear stage moved with 20 mm amplitude sinusoidal or Lujan2 motion [122] while
71

delivering a uniform square profile with eight surrounding spots. The purpose of each test
and the measurement criteria are summarized in Table 4.2.
All films were calibrated in a series of steps. Before the QA tests, standard dosimetry
was performed [41], and calibration films, composed of eight squares with fluences from 2 ×
105 to 4 × 107 particles/mm, were acquired for each batch of films. The calibration plan was
delivered with 280 MeV/u carbon ions to films placed behind 2 cm of water-equivalent
plastic. After delivery, the QA films were scanned with a laser film scanner (VIDAR
DosimetryPRO Advantage Red; VIDAR System Corporation, Herndon, VA, USA) in
landscape orientation, using 16 bit sampling and a 300 dpi resolution. A batch-specific
optical density correction was applied to each film by subtracting out the optical density of an
unirradiated area of the film, using an image analysis software (ImageJ version 1.52a;
National Institute of Health, Bethesda, MD). The calibration films were used to apply a
calibration curve, converting optical density to particle intensities. Each film was cropped,
aligned, and corrected for linear energy transfer (LET) quenching effects [42], by applying a
relative efficiency (RE) correction curve as follows:
RE(LET) =

D280MeV⁄u (netOD)
Dabs

where D280MeV/u(netOD) is the 280 MeV/u carbon ion dose needed to produce the
measured, corrected optical density, and Dabs is the actual dose delivered with carbon ions to
the film. After, calibration, the films were analyzed.
The uniformity was assessed through the homogeneity index (HI), which is defined as
HI = 100 −

Dmax − Dmin
Dp

where Dmax and Dmin are the maximum and minimum measured absorbed dose, respectively,
and Dp is the prescribed dose. The HI was measured in the center 70 % of the target volume.
HI values above 90 % were considered clinically acceptable. Additionally, the beam spot
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position accuracy was assessed by measuring the relative distance between each pair of beam
spots in 2D profiles of the films. The beam spot shape and distortion was measured by
determining the FWHM in the horizontal and vertical directions. Beam reproducibility tests
were performed by comparing the delivery results across several weeks with a coefficient of
variation [123]. Finally, the increases to QA delivery time were assessed by measuring the
setup and delivery time for each test and estimating the increased time for QA, when
performing motion-specific testing alongside the currently performed QA tests in each
treatment room.

Table 4.2. Description of the purpose and pass criteria for each quality assurance test.
Test type

Quantity tested

Pass criteria

Field uniformity

Homogeneity index [124]

≥ 95 %

Spot shape

FWHM in X and Y direction across scan
field [101]

Symmetrical

Spot position

Distance to agreement [34]

< ± 1 mm

Motion-monitoring system
functionality

Function test

Functioning

Coefficient of variation [123]

<1%

Dose distribution with
homogeneous phantom

Percent error from expected dose [35]

<5%

Dose distribution with
heterogeneous phantom

Percent error from expected dose [35]

<5%

Distance to agreement [34]

< 0.1 mm

Daily QA

Weekly QA
Beam monitor calibration
reproducibility
Annual QA

QC
Motion-monitoring system
performance

Equipment quality control (QC) is generally also performed daily to verify the
functionality and accuracy of treatment equipment. To verify the performance accuracy of the
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motion-monitoring equipment (a linear stage and an optical distance (OD) laser) the linear
stage was programmed to move in an increasing stepwise motion pattern, as seen in Figure
4.6. The measured OD laser signal was compared to the motion files for the linear stage.
Annual QA is a series of extensive tests to measure machine performance. Annual QA
tests were performed to measure dose distributions with 3D homogenous setup and a 3D
inhomogeneous setup. First, 4DCTs of an heterogenous phantom (CIRS 062 electron density
phantom; CIRS, Norfolk, VA, USA) and a water tank (MP3-P; PTW, Freiburg, Germany)
were acquired. 60 × 60 × 60 mm3 cubes were delivered to 12 small-sized ionization chambers
(PinPoint 3D ion chamber model T31015; PTW, Freiburg, Germany) in a water tank for both
setups. For the 3D inhomogeneous setup, density compensation measurements were
performed by the heterogeneous phantom mounted in front of the water tank. Both deliveries
were performed without motion, and with motion compensation. Standard deviations for
measured doses of < 5 % were considered acceptable.
4.2.4.3.

Patient Plan Verification

Plan verification, or patient specific quality assurance (PSQA), is performed to assure
the accuracy of a treatment plan. Treatment planning and treatment delivery errors, unique to
the motion mitigation system, can be discovered through PSQA testing. Errors may include
selecting the wrong motion trajectories during planning or delivery, or planning with an
inintended motion compensation strategy. If not detected, these could lead to severe dose
degradations. Several plan verification methods were chosen to test the extent to which
planning errors related to mitigating for respiratory motion can be detected. The chosen
PSQA tests included patient verification protocols that are used in ion therapy clinics,
including 1) 3D dose measurements with small-sized ICs, 2) repeat 2D measurements at
several depths with a 2D ionization chamber array detector (Octavius 1500 XDR; PTW,
Freiburg, Germany), and 3) log file analysis. Additionally, 3D measurements were also
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performed with 4) a stack of radiochromic films [125]. These measurements were analyzed
with standard deviation calculations, gamma index analysis, and through the evaluation of
dose volume histogram (DVH) metrics, respectively. To perform these measurements, the
detector or film was placed into its respective holder, and the holder was mounted onto a
linear stage. 4D-optimized patient plan libraries were created and delivered to each detector
setup. The linear stage was programmed to move with trajectories derived from the patient
4DCTs. Other aspects of PSQA were also considered when designing each setup, including
favoring simpler phantom setup process and the resolution of the recorded data.
3D dose measurements were performed by delivering patient plans to 12 small-sized
ICs. These ICs were selected, as they are used in several clinical ion facilities for patient
verification [126-128]. The ICs were inserted into a custom removable holder, connected to a
linear stage that generated the motion of the ICs (Figure 4.1). The linear stage was mounted
on top of a water tank, similar to the commercially used water tank phantoms, and the water
tank was filled with water. Each patient plan was delivered to this phantom, with the linear
stage moving with the patient’s breathing pattern. Each IC recorded a dose measurement and
standard deviations were calculated from these doses. The chosen prescription dose was 6 Gy
per fraction. Standard deviations of < 5 % are typically considered acceptable.
2D dose measurements were performed by delivering the patient plan to a 2D
ionization chamber array detector at three tumor depths. The chosen depths corresponded to
the proximal end, middle, and distal end of the tumor depth. The appropriate thickness of
water equivalent plastic (RW3; LAP GmbH, Lüneburg, Germany) was placed in front of the
detector for each case. This setup was mounted on the linear stage to generate patient motion
and a patient plan was delivered to the detector with and without motion, as seen in Figure
4.2. The delivery results were compared to the planned doses for each depth with the gamma
index analysis [34], where a criterion of 3 % / 3 mm was used, with a dose thershold of 5 %
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of the prescription dose. Pass rates of > 90 % for measurements made at all three depths were
considered passing.

Figure 4.1. Experimental setup for patient-specific quality assurance (PSQA) measurements
with a) a water tank and b) a linear stage mounted on top. The linear stage is programmed to
move a variety of attachments in periodic, respiratory-like motion patterns. Here, c) a holder
with d) 12 small-sized ionization chambers (IC) inserted inside is attached. This IC holder
aligns with the isocenter markings on the water tank phantom, which is filled with water.
3D measurements with a stack of films were made to acquire higher resolution dose
distributions. Seven 5” × 4” radiochromic films were slotted into an in-house built film
holder phantom. The phantom was composed of a stack of 15 × 13 × 1 cm3
polymethylmethacrylate (PMMA) plastic slabs, with slits for the films, as seen in the
technical drawing in Figure 4.3. This setup was mounted on top of the linear stage, which
generated periodic motion. Each film was numbered and labelled at the top right corner
before delivery. The patient plan was delivered to the film stacks, in the presence and absence
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Figure 4.2. Schematic of the IC detector array setup. The IC array detector is placed inside of
a 5 mm PMMA holder, mounted onto a linear stage. Water-equivalent plastic of thickness
‘d’, corresponding to the distal, middle or proximal depths of a target, are then placed in front
of the detector.
of motion. Calibration films, composed of eight squares with fluences from 2 × 105 to 4 × 107
particles/s, were acquired on the same day. After delivery, the films were processed as
described in section 4.2.4.2. Each film was then analyzed with the gamma index analysis.
The average gamma index pass rates for each film stack were evaluated using an in-house
developed research software for data analysis, ArrayParser, where each film was compared to
the respective treatment plan at the appropriate tumor depth. Gamma index pass rates of
above 90 % were considered clinically acceptable.
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Figure 4.3. Schematic of the film stack. The film stack contains up to nine slabs of PMMA
with precisely machined slots for holding radiochromic films (5" × 4") as well as several
slabs of additional PMMA to vary the delivery depth. The phantom measures 15 × 13 × 9
cm3 when nine slabs are in place. The slabs are aligned and held together by plastic screws at
each corner of the phantom. The lateral cutouts (blue circle) are used for easy access of the
irradiated films (yellow) without the need to disassemble the film stack phantom.
Log file analysis has been used to decrease PSQA measurement time. The patient plan
was delivered to the IC array detector and log files from the scanner magnets and nozzle
detectors were used to reconstruct the delivered doses on the planning 4DCT, using TRiP4D
[51]. The motion signal from the linear stage was used directing plan delivery during motioncompensation. However, a simulated motion signal could also be used for these
measurements. The dose reconstructions were then compared with planned dose distributions
using the gamma index analysis to a criterion of 3 % / 3 mm, where > 90 % pass rates were
considered acceptable.
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4.3.

Results

4.3.1 Process Map
A process map was created to map out the sub-processes of patient treatment at a
typical ion therapy center. The processes for moving tumors are presented in Figure 4.4. This
map consists of five main workflow steps, starting with patient imaging through the last
fraction of treatment delivery. Patient-specific verification procedures were included as well.
Several of these steps were critical to patient errors.

Figure 4.4. Process map for motion-synchronized dose delivery as commonly found in ion
therapy clinics. The treatment process is broken down into five categories: imaging, treatment
planning, plan verification, initial treatment fraction and subsequent treatments. Each step in
these processes is described.
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Table 4.3. Summary of FMEA results for potential errors during patient therapy with motionsynchronized ion beams using a DDS with integrated motion compensation controls. RPNs of
over 125 were considered high risk.
Failure mode

Severity Occurrence Detectability

RPN

Patient movement

7

6

7

294

Absolute change in breathing position

6

7

7

294

Patient alignment

7

5

6

210

No gating during sporadic movements

5

5

8

200

Gating window too large

6

8

4

192

Beam sweeping distance dose

3

8

9

192

Sending incorrect motion phase info

7

3

7

147

Error creating of slice files

7

3

7

147

Failure to gate

9

2

8

144

Position calibration incorrect

8

2

7

112

Changes to respiration pattern

7

8

2

112

Setup of motion management device to
wrong position

9

2

6

108

Patient not re-imaged after anatomy
change

7

3

5

105

Position feedback missing/not working

4

5

5

100

Determined wrong number of motion
phases

6

2

5

90

Incorrect motion direction

9

2

5

90

Loading wrong treatment plan

4

2

10

80

Motion data recording stops

4

2

9

72

Failure to progress to next slice

6

2

5

60

Plan incomplete

6

2

5

60

Motion signal loss

9

2

3

54

4.3.2 Failure Modes and Effects Analysis
A systematic evaluation of the process map identified 58 failures. A subset of these
failures is shown in Table 4.3, including the highest ranked failures during treatment delivery.
Values for S, O and D indices were estimated based on the metrics from Table 4.1 and were
used as a guide to determine the highest risks for conformal, motion-synchronized therapy.
All failures with an RPN of 125 or greater and all failures with a severity > 5 were considered
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in this study. In total, 41% of failures were identified to be low risk (RPN = 1 - 75), 33 %
were found to be medium risk (RPN = 76 - 125) and 26 % were found to be high risk (RPN >
125). The highest ranked failures, with an RPN score of 294 were caused by delivery errors
due to patient movement and absolute changes to breathing position. Potential failures that
are common to both static site and moving site treatments were not included in the analysis,
such as miscommunications between physicians and technicians and certain treatment
planning errors.

4.3.3 Fault Tree Analysis
Fault tree analysis was performed to identify sources for the potential errors identified
in the FMEA. Solutions for each error in the FMEA were identified, implemented and tested.
A sample fault tree can be seen in Figure 4.5 for the case of gating magnet failure. Identified
causes of error included human error, such as setting the treatment to the wrong delivery
mode, machine errors, such as noise on the motion signal, and treatment errors, such as
changes to the breathing patterns between image acquisition and treatment. Proposed
solutions for these errors varied for each error type, and included disabling the option for
gating when a 4D plan library is loaded, implementing a noise reduction filter on the motion
signal, and using a monitoring method that compares planned to measured motion and gates
delivery when out of range. Following implementation, the solutions to the identified errors
were tested.
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Figure 4.5. A fault tree analysis for the case of gating failures during motion-synchronized
dose deliveries.
4.3.4 Safety Testing
Solutions were implemented to prevent the identified errors from occurring and each
solution was tested. The implemented permanent corrective actions included noise filtering to
smoothen the respiratory signal, automatic extraction and setting of the number of motion
phases from the treatment plan library, and implementing a checkpoint to prevent the
beginning of delivery until the motion-monitoring system is calibrated and sending a motion
phase. Many errors were identified to be due to mistakes made by the user. Some examples
include setting up the motion-monitoring system in an orientation other than what was used
during planning image acquisition, and not accounting for changes to the tumor position,
relative to isocenter [129]. In these cases, the proposed solutions included performing a
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second check by another clinician or reimaging the patient periodically. Additionally, using a
checklist to check the patient setup before treatment could reduce the incidence of user errors.
4.3.4.1.

Pass Fail Tests

A series of error handling tests were created to test each of the implemented solutions.
These tests included pass-fail tests, where the expected results included either triggering a
temporary interlock, aborting treatment, or entering the “setup error” state. The summary of
pass-fail test results are listed in Table 4.4.
Table 4.4. Summary of pass-fail tests and results.
Error

Expected action

Result

Wrong number of beam spots in plan library

Setup error state

Passed

Missing motion information in plan header

“

“

Particle numbers below or above limitations

“

“

Plan library larger than size limitations

“

“

Motion signal lost

Beam aborted

“

Motion trajectory deviating from expected
trajectory

Temporary gate

“

Scanning magnet failure

Interlock

“

Gating magnet failure

“

“

Delivery of a beam spot skipped

Treatment is halted

“

MMD file recording error

Treatment stops, errors message,
and file dump

“

Treatment stops prematurely

Delivery data recorded

“

Incorrect plan library structure

Beam delivery errors

Motion calibration incomplete before delivery Beam gate activated
starts

“

Treatment setup errors
Wrong motion compensation strategy selected Set automatically from plan

“

Motion system not fully set up or not on

“

Delivery cannot start
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4.3.4.2.

Daily, Monthly, Annual QA

QA tests were proposed for identifying errors in the functionality of the motionsynchronized delivery components. These tests are summarized in Table 4.2. QA setups were
chosen that are available or are similar to those found in ion therapy centers. Delivered
profiles were analyzed for uniformity, agreement with the treatment plan, and for beam
reproducibility, the uniformity index and gamma index analysis were chosen as analysis
metrics.
Delivery uniformity with motion-compensation was determined by assessing a square
profile for a single energy of 240 MeV/u, delivered with motion-compensation, to a
radiochromic film. HI for the static and 10 phase compensation deliveries were 95.3 % and
94.8 %, respectively. The spot position accuracy was found to be within ± 0.5 mm from the
expected position. The beam spot shape was determined through a measurement of the
FWHM in the X- and Y- directions, where the X-direction was the direction of motion. For
static deliveries, this was found to be 3.9 mm and 3.4 mm, respectively, and for the 10 phase
deliveries, this was found to be 4.7 mm and 3.3 mm, respectively. The observed broadening
of the beam in motion direction is an indication of the residual motion both within and
between the motion phases, and spot size increases of up to ± 0.5 mm were tolerated.
The increased time to perform the QA tests was measured and compared to static QA alone.
For the current clinical QA procedures, setup and irradiation time was found to be 5 minutes
and 3 minutes, respectively, and for the motion compensation QA, the setup and irradiation
time was found to be 5 minutes and 10 minutes, respectively. The estimated increase in QApersonnel time for a facility with three treatment rooms is 3 × 7 = 21 minutes, based on
current QA methods and experience.
Annual QA tests included measuring 3D uniformity in a homogeneous and
heterogeneous phantom. The static cube delivery measured a homogeneity of ± 1.2 % and the
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motion compensated delivery measured a homogeneity of ± 3.5 %. The static cube delivery
of 10 Gy, through the heterogeneous phantom, measured a homogeneity of ± 2.1 % and the
motion compensated delivery measured a homogeneity of ± 2.3 %.

Figure 4.6. a) Correlation of motion position to the measured signal of the motion-monitoring
device (an optical distance laser sensor) for a step-wise motion pattern. The motion positions,
in mm, (red) are uploaded onto the linear stage as a motion file and used to move the linear
stage. The motion-monitoring device then records the relative displacement (blue) as an
analog signal. The left and right portions of the motion signal show where the motionmonitoring device is out of signal range. b) A plot of position accuracy between the optical
distance laser signal (in arbitrary units) and the linear stage position (in mm).
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The basic functions and accuracy of the motion-monitoring equipment were also
determined. The measured motion was within ± 0.5 mm for all steps within the measurement
range of -30 mm to 20 mm, as seen in Figure 6a. The agreement between the programmed
linear stage positions and measured positions from the distance sensor are seen in Figure 6b,
where the linear relationship indicates a high degree of measurement accuracy.
4.3.4.3.

Patient Specific QA Results

Patient plan verification tests were performed to compare the measured accuracy of the
delivered 4D plan libraries. Patient verification deliveries were all found to be within clinical
requirements; however, the measurement resolution varied for each approach. Results are
summarized in Table 4.5. The small-sized IC measurements were found to be within ± 2.4 %
and ± 8.9 % of the prescription dose for static deliveries and 10 phase motion compensation
deliveries, respectively, where ± 5% is ideal, but due to residual motion, ± 10 % was
considered acceptable at this stage; however, higher precision may be necessary before
clinical use. The measurements at three depths, with an ionization chamber array detector
were assessed using the gamma index analysis. As only the distal measurement did not meet
the pass criteria, log file analysis was performed to verify delivery quality. Pass rates
(Pearson correlation score) for the motion-compensated delivery were found to be 91.6 %
(0.9901), 98.6 % (0.9954), 90.9% (0.9971) for distal, middle and proximal profiles,
respectively. The average gamma index pass rates for the film stacks were 92.4 %, and 90.4
% for conventional 4D optimized and robust 4D optimized deliveries, respectively. The
average pass rate for the static delivery was 92.2 %. The homogeneity for robustly optimized
and conventionally optimized 10 phase motion compensated deliveries was 90.6 % and 92.4
%, respectively. Delivered dose data (DDD) log files were reconstructed and compared to
planning simulations. The gamma pass rates were found to be 99.4 % and 96.0 % for static
and motion-compensated deliveries, respectively. The measured motion signals were used to
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reconstruct the delivered beam spot position. The comparability of the data for each setup
was limited by the lack of direct correlation between analysis methods [50]. The small-sized
IC and film stack phantoms were found to have a relatively fast setup and execution. Due to
the limited number of detectors, small-sized IC measurements provided less information in
cases where results were nearly passing. In those cases, DDD dose reconstructions were
necessary to determine the dose distributions. 2D dose measurements with the IC array
detector took multiple times longer to deliver than the film stack and small-sized IC
measurements, due to the multiple measurements at varying depths.
Each PSQA method was also assessed for the ability to detect motion-specific planning
and setup errors. Errors in positioning and orientation of the motion-monitoring system were
visible for all PSQA methods, but were least apparent in the film stack deliveries. Selection
of the wrong number of motion phases were only visible in log file reconstruction and films,
but had little impact on the delivery results. Delivering a few beam spots to the wrong
positions, not delivering a few beam spots and using the wrong motion file during planning
were both only visible in the log file reconstructions, but there were no measurable changes
to the treatment delivery quality. Finally, selecting the incorrect motion compensation
strategy was visible on film stack images and IC detector array measurements but was not
immediately clear without log file reconstructions. Log file reconstructions were quicker than
other methods, due to requiring no phantom setup time. Likewise, log file analysis, and to
some extent, film analysis, did not require precise positioning. IC array detector
measurements took nearly three times as long as small-sized IC measurements, but provided
a higher number of measurement points. In both cases, measurement analysis programs are
available to assess plan accuracy. Films require additional time for digitizing and show a nonlinear dose response. Calibrating the dose response of a film requires considerable effort
before it can be used for QA measurements.
87

Table 4.5. Summary of patient specific quality assurance results for four measurements.
These measurements included calculating 3D dose measurement agreement with 12 smallsized ionization chambers (IC), and calculating gamma index analysis pass rates for
comparisons between log file reconstructions and treatment plans as well as IC array detector
measurements. Acceptable criteria and analysis results are summarized.
QA test

Metric (pass criteria)

Static results

Pinpoints
Log files (planned
to reconstructed)
Film stacks

Dose deviation (± 5 %)
Gamma index analysis (> 90
%)
Gamma index analysis (> 90
%)
IC detector to log
Gamma index
Distal
file reconstructions analysis (> 90
%)
Middle
proximal
4.4.

± 2.4 %
99.4 %

Motion
mitigation
results
± 8.9 %
96.0 %

92.4 %

90.4 %

84.1 % (0.9883)

91.6 %
(0.9901)
98.6 %
(0.9954)
90.9% (0.9971)

100.0 % (0.9947)
99.4 % (0.9983)

Discussion
We have designed and tested a prospective risk analysis strategy for the motion-

synchronized dose delivery system, developed for scanned ion beam therapy of moving
targets. We created this strategy specifically to assess the safety of the motion mitigation
portion of the DDS for its eventual use in the clinic. Additionally, we have implemented and
tested solutions for possible errors related to motion mitigation. The major finding of this
study is that we have identified the sources of and solutions to major errors with a
comprehensive risk assessment strategy. We also obtained pre-clinical test results that
suggest the clinical reliability in motion-synchronized dose delivery. The results of this study
have determined that the proposed safety assessment tests can be utilized at ion therapy
centers, which operate with the modular M-DDS.
The implication of this study is that the described comprehensive risk analysis
strategy and proposed tests can serve as an example during initial safety, commissioning, and
QA tests leading to implementation of the M-DDS into clinical use. This assessment is part of
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a larger effort to confirm and maintain the clinical safety of the M-DDS from the design stage
through clinical implementation. The M-DDS has been implemented following good
manufacturing practices, including testing at several stages and maintaining extensive
documentation. The described preliminary safety tests suggest that the M-DDS is safe,
reliable, and ready for additional tests, leading to eventually treating patients. Further, the
proposed error tests and QA tests could be performed within clinically reasonable
timeframes. The safety tests are not the final solution for commissioning and QA procedures
within the clinic, but rather are an example of a general safety strategy for the M-DDS, which
can be modified and extended to meet the specific needs of a particular clinic. Full
acceptance testing and commissioning will be performed before re-implementing the
modified DDS into the clinic.
This is the first implementation of a comprehensive, prospective safety assessment for
pre-clinical testing of a motion-synchronized dose delivery system. The results of this study
are coherent with the recommendations found in the TG-100 and other AAPM reports [92,
96, 101, 103, 130]. All plan verification and QA tests were within clinical specifications. Log
file analysis provided the additional benefit of recognizing individual beam spot errors and
indicating other errors during treatment preparation that could otherwise be unnoticed and
should be performed alone or along with regular plan verification.
Several studies have applied the safety assessment protocols presented in TG-100 to
ion therapy [111, 131]. To our knowledge, no studies have been performed to apply this
approach to new technologies in ion therapy, including motion mitigation systems.
Additionally, several studies have assessed the practicality of QA procedures. One study, by
Hara et al. [86], describes a plan verification procedure for moving tumors. This strategy
involves delivering patient plans to a 2D IC at three depths, and performing gamma analysis
on each measurement. This study also concluded that this procedure is a beneficial QA
89

procedure for moving tumors. Another study [132] described the process of plan verification
with small-sized IC deliveries. The procedure and phantoms were modified in our study for
motion compensation. Further, Matter et al. [133] investigated the capabilities of various plan
verification procedures to ensure the integrity of treatment plans under a variety of planning
errors. Of the measured errors, two cases were relevant considerations for motionsynchronized deliveries with the M-DDS: the ‘all spots shifted randomly’ case, and the
‘increase in spot weights’ case. In particular, residual motion within a motion phase can be as
high as 1-2 mm, and is accounted for in planning margins. In contrast, small increases in spot
weights may be possible when the beam is frequently gated or when there are frequent jumps
in the scan position due to non-optimally created plans can result in non-trivial increases to
the integral dose. As such, we conclude that log file analysis could provide a supplement to
plan verification measurements. This study did not consider failures associated with using
real-time imaging to monitor target motion. This is a vital part of motion-mitigation and will
be investigated in future studies. Though a variety of imaging techniques and motion
monitoring devices can be integrated with the M-DDS, additional risk analysis must be
performed to identify and mitigate for failures associated with these devices.
Our study has several strengths. One is that this method is based on established
methods (e.g., FMEA, FTA) that have been applied in clinics worldwide. It can be extended
to any modular device with integrated motion mitigation strategies. Yet, it allows for
identifying errors that may specifically occur when using motion synchronized delivery
devices. Further, the strategy uses the official risk assessment proposed by the AAPM, can be
applied to any motion-synchronized dose delivery implementation, and to any clinic that
integrates the described M-DDS to their treatment systems. This strategy is a well-developed,
well-known, and comprehensive risk analysis strategy. Though clinic-specific modifications
will need to be made, the described approach can provide insight into potential
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complications, which could arise with the M-DDS. Finally, the presented quality assurance
tests were designed with phantoms that are regularly found in proton and ion therapy clinics.
These tests were performed at an ion therapy center (CNAO) under clinical conditions, with
interlocks in place. QA and most PSQA tests were also performed at CNAO and GSI, except
the film stack analysis, which was only performed at GSI.
One limitation of this study is that all safety procedures were tested with a predefined,
1D movement, generated by a motion-phantom. The motion patterns were well known and in
complete agreement between the measured and actual motion. This is not a major limitation,
as the delivery results with irregular motion will be characterized in future studies. Another
limitation of this study is that no high-precision 3D dose distributions could be measured. 3D
gels could potentially provide nearly instantaneous 3D dose distribution information. Gels
produced by Maryanski et al. [134], which are readout with optical CT have recently been
developed for 3D dosimetry of carbon ions. However, this strategy is still in the early stages
of testing and has only been optimized for high doses for carbon ions. Another dosimeter for
high precision 3D dose measurements would be measurements with a 2D IC array detector in
a water tank phantom [135, 136]. Though this strategy automatically provides high-resolution
3D dose information, this strategy requires delivering prohibitively long times for patient
specific QA and assumes no phase dependence for motion-compensated deliveries; therefore,
this method is better suited for beam commissioning. Another limitation of this study is that
no independent dose calculations, such as Monte Carlo (MC) based dose calculations, were
performed. However, this is not a major limitation, as MC dose calculations are typically
time consuming; therefore, they are currently mainly performed to verify dose distributions
when patient QA measurements do not pass. Additionally, the proposed patient verification
methods are example solutions, and each clinic should select their appropriate plan
verification method. Finally, MC performed at CNAO showed that MC simulations are
91

sensitive to input conditions and simplifications to the MC models [137]. Nevertheless, MC
verification of patient plans has been growing in popularity and can serve as a powerful tool
for independent dose calculation on well-characterized data sets.
The M-DDS is substantially complete and the current version has been transferred
back to CNAO for use in the research room there. Additional features are still in development
that aim to handle irregular respiratory scenarios and other complications related to
respiration; these will be completed before the M-DDS is implemented for clinical use.
Additionally, interoperability with other centers and full compatibility to DICOM and IHERO standards will be implemented, along with any necessary regulatory approvals for
human use, followed by a full clinical commissioning. Before clinical use, the plan library
structure must also be implemented into commercial treatment planning systems.
4.5.

Conclusion
We have applied a comprehensive safety assessment strategy for the motion-

synchronized portion of the dose delivery system. This work has shown that M-DDS is a
clinically viable motion compensation strategy. The efficacy of possible QA procedures for
motion-synchronized deliveries have been confirmed. Importantly, this strategy is specific to
the motion-synchronized dose delivery system, but not to a specific clinic. Therefore, the
presented methods can be adapted to other facilities using the M-DDS.
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Chapter 5. Dosimetric Validation of a Modular System to Treat Moving
Tumors Using Motion-synchronized Scanned Ion Beams
5.1.

Introduction
Proton and ion therapy provide conformal dose distributions for static targets, and in

the past few decades, have emerged as a formidable alternative to photon therapy. Ion
therapies have mainly been used to treat static tumors, including several in the regions of the
head and neck, cranium, retina, and the spine, with high conformity [43, 138], resulting in
reduced toxicities and tumor recurrence [6]. Conformal treatments have been shown to be
partially effective in reducing complications associated with radiotherapy of moving tumors,
such as non-small cell lung cancer (NSCLC), including pneumonitis and cardiac
complications [139, 140]. However, contemporary ion beam therapies for thoracic tumors
still have high complication rates and low survival rates [141]. Additional unmet clinical
needs include shorter treatment times and streamlined patient-specific quality assurance
procedures. Thus, it is imperative to develop treatment methods that can meet these clinical
needs.
Currently, about two thirds of proton and ion therapy centers use relatively simple
motion mitigation strategies to treat moving tumors, including various combinations of
techniques such as breath hold, beam gating, and internal target volumes (ITV), used with or
without rescanning [116]. These motion mitigation strategies for scanned ion therapy have
successfully eradicated some, but not all, moving tumors, yet treatment complication rates
remain a serious problem [142, 143]. The local failures are largely believed to be caused by
insufficient dose to the tumor and complications are believed to be caused by excessive dose
to surrounding healthy tissues [144]. An obvious approach to overcome these limitations is to
amend treatment planning and dose delivery methods to increase tumor coverage and reduce
dose to normal tissues. To achieve these, improvements are needed to mitigate against range
variations that are induced by moving heterogenous anatomy, including cases where the
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movements of the tumor and surrounding healthy tissue differ from one another. The most
advanced motion mitigation approach currently in clinical use, namely the phase-controlled
rescanning method at the National Institute of Radiological Sciences (NIRS), combines rapid
beam delivery with fluoroscopy-guided beam gating. This requires minimal changes to the
target position during the time where the treatment unit actively delivers beam to the tumor.
With this approach, treatments must be halted if tumor motion changes substantially from the
expected tumor location [145]. The advantage of the gating approach is that it avoids the
technical complexity of motion mitigation, but increases the compliance requirements of
patients, and some patients cannot comply with respiratory requirements. The most
technologically advanced approach, commonly called 4D-optimized tracking, allows the
patient to breath freely and requires the treatment system to modify the trajectories of the
delivered ion beams to follow the moving tumor, using real-time monitoring of the tumor
position. This approach, developed at GSI for more than a decade [14], revealed promising
dosimetric qualities and technical feasibility, but its vast technological complexity required to
compensate anatomical motion has thus far been a major obstacle to its translation to clinical
practice. To overcome these obstacles, Lis et al. [51] developed a technologically
straightforward approach, called multi-phase 4D beam delivery (MP4D), which provides
comparable dosimetric quality to that of beam tracking without the associated complications.
It takes anatomical and tumor motion into account during treatment planning and
subsequently synchronizes the beam delivery in real-time so that it follows the moving tumor.
The MP4D approach was previously characterized for moving targets with promising
preliminary results, but the tests did not attempt to compensate for range changes that occur
in a heterogeneous phantom. To our knowledge, no system with such capabilities has yet
been validated or clinically commissioned.
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The objective of this study was to validate, by measurement and calculation, the
performance of a recently created motion-synchronized dose delivery system (M-DDS) [51],
used to deliver MP4D treatments. In particular, we validated, for the first time, the ability of
the M-DDS to compensate for tumor motion in the presence of anatomical, motion-induced
range changes. Libraries of 4D-optimized carbon-ion treatment plans were delivered to
phantoms and absorbed dose distributions were measured. The dosimetric quality was
assessed by examination of the dose coverage, conformity, overdose and uniformity. These
quantities were compared for deliveries with a variety of test cases, including those with
stationary and moving tumors, with and without the application of motion synchronization.
5.2.

Materials and Methods
We validated a prototype system to treat moving targets with scanned ion beams. The

overall approach was to synchronize the delivery of the beam to the periodic motion of the
target, to allow for almost continuous delivery of the beam to the moving target. This
capability included compensating for motion in heterogenous anatomy, which would
otherwise cause range over- and under-shoots due to the anatomical, motion-induced range
changes. For the convenience of the reader, we briefly review here the previously reported
methods for motion mitigation with MP4D deliveries [29, 51], the treatment planning system
[145], and the experimental apparatus [51]. We then describe the analysis methods for
assessing the impact of managing organ motion.
5.2.1

Treatment Planning System and Treatment Delivery System
Treatment plans were created with the research treatment planning system developed

at GSI Helmholtzzentrum für Schwerionenforschung GmbH (GSI), called TRiP4D [26]. This
is an extension of TRiP98 [76, 77], which takes into account changes in patient anatomy
caused by respiratory motion. Several previously established planning strategies were used,
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including conventional- and robust 4D optimization and conventional- and robust 3D
optimization (these are each explained below). To create a 4D treatment plan, a 3D sub-plan
is created on each of the respiratory motion phases found in a 4DCT image set. The library of
sub-plans is utilized together as a complete, or composite, treatment plan. In this study, we
used two simple phantoms to represent the human thorax and a moving tumor. We
purposefully selected simple phantoms to facilitate direct comparisons of calculated and
measured dose distributions. These comparisons were essential for validating the dosimetric
performance in test scenarios where the target depth or range varied in time. More
specifically, two types of variations were considered, including constant range variations
(created with a stationary, homogenous wedge), and discrete range variations (created by a
stationary slab containing heterogeneities).
4D treatment plans were created for each phantom. First, 4DCT image sets were
created by shifting a 4/3π 3 × 3 × 2 cm3 ellipsoid target or a 6 × 6 × 4 cm3 cuboid target
contour within a simulated water box phantom. The targets followed a Lujan2-type motion
trajectory [122] that was lateral to the beam axis. To explore the impact of the number of
motion phases on delivery quality, we created 4D plans containing 3, 6 and 10 motion phases.
Sub-plans were optimized to cover the clinical target volume (CTV) in each motion phase
with a fraction of the prescription dose, such that the sum of the sub-plan doses results in the
target receiving the prescription dose. The preceding planning method will be referred to as
4D optimization for brevity. For 3D optimization, 3DCT image sets of the ellipsoid and
cuboid targets were created and used during treatment planning.
Both conventional and robust optimization planning techniques were used. For
conventional optimization, treatment plans were created for CTVs which had 3 mm isotropic
margins, while for robust optimization, margins were calculated from nine uncertainty
scenarios, including range uncertainties and target position shifts, to minimize their
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dosimetric impact. Robust optimization was described by Wolf et al. [146]. Plan libraries
were created for ellipsoid and cuboid target volumes, on 3, 6 and 10 amplitude-based motion
phase 4DCT images and optimized to a homogenous absorbed dose of 3 Gy.
The plan libraries were delivered with the motion-synchronized dose delivery system
(M-DDS) [51], which was created to accelerate research and translation of motion mitigation
strategies in ion therapy. This system was implemented in a research version of the dose
delivery system (DDS) that is used clinically at the National Center for Oncological
Hadrontherapy (CNAO) [25]. It was similarly implemented in the radiotherapy research
facility (Cave M) at GSI [147].
The general approach considers motion of the entire anatomy during treatment
planning. This allows for compensating for the motion of heterogeneous tissue and variable
target depths without the need for real-time modifications to the beam spot delivery positions
during delivery. Instead, the real-time target position is monitored to redirect delivery from
sub-plan to sub-plan, as the target moves to another motion phase. As such, the sub-plans are
delivered as a series of discrete stationary plans. This continues until the entire prescription
dose is delivered. For this study, up to 10 motion phases were considered, corresponding to
the number of phases typically found in a 4DCT for lung cancer patients; however, additional
motion phases can be trivially added if needed. Though the number of motion phases is
discrete, the tumor motion is continuously monitored, and a variety of motion monitoring
devices can be selected.
In this study, we used continuous monitoring of target motion to adapt the delivery
sequence of sub-plans. The 1D target motion was monitored with an optical distance sensor
(OD100—35P840, SICK, Waldkirch, Germany). The signal amplitude was digitized and
analyzed to yield a discrete motion phase. The sub-plan found in the plan library,
corresponding to the detected phase, was then accessed. During beam delivery, the beam
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spots in the sub-plan that corresponded to the detected motion phase were delivered in
sequence until complete, or until another motion phase was detected. When another phase
was detected, the delivery was then redirected to the nearest beam spot within the
corresponding sub-plan and delivery continued as before. Once all of the spots in an isoenergy slice (IES) were delivered for the given sub-plan, the beam was suspended until
delivery was directed to a sub-plan containing yet undelivered spots of the same energy. This
process continued until all beam spots for that IES were delivered, then delivery progressed
to the next IES. For deliveries to static targets (plan libraries with one motion phase), all the
beam spots are delivered in sequence for each IES until all beam spots were delivered.
At the time of this study, the refurbished accelerator system at GSI was only capable
of single-energy deliveries; subsequent work will implement fast and automated switching
between accelerated beam energies to efficiently deliver multiple beam energies. Therefore,
all plans were delivered with 280 MeV/u carbon ion beams. As a provisional means to
produce multiple beam energies and ranges within a single delivery, we used a binary range
shifter comprised polyethylene (PE) plastic slabs [73]. The beam energies, as specified in
treatment plans, were converted to binary codes that correspond to range shifter settings. The
range shifter settings specify the insertion of a combination of range shifting absorber slabs to
modulate the beam range. Each of the selected binary codes corresponds to a combination of
plastic slabs that allowed for shifting the beam spots longitudinally by as little as 0.1 mm
increments. The range shifter was further described elsewhere [73].
This motion-synchronized dose delivery system was previously implemented into the
M-DDS and preliminary tests were reported [51].
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5.2.2 Experimental Setup
Plan libraries were delivered to two setups, containing a heterogenous phantom, and
moving slabs and dosimeters (Figure 5.1). Treatment deliveries were repeated twice for each
setup: once to irradiate a 2D ionization chamber (IC) array detector (Octavius 1500XDR;
PTW, Freiburg, Germany) and again to a stack of six radiochromic films (EBT3 Gafchromic;
International Specialty Products, Wayne, NJ). The 2D IC array detector was placed within a 5
mm thick PMMA holder, and the film stack comprised 6 films was placed between 10 mm
slabs of PMMA [148]. The 2D IC array detector, containing ICs filled with air at ambient
pressure, was set to integral mode to measure total delivered dose. Both holders were
mounted on top of a motorized linear stage (M-414.2PD; Physik Instrumente (PI) GmbH,
Karlsruhe, Germany), aligned perpendicularly to the beamline. Slabs of water equivalent
plastic, corresponding to 56.7 mm water-equivalent thickness (WET) were placed in front of
these holders, on the linear stage. The linear stage was programmed to move with a 20 mm,
uni-axial Lujan2-type respiratory motion-like pattern [122], and the motion was monitored in
real time with an optical distance laser sensor [51, 149].

Figure 5.1. Setups for testing motion compensation through heterogenous targets. A
combination of four setups were used with either the wedge or density phantom and where
measurements were made with either an IC array detector or film stack. A top view of the
wedge-shaped phantom (left) and slab phantom with density heterogeneities (right) are
shown, placed in front of a periodically moving linear stage. For all setups, the dosimeter was
placed behind a set of plastic slabs. Isocenter is marked with a red circle and the linear stage
movement is indicated with a red arrow.
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Both setups contained a range modifying phantom. These included a wedge-shaped
piece of PMMA (‘wedge phantom’) and a rectangular shaped piece of PMMA (‘density
phantom’) with three air cavities (Figure 5.1). These were used to test uniform, gradual
changes to the thickness proximal to the target, and discrete gradients from air gaps
respectively. The wedge phantom was 100 × 70 × 128 mm3, with a lateral slope of 0.3
mm/mm. The density phantom was a 160 × 109.9 × 30 mm3 block of PMMA with 15.8, 12.0,
and 8.1 mm diameter cylindrical air gaps. In both cases, the wedge and density phantoms
remained stationary and were placed in front of the detector and water-equivalent plastic
slabs, which were placed on top of the moving linear stage. The density phantom induced
range changes of 5.5 to 18.4 mm and the wedge phantom induced a maximum range gradient
of 8.8 mm/mm. In addition to the MP4D deliveries, 3D optimized plans were delivered to
moving targets, without motion mitigation, to assess the dosimetric impact of motion
interplay effects. Similarly, 3D-optimized plans were delivered to static targets to determine
the reference dosimetric performance of the treatment delivery system.
5.2.3 Data Analysis
The dosimetric quality of deliveries through the multiple range phantoms was
analyzed by reconstructing beam monitoring data from treatment delivery log files of the MDDS. The dose delivery data log files were reconstructed on the 4DCT images containing a
simulated water-box phantom. The dose delivery data log files and motion monitoring data
log files, from the motion monitoring system [51], were parsed and reformatted into the
TRiP4D treatment plan format. TRiP4D was then used to calculate (reconstruct) the delivered
dose distributions from the reformatted files. Virtual target volumes were created within each
water-box phantom to calculate the dose distributions on. We then compared the
reconstructed, planned and measured dose distributions. The dosimetric quality metrics we
selected to assess motion management included uniformity, conformity, dose coverage and
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overdose. Each of these metrics were calculated from dose volume histogram (DVH) data
from planned and delivered dose reconstructions. Conformity number is
𝐶𝑁 =

𝑉𝑇,𝑝
𝑉𝑇

×

𝑉𝑇,𝑝
𝑉𝑝

(1)

where VT,p is the portion of the planning target volume (PTV) that receives a dose that is
greater than or equal to the prescribed dose, Dp, VT is the PTV, and Vp is the volume that
receives a dose that is greater than or equal to Dp [36]. A CN value of 100 % is ideal and,
while there is no threshold for an acceptable CN, we considered > 60 % to be acceptable.
Homogeneity (HI), which is a measure of delivery uniformity, is
𝐻𝐼 = 𝐷5 − 𝐷95

(2)

where D5 and D95 are the percentages of the prescription dose, Dp = 3 Gy, which are
delivered to 5 % and 95 % of the tumor volume, respectively [150]. An HI of 0 % is ideal and
< 5 % is considered acceptable [35]. Tumor dose coverage, which is the percentage volume
of the PTV that received at least 95 % of the Dp, is represented by V95. A V95 of 95 % is
considered clinically acceptable. Overdose, denoted by V107, is the percentage of the PTV that
receives over 107 % of the prescription dose. Zero overdose is ideal. The acceptable ranges
for these metrics were selected for the purposes of this study.
Each measured dose distribution was compared to the corresponding planned dose
distribution and reconstructed dose distribution. The 3D generalized gamma index analysis
[151], was used to compare the distributions, including, to quantify the degree of agreement
between each pair of dose distributions. Pass criteria of 3 % dose difference and 3 mm
distance to agreement were applied in all cases. Pass rates of > 90 % were considered
acceptable. The purpose of comparing measured and reconstructed dose distributions was to
validate the accuracy of the dose reconstruction method. The purpose of comparing measured
and planned dose distributions was to determine the amount of unintended delivered dose
during beam gating and spill pauses.
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We performed limited quality assurance (QA) on the beam output prior to dosimetry
measurements. The QA comprised relative dosimetry, using the methods described by Luoni
et al. [152]. Specifically, the constancy of the beam output (relative absorbed dose) was
measured with a farmer-type ionization chamber (PTW 30010 Farmer Chamber; PTW,
Freiburg, Germany), placed at isocenter. The farmer chamber was inserted into a 30 × 30 × 1
cm3 water-equivalent plastic holder slab, with a water-equivalent point of measurement at 5
mm depth. A 5 × 5 cm2 square field of 2 Gy absorbed dose was delivered with 280 MeV/u
carbon ion beams without range modulation. Each measurement was repeated three times.
The same field was delivered to a film at 5 mm depth to measure field homogeneity. This QA
approach was selected because it is well established, fast and because beamtime for QA
procedures was severely limited at the time of this study.
We defined reference conditions to facilitate calibrations of two dosimeters (a 2D IC
array detector and radiochromic films). The reference conditions comprise three major
elements, namely, a reference radiation field, a reference phantom, and a reference
measurement location. The reference radiation field comprised a 280 MeV/u carbon ion beam
without range modulation and with an incident beam spot size of 6.7 mm full-width half
maximum, delivered to a measurement depth of 5 mm, at isocenter.
We calibrated the 2D IC array detector and film to absorbed dose under reference
conditions. The calibrations of these dosimeters were based on measurements of their
responses to irradiations of known absorbed dose. The known absorbed dose was determined
from dose reconstructions, which were previously calibrated and are described elsewhere
[145]. We simultaneously calibrated the IC array detector and films. The detector was
positioned at isocenter, inside of a 31 × 40 × 4 cm3 box-like holder with 5 mm waterequivalent thick walls. A film was taped directly in front of the 2D IC array detector, inside
the holder. A calibration plan was delivered that comprised eight 30 × 30 mm2 square fields,
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ranging in fluences from 5 × 104 to 1 × 107 particles/ mm2, corresponding to absorbed doses
of 0.1 to 9.9 Gy at 1 cm depth, in the plateau region. The initial beam energy was 280 MeV/u,
and no additional range modulation was introduced. This interval of absorbed dose values
was selected to encompass the dynamic range anticipated for the clinical deliveries and to
remain within the dynamic range of optical densities for radiochromic films.
We used an established formalism to calibrate the IC array detector [51, 148, 153].
These are briefly reviewed here for the convenience of the reader. The IC array detector was
calibrated to absorbed dose to water under reference conditions. Measured absorbed dose is
given by
𝐷𝐼𝐶 = 𝑀 × 𝐶 × 𝑘𝑄

(3)

where M is the measured response (corrected for leakage, temperature, and pressure) and C is
the calibration coefficient under reference conditions, kQ corrects for the effects of the
difference between the reference conditions and the non-reference conditions. We confirmed
the stability of the previously determined value of C = 1.2 Gy per unit of measured response,
following methods similar to those described by Stelljes et al. [154]. The effects of nonreference conditions were negligible and kQ was approximated as unit value. The absolute
absorbed dose values, at the same locations as the ICs and under reference conditions, were
also reconstructed from delivery log files, which allowed us to calculate dosimetric outcomes
from the reconstructions.
We used radiochromic films to simultaneously measure relative 2D absorbed dose
distributions under reference and non-reference conditions. Films allowed for faster data
acquisition at multiple depths during the limited beamtime available. They also provided the
high spatial resolution needed to measure dose distributions distal to the wedge and density
phantoms. We used methods similar to those of Yonai et al. [155] for calibrating the film
response to relative absorbed dose, which is briefly reviewed here for the convenience of the
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reader. First, the treatment planning system was used to create a calibration plan under
reference conditions, described above. The calibration plan was delivered to the radiochromic
film, in the geometry described above. The exposed films aged for one day, then were
digitized (DosimetryPro Advantage Red; VIDAR Systems Corporation, Herndon, VA, USA)
using a 16-bit sampling and 300 dots per inch resolution. The net optical density of the
scanned film was determined by
𝑂𝐷𝑛𝑒𝑡 = 𝑂𝐷𝑚 − 𝑂𝐷𝑏𝑘𝑔

(4)

where ODm is the measured (scanned) optical density, and ODbkg is the background optical
density scanned in an unirradiated area on each film. The ODnet was determined in the central
region of each square field in the calibration film. The known absorbed dose values at the
center of each square field, Dfilm, were fit to eight measured ODnet values according to
𝐷𝑓𝑖𝑙𝑚 = 𝐷𝑓𝑖𝑙𝑚,𝑢𝑛𝑐𝑜𝑟𝑟 × 𝑘𝑄,𝑓𝑖𝑙𝑚

(5)

where Dfilm,uncorr is the uncorrected, measured absorbed dose from films, and kQ, film is a
correction factor for changes in the film response due to changes in beam quality at nonreference conditions. The uncorrected absorbed dose from the film under reference or nonreference conditions is given by
𝐷𝑓𝑖𝑙𝑚,𝑢𝑛𝑐𝑜𝑟𝑟 = (𝑎 × 𝑂𝐷𝑛𝑒𝑡 + 𝑏 × 𝑂𝐷𝑛𝑒𝑡 𝑐 )

(6)

where a, b, and c are empirical calibration fit parameters. A second order polynomial was
selected to take non-linearities in film response due to saturation and non-linearities of the
film scanner into account. By definition, kQ,film took a value of 1 at the reference condition
used for the calibration. The calibration procedure above was performed separately for each
batch of film used. Conceptually, Equation 6 is a generalized form of the product of M × C
given in Equation 3 for ionization chamber dosimetry. The generalized form is necessary
because the film’s response exhibits a nonlinear dependence on ODnet (i.e., 𝑏 × 𝑂𝐷𝑛𝑒𝑡 𝑐 ) in
addition to a linear dependence (i.e., 𝑎 × 𝑂𝐷𝑛𝑒𝑡 ).
104

In addition to calibrating the film to respond linearly with absorbed dose under
reference conditions, it was also necessary to correct the film’s absorbed dose response to be
independent of beam quality at depths of measurement other than at the reference depth, do.
Under non-reference conditions, the value of the correction factor kQ,film corrected for changes
in the film response due to quenching, which depends on beam quality, as specified by the
beam’s linear energy transfer. We determined kQ,film values as a function of average linear
̅̅̅̅̅) using methods modified from Yonai et al. [155], given as
energy transfer (𝐿𝐸𝑇
̅̅̅̅̅) =
𝑘𝑄,𝑓𝑖𝑙𝑚 (𝐿𝐸𝑇

̅̅̅̅̅)
𝐷(𝐿𝐸𝑇
̅̅̅̅̅)
𝐷𝑓𝑖𝑙𝑚,𝑛 (𝐿𝐸𝑇

(7)

̅̅̅̅̅) is the absorbed dose that must be delivered (𝐿𝐸𝑇
̅̅̅̅̅) to obtain the same
where 𝐷𝑓𝑖𝑚,𝑛 (𝐿𝐸𝑇
̅̅̅̅̅) and the known value of 𝐷(𝐿𝐸𝑇
̅̅̅̅̅)
value of ODnet measured at reference conditions. (𝐿𝐸𝑇
̅̅̅̅̅) is the absorbedwere calculated by the TPS using dose reconstructions. The quantity (𝐿𝐸𝑇
dose-weighted average of the LET of all charged particles present at a position (x, y) in
̅̅̅̅̅)corresponds to a factor that is called relative efficiency
film n. The function 𝑘𝑄,𝑓𝑖𝑙𝑚 (𝐿𝐸𝑇
elsewhere [155, 156]. The values of kq,film were determined from one delivery of the
calibration plan in which the entire phantom assembly was stationary.
The calibration and corrections embodied in Eqs. 4-6 were applied to all film
measurements of absorbed dose from other beam deliveries, e.g., those to confirm the
̅̅̅̅̅) values
accuracy of the dose reconstruction method (Section 5.2.1). For all deliveries, (𝐿𝐸𝑇
were obtained from the TPS at locations in the phantom corresponding to the measurement
point of interest in the film.
5.3.

Results
Figure 5.2 reveals that the reconstructed dose distributions agree well with the

corresponding dose distributions obtained from measurements with film. This result
confirms the suitability of the method for reconstructing dose distribution for the main
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purpose of this study, which is to assess the quality of dose distributions delivered by various
techniques. We defer discussion of the results on confirming of the reconstruction methods
until later in this section.

Figure 5.2. Comparison of film measurements (top row) to dose reconstructions (middle row)
and 2D ionization chamber array detector measurements to dose reconstructions (bottom
row). The top row shows the films from a film stack for a multi-phase 4D irradiation using 10
motion phases to the wedge phantom with 20 mm uniaxial motion. Films are ordered left to
right with increasing depth in the density phantom. The depth increment between films is
approximately 11 mm water-equivalent thickness. The corresponding dose reconstructions
for the same delivery are shown in the middle row. The bottom row shows measured
absorbed dose values (values inside of small white squares) overlaid on reconstructed
absorbed dose distributions (values outside of the small white squares). The dose
distributions are distal to the density phantom (see Figure 1). Distributions are from four
delivery techniques: static target, moving target without motion compensation (interplay),
and moving target with multi-phase 4D motion compensation. Multi-phase 4D deliveries are
shown using 3, 6, and 10 motion phases in the treatment plan libraries.
We assessed the dosimetric quality of deliveries through the wedge and the density
phantoms. Measured absorbed dose distributions were compared to the corresponding dose
distributions from reconstructions and treatment plans. Figure 5.2 plots the absorbed dose
distributions for these deliveries, including those with a static target, moving target without
motion compensation (revealing the extent of interplay), and moving target with the multiphase 4D approach (revealing the effectiveness of motion mitigation).
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Specifically, dosimetric quality was assessed with four metrics: conformity,
homogeneity, coverage, and overdose (Figure 5.3). The major qualitative finding from these
results is that 10-phase MP4D deliveries provided the best overall dosimetric quality. The
major qualitative finding is that 10-phase and 6-phase MP4D deliveries had acceptable
dosimetric quality, while quality metrics for 3-phase MP4D were mixed. Figure 5.2 reveals
that the reconstructed dose distributions agree well with measurements. Acceptable
conformity (CN > 60 %) was obtained in all multi-phase 4D deliveries with 6 and 10 phases.
However, at least 10 motion phases were required to achieve acceptable homogeneity (HI <
5 %) of the absorbed dose in the PTV. Fewer motion phases produced unacceptably large
heterogeneities, due to interplay effects within each motion phase (so-called “residual
motion”). The average HI value for all of the 10-phase MP4D deliveries (both phantom types
and PTV shapes) was 8 %, approaching the criteria of < 5 %, which was achieved for static
deliveries and is considered acceptable for other deliveries. Target coverage was 100 % for
10-phase MP4D deliveries and was > 98 % for 6-phase MP4D deliveries, also approaching
the ideal results of 100 %, which were obtained from deliveries to a static target. These
findings on coverage and heterogeneity are qualitatively supported by dose distributions
plotted in Figure 5.2, which shows that the MP4D approach produces similar results for the
static and 10-phase MP4D deliveries. It was expected that the deliveries using 10 motion
phases would have superior results, since the residual motion was less than that with 6 or 3
motion phases. The increasing homogeneity is also seen in Figure 5.4A, where the range of
average measured absorbed dose values narrow with increasing number of motion phases.
Here, the average absorbed dose was within ± 1.5 % of the prescription dose for MP4D
deliveries. Finally, the 10-phase MP4D approach produced hotspots in the PTV that were <
103 % of the prescribed absorbed dose. Together, these findings suggest that the 10-phase
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MP4D approach provides good dosimetric quality that closely approaches the quality that
was achieved for static-target deliveries.

Figure 5.3. A) Dose coverage (V95), B) conformity (CN), C) overdose (V107), and D)
homogeneity (HI) for static deliveries to stationary targets (static), static deliveries to moving
targets (interplay), and 3-phase, 6-phase and 10-phase multi-phase 4D deliveries to cube and
ellipsoid target volumes, through the wedge and density phantom.
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Figure 5.4. A) Average measured absorbed dose versus delivery technique evaluated using
the density and wedge phantoms. The dashed grey lines delineate the ± 5 % tolerance interval
centered about the prescription absorbed dose of 3 Gy and the bars indicate the spread
measured dose values from each ionization chamber (IC) of the 2D IC array detector in the
planning target volume (PTV) B) Homogeneity (HI) and coverage (V95) for measured versus
reconstructed absorbed dose distributions in the target volume. Dosimetric quality was
calculated in a single iso-energy slice within the PTV and in the entire PTV for each delivery.
All delivery techniques for both phantom types and for both VOIs are plotted. Data points
that fall on the line indicate full agreement of measured and reconstructed HI and V95 values.
The results of MP4D deliveries also yielded important findings regarding over- and
undershoot of the beam range and regarding the inverse interplay effect. Regarding range
effects, absorbed dose distributions from treatment plans and dose reconstructions are shown
in Figure 5.5, which illustrates that static robust optimization created dose distributions with
range over- and undershoots. These are a consequence of taking the large range uncertainties
in low density material of the phantom into account. These range effects manifest distal to the
cavities of the density phantom, near the end of range. The MP4D approach reduced these
range defects as, the dose delivered to these regions were “blurred out” by delivering multiple
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subplans to the target volumes. Regarding the inverse interplay effect, the MP4D approach
exhibited no dose defects from this (Figure 5.5B and 5.5D). The inverse interplay effect is a
serious concern that is associated with the beam tracking delivery approach [26], which can
deliver uniform doses to the target but increases hotspots proximal to the target in healthy
tissue. With the MP4D approach, there were no hotspots in the proximal healthy tissue.
Instead, the lateral extent of the irradiated healthy tissue was broadened by the amplitude of
the target motion. These findings on range defects and inverse interplay further suggest that
MP4D approach can provide high quality deliveries.
Figure 5.2 reveals that the dose reconstruction methods were confirmed by
measurements. In particular, high gamma-index pass rates confirmed the accuracy of the
treatment planning and dose reconstructions in this study. Specifically, we compared dose
distributions from measurements with the IC detector array to those from the corresponding
log file reconstructions (Figure 5.6C) and planned dose distributions (Figure 5.6B) obtained
with moving targets. Average pass rates increased with the number of motion phases, due to
the decreasing residual motion within each motion phase. In all cases, reconstructed dose
distributions agreed well with measured dose distributions (Figure 5.6C), with pass rates
> 90 %, confirming the validity of the dose reconstruction strategy. Gamma index analysis
pass rates were lower for comparisons between planned and measured dose distributions and
only static deliveries and 10-phase MP4D deliveries had pass rates > 90 %.
Similarly, we compared all dose distributions from measurements to reconstructions
of static deliveries (Figure 5.6A). This comparison provided important contextual information
on the magnitude of dose degradations that were caused by target motion occurring within a
motion phase and without motion compensation. Pass rates were < 90 % for comparisons
between static reconstructions and 3 phase MP4D measurements and were < 60 % for
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comparisons between static reconstructions and interplay deliveries. For planning studies, 10
or more motion phases should be selected.
The total delivery time was calculated from treatment log files. Average total delivery
time for static ellipsoid deliveries was 7.4 min. The relative increase in delivery time for 3phase, 6-phase and 10-phase MP4D deliveries, compared to static deliveries, was 7 %, 17 %,
and 21 %, respectively. This suggests that the MP4D method provides motion-mitigated
deliveries with increases to delivery time that would be well-tolerated by most radiotherapy
patients and compatible to existing patient caseloads.

Figure 5.5. Dose distributions in ellipsoid targets (white ovals) for A) static and B) 10-phase
multi-phase dose deliveries through the wedge phantom and for C) static and D) 10-phase
multi-phase 4D deliveries through the density phantom. Deliveries were reconstructed from
beam delivery log files and motion monitoring log files.
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Figure 5.6. Gamma index analysis pass rates versus beam delivery technique. The pass rates
indicate good agreement between measured absorbed dose distributions and A) reconstructed
absorbed dose distributions for the static delivery, B) planned absorbed dose distributions and
C) reconstructed absorbed dose distributions. Comparisons were made for static deliveries to
stationary targets (static), static deliveries to moving targets (interplay), and multi-phase
deliveries to moving targets with 3 phases, 6 phases, and 10 phases of motion compensation.
Pass rates showed only a weak dependence on phantom type (wedge or density types) and
target shape (cube or ellipsoid types).
5.4.

Discussion
In this study, we validated the dosimetric performance of a novel multi-phase 4D

treatment approach with deliveries to heterogenous phantoms. Specifically, we measured
dosimetric quality of absorbed dose distributions from plan libraries delivered through two
phantoms. The major findings of this study are that the multi-phase 4D (MP4D) dose delivery
approach has acceptable dosimetric quality without introducing inverse interplay effects.
The implication of this study is that MP4D delivery offers a promising new
alternative approach to motion mitigation that provides good dosimetric quality with
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moderate technical complexity. The magnitude of technical complexity is an important
characteristic because it can be a barrier on the path of translation of new technologies to
clinical practice. One such technology, ion beam tracking, entails rapidly modifying planned
beam spot positions to the real-time detected target motion [14, 157]. Consequently, the dose
distributions delivered to a patient cannot be fully confirmed by pre-treatment quality
assurance testing. One type of beam tracking, called 4D-optimized tracking, that precomputes tracking vectors to take anatomical motion from 4DCTs into account during
planning, still exhibited inverse interplay effects and other dose degradations [144]. Our
results suggest that, in the absence of respiratory-motion-related uncertainties (baseline drifts
and changes to the tumor trajectory), clinically acceptable projected therapeutic outcomes
could be achieved without inducing significant hotspots in normal tissues (due to inverse
interplay effects) and the target volume (due to interplay effects). This study provides new
evidence that, when considered with other recent studies [51, 153], suggest it may be feasible
to translate the MP4D approach to clinical practice for both carbon ion and proton beam
treatments. It must be emphasized that the MP4D approach is still in the early stages of
preclinical development and testing; further work is needed to understand how dosimetric
quality is impacted by irregular motion (e.g., baseline drifts and changes to target trajectories
caused by coughs and sneezes). Furthermore, additional research is needed to implement and
evaluate MP4D deliveries with real-time corrective tracking and to compare the MP4D
approach to the 4D-optimized tracking approach.
This work is broadly coherent with previous literature on motion mitigation
approaches for proton and ion therapies. Our findings extend previous preliminary studies
that suggested feasibility of a novel dose delivery system (M-DDS) with integrated motionsynchronization strategies [51, 153, 158]. The MP4D delivery approach poses a
straightforward solution to solve the limitations of 3D tracking and 4D-optimized tracking.
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Previous research at GSI focused on 3D tracking, which required utilizing a fast wedge
system to compensate for motion-induced range changes in real-time, during dose delivery
[157]. Experiments confirmed the range compensation capabilities of this system. The 3D
tracking method, reported by Saito et al. [157], compensated for translational target motion
(only), but beam spot delivery accuracy was still within 5 mm in the lateral and longitudinal
directions. Importantly, this work revealed several complications with potentially important
clinical implications for certain situations. First, the so-called “inverse interplay” effect was
observed, due to differences in motions of the target and the tissue of the entrance channel
[159]. Second, complex motion, such as tumor rotations or deformations could not be fully
compensated for [24]. Finally, for tissues with large heterogeneities, no solution was found to
compensate for motion-induced range changes. 4D-optimized tracking [14], or online
adaptive tracking [160] partially solved the latter problem. However, that 4D tracking
implementation encountered several obstacles, including limitations on the available
hardware speed and memory, and difficulties with synchronizing the system timing. These
issues rendered the system obsolete; it was dismantled and replaced with the motionsynchronized dose delivery system described here and elsewhere [51].
In consideration of the above, the MP4D delivery strategy is generally less complex,
and allows for integrating a variety of treatment planning strategies, such as 4D optimization
[78]. It also accommodates the pre-treatment quality assurance methods similar to those
currently used clinically [161]. Our findings on dosimetric quality are comparable to those of
the system at NIRS. At NIRS, phase-controlled rescanning is used to deliver a full set of
rescans during each gating window [38]. X-ray fluoroscopy detects when the tumor is within
a pre-defined gating window, resulting in accurate treatment to the tumor volume. Typical
results for phase-controlled rescanning were a D95 of over 95 %. Further, clinical outcome
data revealed 2-year survival rates were as high as 82 % for stage 3 lung cancers treated with
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passive ion beams [162]. This method relies on the fast-scanning magnets of the HIMAC
accelerator at NIRS, and slower beam deliveries may not be able to achieve the same results.
In contrast, our approach allows for continuously adapting the delivery sequence to detected
motion, with minimal delivery pauses (a maximum 21 % observed increase to total delivery
time with regular motion), and with minimal residual motion during active beam delivery.
For these reasons, it appears that the MP4D approach may find broader applicability than is
possible with other approaches.
Our study has several strengths. First, we performed all of our measurements with a
modular and portable dose delivery system [51], with integrated solutions for motionsynchronized dose delivery. This is potentially broadly applicable and the M-DDS has
already been demonstrated at multiple centers, including CNAO and GSI. Additionally, as
the motion mitigation portion of the M-DDS is an optional module, the M-DDS requires no
modifications to run either with or without the motion mitigation module. This allows for
implementing the M-DDS in a stepwise manner into existing facilities. We also selected
methods for assessing dosimetric quality that are standard techniques within ion therapy
centers [35, 87]. Further, the range changes were measured by delivering beams to simple
phantoms rather than anthropomorphic phantoms, eliminating additional variables, such as
range uncertainties associated with variations in tissue density, irregular breathing patterns,
and generally more complex range changes that are found in a human anatomy.
Our study had several limitations. At the time of these experiments at GSI, our beam
gating system (based on radiofrequency knockout extraction) could not yet fully gate the
beam [147], and the accelerator system could not yet provide beams of multiple energies in
any one delivery. We discuss both of these limitations in detail here. The inability to
completely gate off the beam results in an insignificant but observable amount of undesired
radiation that only slightly degraded the dose distributions. Specifically, a trend was apparent
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(Figure 5.6) that, as the number of motion phases increased, the average absorbed dose in the
PTV increased as well. The increase was under 0.4 % undesired, additional dose. To
overcome the limitation of having only single energies available, a passive range shifter
system was utilized to modulated beam energy and range. Due to the additional material and
air gaps between the range shifter plates, the beam spot size was strongly dependent on the
amount of range shifter material [161]. This was not a serious limitation, as the range
compensation capabilities could still be demonstrated, and the TRiP4D treatment planning
system was updated to take the correct spot sizes into account in the dose calculation
algorithm. In the next stage, the experiments reported here will be reproduced at CNAO,
where the gating system is tuned for therapy and beam energies of 120 – 400 MeV/u are
available for carbon ions [25]. Another limitation of our study is that we have not tested the
MP4D delivery strategy under more complex respiratory scenarios, including baseline drifts,
changes to breathing amplitude and changes to breathing speed, as well as more extreme
respiratory irregularities, including coughing. These capabilities will be implemented in later
stages, along with improved beam gating, which will be used for handling unforeseen motion,
including coughing. Additionally, we did not use anthropomorphic phantoms for testing
[163]. Geometries that are more complex could further confirm that our motion-synchronized
dose delivery strategy can compensate for range changes and represent scenarios that are
closer to clinical conditions. However, this is not a major limitation, as the performance
results presented in this work provide a more representative example of the extent to which
this delivery strategy can handle two individual range change scenarios. Other studies have
investigated the impact of tumor motion with scanned ion beams using anthropomorphic
phantoms [164]. Further, in later stages, pre-clinical tests will be performed with
anthropomorphic phantoms to characterize the full capabilities of the M-DDS. Finally, we did
not compare the MP4D delivery strategy to other motion handling methods currently used in
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clinics (including the gating methods, and ITV-based deliveries with rescanning [165]) or
study the results of combining motion mitigation strategies. These strategies are studied in
detail elsewhere [165, 166], and delivery degradations in the complete absence of motion
mitigation are shown in this study.
The results presented in this work are part of an ongoing effort to develop motionsynchronized dose delivery strategies at GSI. The motion-synchronized dose delivery system
was previously assessed for safety [161], and the strategy has been validated against other
approaches, including ITV-based deliveries with rescanning [165]. In the future, dose
degradation due to irregular motion and differences between motion during imaging and
during delivery will be quantified, and corrective motion tracking will be implemented to
correct for irregular target motion. The long-term goal is to translate the multi-phase 4D
delivery approach and motion-synchronized dose delivery system into clinical use at CNAO.

5.5.

Conclusion
We validated the dosimetric performance of multi-phase 4D treatment delivery with

scanned ion beams in the presence of multiple beam ranges. The results of this work
demonstrate that it is possible to deliver motion compensated dose distributions in the
presence of anatomical heterogeneities. Notably, the dosimetric performance was achieved
without high technological demands or specialized equipment for mitigating target motion.
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Chapter 6. Treatment Quality and Projected Therapeutic Outcomes for
Multi-phase 4D Dose Deliveries of Treatment Plans with Proton and
Carbon Ion Beams
6.1.

Introduction
Almost 290,000 people in the USA were diagnosed with lung or pancreatic cancer in

2019 [2]. Of these, over 40 % were diagnosed at late stages, and 5-year survivorship was only
15 % for late-stage lung cancer and 8 % for late-stage pancreatic cancer, respectively. Low
survival rates are thought to be due, in part, to difficulty in treating these cancers [144].
Several prospective clinical trials have revealed that, for some cancers, proton and ion beam
therapies reduce the risk for treatment complications compared to photon therapies [43, 167].
Carbon ion and proton therapy have been used to treat deep-seated tumors, moving tumors,
and certain radioresistant tumors [168, 169]. One such radioresistant tumor, early-stage nonsmall cell lung cancer (NSCLC), responds well when treated with stereotactic body radiation
therapy (SBRT). In contrast, late stage NSCLC treatments with photons have not
demonstrated a clinical advantage with dose escalation [170, 171], and severe normal tissue
complications have been seen in over 20 % of cases [172]. Proton and heavier ion beams
have also proven advantageous relative to photon beams in cases where tumors are located
near critical organs [173]. These ion beams have emerged as effective treatments for some
thoracic tumors [174].
Considerable attention has been paid to studying the physical aspects of methods to
treat moving tumors with radiation beams, particularly with photon beams [141, 175], but
also with ion beams [176]. Approaches used in the clinic include immobilization (such as
breath hold [177] and abdominal compression [178]), free breathing with expanded safety
margins (such as the internal target volume (ITV) method [165]), and free breathing with
respiratory-synchronized beam gating [166]. Several well-characterized methods exist for
monitoring respiration, including chest wall motion monitoring, surgically implanted
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radiopaque fiducial marker monitoring [179] and transmission photon imaging techniques
(e.g., fluoroscopy). Even with these approaches, poor clinical outcomes have persisted, likely
due to the dose distributions in the tumor and normal tissue being compromised by tumor
movement [176]. Motion mitigation strategies have not yet fully exploited the technical
aspects of ion therapy, such as sharp gradients and fast pencil beam scanning, to deliver
conformal, motion mitigated beams. To overcome these limitations, two approaches have
emerged: sparing surrounding healthy tissue by minimizing tumor motion during active
delivery and synchronizing beam delivery to tumor motion. To date, only a few prototypes
have explored the latter approach [14, 29, 31, 157]. These early studies revealed promising
preclinical results, but also revealed that the treatment planning and delivery processes were
generally complex, machine specific, and fraught with obstacles on the path to translate them
to clinical practice. Also, knowledge of the differences in dosimetric performance of these
approaches was incomplete.
Further, the literature is replete with studies that explored the superior conformity and
theoretical radiobiological advantages of carbon ion therapy regarding tumor control [180183]. It has also been suggested that conformity is even more important in treatments with
dose escalation [43, 169]. Both radiobiological advantages and conformity are especially
important for late-stage cancers, which are often radioresistant, such as pancreatic tumors and
stage III/IV NSCLC [184]. Recent clinical outcome studies have suggested that conformal
carbon ion therapy results in superior complication-free survival as compared to SBRT for
stage II/III NSCLC [185] and for pancreatic cancers [186], due to the radiobiological
advantages of carbon ion beams, but few clinical studies have been performed on treating
late-stage lung cancers with ion therapy. A recent clinical outcome study at the National
Institute of Radiological Sciences (NIRS) revealed that conformal carbon ion therapy resulted
in nearly 55 % overall survival at two years [187]. These results are promising, but the
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approach appears suitable only for patients with minimal changes to the respiratory motion
trajectory. A recent treatment planning study by Eley et al. [14] revealed that the beam
tracking approach achieved superior dosimetric results, but introduced a high degree of
technical complexity that have hindered efforts to translate the technique to clinical practice.
It was not known if the dosimetric advantages of beam tracking could be obtained with a
simpler approach that is more amenable to clinical translation.
The objective of this pre-clinical study was to assess the characteristics of a motionsynchronized treatment delivery approach, called multi-phase 4D dose delivery (MP4D).
Characteristics considered included dosimetric quality and projected therapeutic outcomes.
For context, compared results from MP4D deliveries to those from unsynchronized
approaches for treating moving tumors. We evaluated MP4D separately for proton beams and
carbon ion beams using image sets from two patients who had previously received
radiotherapy. Calculations were verified against measurements using two motion mitigation
strategies. We assessed plan quality in terms of dose conformity, uniformity, and tumor
coverage, as well as the projected therapeutic outcomes by normal tissue complication
probabilities and tumor control probabilities.
6.2.

Materials and Methods
In this study, we compared the dosimetric quality and projected therapeutic outcomes

achieved by motion compensated approaches with proton and carbon ion beams. These
approaches were ITV-based rescanning and MP4D. For the convenience of the reader, we
briefly review the previously developed methods for motion mitigation [51] and treatment
planning [51] that are used in this study. We also describe the experimental set-up, as well as
metrics used to characterize and compare treatment plans. We compared the relative
performance of these motion mitigation methods in terms of dosimetric quantities and
projected patient outcomes. The results from motion mitigations approaches were compared
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to static deliveries without target motion (to estimate the best achievable results) and
deliveries with target motion and no motion compensation (to estimate the magnitude of dose
degradation caused by anatomical motion).
6.2.1 4D Treatment Planning and Motion Mitigation
We used a research treatment planning system developed at GSI Helmholtzzentrum
für Schwerionenforschung GmbH (GSI), called TRiP4D [145]. This treatment planning
system extends TRiP98 [76, 188] to consider patient motion during the treatment planning
process. Specifically, 4DCT images were utilized to create a conformal, 4D optimized
treatment plan using each motion phase. In this study, two forms of 4D optimized treatment
planning and delivery approaches were used: conformal treatment plan libraries for MP4D
deliveries, and ITV-based plans for rescanned deliveries.
In order to create an MP4D plan, or a library of treatment plans, a 3D sub-plan was
optimized on each of the respiratory motion phases contained in the patient 4DCT image sets.
Each of these sub-plans were initially optimized separately to the entire prescription dose.
Two forms of optimization were used for the MP4D plans: conventional optimization on a
geometrical planning tumor volume (PTV) with 3-mm isotropic margins, or with robust
optimization on a clinical tumor volume (CTV) with ± 3.5 % range margins to incorporate
uncertainties in Hounsfield units in the CT images and 3 mm margins to consider tumor
position uncertainties [78, 146]. 4D optimization involved using a cost function to create a
uniform dose distribution on the PTV to at least 95 % of the prescription dose in the entire
plan library, while minimizing the dose to surrounding organs at risk (OAR). The
optimization incorporated information about temporal anatomy changes due to respiratory
motion and included margins for range uncertainty in the treatment plan. After optimization,
the number of particles in each beam spot was scaled by a weighting factor, such that the total
absorbed dose of the plan library was equal to the prescribed dose [146]. The library of
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optimized and weighted sub-plans was then utilized together as a single MP4D treatment
plan.
We note that for simplicity and clarity, we simplified the treatment planning methods
by assuming a generic relative biologic effectiveness (RBE) of unit value for all tissue and
endpoints. The higher RBE of carbon beams was implicitly taken into account by taking into
account α/β values for the tumor, heart and lung. This approximation is discussed later in the
manuscript.
A similar process was utilized to create ITV-based treatment plans. 3D sub-plans were
optimized simultaneously on each of the motion phases found on the patient 4DCT image
sets [78]. An ITV was created which encompassed to entire tumor trajectory. Both
conventionally and robustly optimized plans were created with 15 rescans to mitigate
heterogeneities due to tumor motion [189]. Additionally, plans were created for deliveries to
static PTVs and moving PTVs without motion compensation by optimizing the entire
treatment plan on the reference motion phase of the 4DCT images. This study was designed
as a proof of principle, and is not representative of actual patient treatment. Two
simplifications were afforded for this study to facilitate direct comparisons of various
treatment strategies. Specifically, each treatment plan contained only one beam orientation,
and dose constraints were not applied to OARs during the treatment planning optimization
process.
The MP4D motion mitigation delivery strategy was to synchronize the delivery of
various 4D optimized treatment plans to the motion of a moving target. To accomplish this,
we used a recently developed motion-synchronized dose delivery system (M-DDS), as
described by Lis et al. [51] and reviewed here for the convenience of the reader. The M-DDS
extends the dose delivery system (DDS), which was originally developed and is currently
used clinically at the National Center for Oncological Hadrontherapy (CNAO, Pavia Italy), in
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two major ways, namely, to provide integrated motion mitigation capabilities and to contain
the necessary modularity to operate at multiple accelerator facilities. Specifically, the M-DDS
is available for research studies at the radiotherapy research beamlines at CNAO and at GSI
[147]. The system is embodied by a portable crate that contains eight electronics modules.
Each module is a field programmable gate array (FPGA) that is dedicated to controlling one
or more dose-delivery functions. These functions include transfer of beam delivery data
(loading and sending of delivery information), monitoring beam intensity, monitoring beam
spot position, controlling magnetic scanning of the beam, monitoring target motion and
synchronizing it with beam delivery, interfacing with the accelerator timing system, initiation
and termination of the irradiation, and various safety functions [161]. The motion mitigation
features are implemented in two of these modules. The FPGA modules are commercial units
(PCI Extensions for Instrumentation Express (PXIe); National instruments, Austin, Texas).
The hardware and software interfaces to the accelerator control systems were developed in
house [147].
The MP4D approach requires continuous monitoring of the tumor motion in real time.
The continuous motion signal is used to select the corresponding discrete motion phase from
the library of phase-specific treatment plans. The beam spots from the treatment plan
corresponding to the current motion phase are delivered in their planned sequence until a
change in the motion phase is detected. The corresponding treatment plan is then selected,
and beam spots are delivered starting at the location where the delivery was suspended in the
previous plan. This is repeated until all beam spots in the iso-energy slice (IES) are delivered.
The process continues until all IES have been delivered. For deliveries to static targets and
deliveries to moving targets without motion compensation, the treatment plan is delivered in
sequence for all IES.
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We retrospectively created robust 4D optimized and conventional 4D optimized
treatment plans for two patients who had previously received radiation therapy for lung
cancer. We planned and delivered them with proton beams and carbon ion beams using two
motion mitigation methods and compared these deliveries to corresponding static deliveries.
These motion mitigation methods included MP4D and ITV-based deliveries with rescanning.
The former approach has the theoretical advantage of better dosimetric performance, and the
latter has the advantage of greater conceptual and technical simplicity.
The MP4D approach, which has not yet been used clinically, is described above and
elsewhere [29, 51]. The approach to ITV-based rescanning, which has been used previously
in clinical studies, involves creating an ITV from 4DCT images to encompass the tumor
movement and delivering beam spots multiple times. This so-called “layer rescanning” blurs
out the dose heterogeneities due to interplay effects between the scanning beam and the
moving tumor. ITV-based deliveries with carbon ions were rescanned 10, 15 and 20 times to
determine the appropriate number of rescans. 15 rescans were subsequently selected for
deliveries with ITV-based rescanning.
The treatment plans in this study were created from 10 phase 4DCTs of a patient
(patient 1) from the University of Texas MD Anderson Cancer Center in Houston, Texas and
another (patient 2) from the Champalimaud Centre for the Unknown in Lisbon, Portugal.
Patient 1 was a 59-year-old female, diagnosed with T2N2M1 adenocarcinoma and treated
with SBRT. Patient 2 was an 83-year-old male, diagnosed with stage 4 NSCLC and was
treated with single fraction radiotherapy. The tumor volume for patient 1 was 260 cc, located
in the left lower lobe of the lung at 75 mm physical depth in the reference phase. The peakto-peak motion from the 4DCTs was estimated at 22 mm. The tumor volume for patient 2
was 54.0 cc, and was located in the right lower lung lobe, near the chest wall. The peak-topeak motion was estimated to be 19.5 mm. Treatment plans for patient 1 were delivered with
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both carbon ions and protons, and treatment plans for patient 2 were delivered with protons.
Patients with large tumor motion amplitudes were selected to severely test and compare
motion mitigation approaches. That is, neither the selected patients nor the treatment plans
were intended to be representative of typical clinical treatments.
Before dose distribution measurements began, we performed quality assurance
procedures, including relative dosimetry using the methods described by Luoni et al. [152].
Measurements included dose output constancy, and beam spot stability. Dosimetry
procedures are further described by Lis et al. [190]. The detector used in this study was
calibrated according to the protocols described elsewhere [154, 190].
We measured dose distributions using an ionization chamber (IC) array detector
(Octavius 1500 xdr; PTW, Freiburg, Germany). The IC array detector was placed within a 5mm thick polymethylmethacrylate (PMMA) plastic holder and PMMA slabs were placed in
front [51]. Each measurement with the IC array detector was repeated three times, with the IC
array detector placed at three water equivalent depths corresponding to the distal, middle, and
proximal ends of the PTV or ITV: 72 mm, 96 mm, and 110 mm for patient 1, and 95 mm,
107 mm, and 121 mm for patient 2. The phantoms were mounted on top of a computercontrolled motorized linear stage (M-414.2PD; Physik Instrumente (PI) GmbH, Karlsruhe,
Germany), which was programmed to move with a uni-axial projection of the motion from
the patients’ 4DCTs, thus mimicking respiratory motion.
The delivered dose distributions were reconstructed onto a water cube (to verify dose
calculations) and onto the 4DCT images (to project clinical outcomes). The reconstructions
were performed by parsing the delivered dose data (DDD) log files from the M-DDS and
motion information from motion log files [51], which provided information on the position of
each delivered beam spot. The file information was then reformatted into the TRiP4D
treatment plan format. TRiP4D was then used to calculate the absorbed dose distributions of
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the reconstructed treatment plans in water and on the 4DCT images. Measured absorbed dose
distributions were compared with delivery reconstructions in water and planned absorbed
dose distributions in water, and dose reconstructions on the patient 4DCT images were used
to assess dosimetric quality and estimate therapeutic outcomes.
Gamma index analysis was performed to confirm the accuracy of the planned and
reconstructed absorbed dose distributions, both of which were calculated. Data measured
with the IC array detector was compared with planned and reconstructed distributions,
calculated on a water box phantom using a generalized gamma index analysis [151]. Gamma
index pass rates of > 90 % were considered acceptable.
The ideal dosimetric characteristics of successful motion management are high
uniformity, tumor coverage, and conformity, as well as the absence of hotspots. Each of these
were assessed from dose volume histogram (DVH) data derived from dose distributions from
treatment plans or dose reconstructions on the patient 4DCT images. The first of these,
dosimetric uniformity, was assessed with the homogeneity index 𝐻𝐼 = 𝐷5 − 𝐷95 , where D5
and D95 are the percent of the prescription doses that cover 5 % and 95 % of the PTV,
respectively [150]. An HI of 0 % is ideal. Target dose coverage is the relative volume of the
PTV that receives at least 95 % of the prescription dose, and it is represented by V95. A V95 of
100 % is ideal and 95 % is commonly considered clinically sufficient target coverage of the
prescription dose [191]. The extent of hotspots or overdose, V107, is the relative target volume
that receives over 107 % of the prescription dose, and 0 % V107 is ideal. Finally, dose
conformity number (CN) is calculated by 𝐶𝑁 =

𝑉𝑇,𝑝
𝑉𝑇

×

𝑉𝑇,𝑝
𝑉𝑝

, where VT,p is the volume of the

target which receives a dose that is greater than or equal to the prescription dose, VT is the
PTV of the target, and Vp is the volume that receives a dose that is greater than or equal to the
prescription dose [36]. It was used to assess the degree of conformity of the irradiated volume
to the target volume. The ideal value on CN is 100 %, but this is rarely achieved in practice.
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6.2.2 Comparison of Proton and Carbon Ion Treatment Plan Deliveries
We omitted dose constraints on normal tissues during the plan optimization process to
facilitate comparisons between delivery approaches. However, to confirm that the resulting
plan libraries were still clinically realistic, DVHs for lung and heart volumes were compared
to the Quantitative Analyses of Normal Tissue Effects in the Clinic (QUANTEC) dose
criteria [192]. The selected criteria were calculated with the equivalent dose formula [193].
The mean absorbed dose for symptomatic pneumonitis in the lung was < 14.1 Gy for 2.5 Gy
fractions, which is expected to have a 10 % complication rate, and a V30 < 46 % for
pericarditis, which is expected to have a complication rate of < 15 %. Mean doses were
calculated for each structure from the cumulative DVHs of the lung and heart for static,
MP4D deliveries, and ITV rescanned deliveries.
6.2.3 NTCP and TCP Calculations
We estimated, in a rudimentary manner, therapeutic outcomes for each delivery in
order to check if the dosimetric finding are of clinical importance. Outcomes depend, in a
complex way, on treatment factors, including dose, dose rate, irradiated volume, radiation
quality (e.g., particle types and energy distributions), and other factors. They also depend on
host factors, such as sex, age, tissue, endpoint, timepoint, and inter-patient variations in
biologic responses. In this work, simplified the prediction methods for simplicity, brevity,
and to avoid confounding our main (dosimetric) findings with complex biologic uncertainties.
The outcomes were predicted with normal tissue complication probability (NTCP)
and tumor control probability (TCP) calculations [194]. The NTCP values were calculated for
cumulative probabilities at 5 years after treatment for the following complications: lung
pneumonitis and cardiac perfusion or pericardial effusion. TCP calculations estimated the
likelihood of local tumor control (no recurrence) [195]. Ideally, NTCP is 0 % and TCP is
100 %, although this is rarely realized in practice. Several models exist for NTCP and TCP
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calculations, including models that consider non-standard fractionation schemes [196], the
effects of different dose regions [197, 198], and the radiosensitivity of the tissues [199]. For
this study, an updated version of the Lyman Kutcher-Burman (LKB) model was used, which
uses the equivalent uniform dose (EUD) to reduce dose distributions into a single equivalent
dose value. NTCP and TCP calculations for each delivery strategy (MP4D, ITV-based with
15-rescans, and static) were then compared for a relative estimate of the clinical benefit of
each. It must be emphasized that the TCP and NTCP models and calculations in this study
were used to aid the interpretation of dosimetric differences of various motion management
strategies. That is to say, they provide a rudimentary means to assess the potential clinical
importance of the observed physical differences in various deliveries. The calculations are
not intended to provide predictions of clinical outcomes for any other purpose.
The TCP and NTCP for the lung were calculated from differential DVHs (dDVH).
The dDVHs were an output of dose reconstructions. The percentage of the prescription dose
delivered to each voxel of the dDVH was converted to absorbed dose values per voxel
(Gy/mm3) by multiplying the percentage prescription dose by the prescribed absorbed dose
per fraction (fx) to the PTV: 2.5 Gy. The biologically effective dose (BED) [200-202], factors
in the dosimetric impact of the chosen fractionation scheme and of the tissue-specific dose
response, with the 𝛼/𝛽 was calculated on each voxel with a BED calculation [200-202],
𝑑𝑖
𝐵𝐸𝐷𝑖 = 𝑛 × 𝑑𝑖 (1 + 𝛼 )
⁄𝛽

(1)

where n is the number of fractions, di is the absorbed dose in each voxel (Gyα/β/mm3), and
𝛼/𝛽 is dependent on tissue type, particle type and fractionation scheme. The 𝛼/𝛽 ratio is a
quantity that describes a tissue’s cellular response (cell killing or altered tissue function) to
radiation. Low 𝛼/𝛽 ratios are associated with late responding tissues, whereas high 𝛼/𝛽 ratios
are associated with early responding tissues. Values of 𝛼/𝛽 ratios of 4, 2.5 and 12 Gy [192]
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were selected for the lung, heart and NSCLC tumor, respectively, for proton and carbon ion
beams. Uncertainties in 𝛼/𝛽 ratios range from 0.5-2.1 Gy [203], 1.8-5.6 Gy [204], and 12-16
Gy [205], respectively. The variations in RBE wih beam quality (e.g., linear energy transfer)
were omitted for simplicity and clarity. The prescribed absorbed dose to the target volume
was 2.5 Gy / fx. Following Sun et al. [206], we prescribed the number of fractions at 26.
The dose distribution information from the BED-adjusted absorbed dose per voxel
was then reduced to a single equivalent uniform dose value (GyEUBED), called the Equivalent
Uniform Dose (EUD). This equation is a power-law equation
1
𝑎

𝐸𝑈𝐷 = ( ∑ 𝑣𝑖 × 𝐷𝑖 𝑎 )

(2)

𝑖

where vi is the i’th partial volume of the structure that receives a differential BED-adjusted
absorbed dose of Di, and a is an organ specific factor that is derived from clinical data. For
this study, a values of 1, 3 and -10 were used for the lung, heart and NSCLC tumor,
respectively, as reported by Emami et al. [207], Okunieff et al. [208], and with QUANTEC
data [192]. These values were derived from photon therapy. The EUD was then used to
calculate the TCP [209] and NTCP.
TCP was calculated with
𝑇𝐶𝑃 =

1
𝑡𝑐𝑑504 × 𝛾50
1 + 𝐸𝑈𝐷

(3)

where tcd50 is the tumor dose to control 50 % of tumors, and γ50 is a unitless tumor-specific
factor that describes the slope of the dose response curve. For this study, a tcd50 value of 60
Gy and a γ50 of 2 was selected for the NSCLC tumor. Other, more complex TCP models are
available, but for the intents and purposes of this study, simplicity and brevity were favored
in model selection.
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The NTCP for the heart and lung dose were calculated with a serial and parallel
model, respectively. For the lung and heart, the following logistical function [200, 210, 211]
was used:
𝑁𝑇𝐶𝑃 =

1
𝑡𝑑504 × 𝛾50
1 + 𝐸𝑈𝐷

(4)

where td50 is the maximum tolerance dose for a 50 % complication rate within 5 years [207],
and γ50 is a unitless organ-specific parameter that describes the slope of the dose response
curve. Reported values for γ50 are 0.97 – 2 [192, 211], and 0.94 – 3 [200] for the lung and
heart, respectively, and reported values for td50 are 24.5 – 40 Gy [207, 212], and 48 – 57 Gy
for the lung and heart, respectively. For this study, γ50 of 2 and 0.94 were selected for the
lung and heart, respectively [54, 58], and td50 values of 30.8 Gy and 50 Gy were selected for
the lung and heart, respectively [207, 211, 213].

6.3.

Results
We assessed the dosimetric quality of MP4D deliveries with protons and carbon ions

and compared the corresponding results from ITV-rescanned deliveries, static deliveries, and
uncompensated deliveries, using the metrics described in section 6.2.3.
First, we used the generalized gamma index analysis [151] to calculate the agreement
between the IC detector array measurements and planned dose distributions in water. The
purpose of comparing measured and planned dose distributions was to quantify the impact
motion-related dose defects. Figure 6.1 plots gamma index pass rates (and Pearson
correlation score) for static, uncompensated, ITV-based deliveries with 15 rescans, and
MP4D deliveries. Similar analyses were performed for ITV-based deliveries with 10, 15 and
20 rescans, using carbon ions. Pass rates for these deliveries were 100.0 % (Pearson
correlation score of 0.993), 100.0 % (0.993), 80.9 % (0.992), respectively. ITV-based
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deliveries with 15 rescans were selected for further study with proton ions due to faster
delivery times and higher pass rates, relative to deliveries with 20 rescans. Moreover, low
pass rates were found for uncompensated deliveries due to the significant dose
heterogeneities produced by interplay effects in the absence of motion mitigation. The pass
rates for the MP4D deliveries were relatively lower than ITV and static deliveries, as well,
due to incomplete gating, as described further below.
Second, we quantified the agreement between reconstructed and measured dose
distributions using the generalized gamma index analysis. The purpose of comparing
measured and reconstructed dose distributions was to validate the accuracy of the dose
reconstruction method. Pass rates were generally higher for reconstructed and measured dose
distributions than they were for planned and measured dose distributions. The results for
static, uncompensated, and ITV deliveries with 15 rescans, were > 90 % for seven of the
eight cases, indicating a high degree of correlation between reconstructed and measured data,
and results for MP4D deliveries were 96.0 % (0.996). The average pass rates for the MP4D
dose reconstructions were approximately 10.7 % and 1.8 % higher than the gamma index
analysis results for the planned dose distributions for carbon ion and proton dose deliveries,
respectively. This suggests that the differences between planned and delivered dose
distributions were mainly due to an experimental problem of incomplete beam gating through
radiofrequency knockout (RFKO) rather than an inherent limitation of the conformal, MP4D
approach. (The incomplete gating was a performance defect of the delivery system that was
addressed subsequent to the completion of the experimental portions of this study.) This was
confirmed by assessing measured particle counts during incomplete beam gating. This
revealed that incomplete gating increased the delivered particles by up to 9.0 % more than
were called for in the treatment plan.
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Figure 6.1. A summary of gamma index analysis results for multi-phase 4D deliveries (10
phase), ITV-based deliveries with 15 rescans, uncompensated (interplay) and static deliveries
with criteria of 3 % dose difference and 3 mm distance to agreement. Carbon ion deliveries
are represented in red and proton deliveries are represented in blue. Gamma index analysis
results comparing planned dose distributions to measurements are represented as circles,
while results comparing reconstructed log file dose distributions measurements are
represented as triangles.
DVH data was used to calculate four dosimetric quality metrics: conformity number
(CN) and homogeneity index (HI), dose coverage (V95) and overdose (V107) for each delivery.
Results are summarized in Error! Reference source not found. The MP4D approach generally p
rovided favorable outcomes, however, delivery artifacts (with incomplete beam gating)
compromised carbon ion delivery results. The average CN for the MP4D deliveries was
57.3 %, which are more conformal than ITV rescanned (48.7 %) and static deliveries
(53.7 %). V107 results were 0.0 % for rescanned, ITV deliveries and static deliveries. In
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contrast, MP4D deliveries showed V107 values of up to 60 % and 22 % for carbon ions and
protons, respectively, likely due to incomplete beam gating. While this decreased the
dosimetric quality for the MP4D deliveries, the overdose was concentrated in the target, and
the conformity from carbon ion beams was still superior to the conformity of ITV based
rescanned deliveries. Uncompensated deliveries also contained hotspots due to motion
interplay effects. Similarly, HI results for static and rescanned ITV deliveries were, on
average, below 10 %, while MP4D deliveries were as high as 30 % for carbon ion deliveries.
In contrast, MP4D proton deliveries, which were delivered at higher speeds and required less
beam gating, resulted in substantially more favorable values of V107 and HI. The dose
coverage, V95, was within typical clinically acceptable ranges for all deliveries, and average
V95 values were 99.5 ± 0.37 %, 100 ± 0.03 % and 99.5 ± 0.54 %, for MP4D deliveries, static
deliveries, and ITV deliveries with 15 rescans, respectively. These results are summarized in
Figure 6.2. Broadly, this finding reveals that MP4D delivery resulted in the most conformal
dose distributions, with a sharper dose fall off than in the ITV rescanned deliveries but with
hotspots in the target.
6.3.1 Comparison of Proton and Carbon Ions
Delivery quality with carbon ions were compared to that with protons for patient 1 by
assessing DVH data. Doses to two OARs, the heart and the normal tissue of the left (healthy)
lung, were compared for each of the delivery strategies. Representative DVHs for both ions
to the target volume and to the OARs are shown in Figure 6.4, for static deliveries, MP4D
deliveries, and ITV-based deliveries with 15 rescans. In all cases, better dose coverage was
achievable for carbon ions, and, for both motion mitigation strategies, lung sparing was
greater for carbon ion deliveries. Lung and heart doses were highest for ITV deliveries with
15 rescans and lowest for MP4D deliveries. However, for MP4D deliveries with carbon ions,
hotspots due to radiation leakage through the RFKO gating system compromised the dose
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delivery results to the PTV and OARs, resulting in higher doses to regions of the heart.
Carbon ion deliveries also had additional dose to the heart due to the fragmentation tail.
These doses were lower for MP4D deliveries, possibly due to the higher conformity of this
strategy. Coronal and sagittal planes for each delivery are shown in Figure 6.3.

Figure 6.2. Selected delivery quality metrics, from dose-volume histogram data, including a)
dose coverage, V95, b) conformity, CN, the c) overdose, V107, and d) homogeneity, HI, for
carbon (red) and proton (blue) plans, for multi-phase 4D (10 phases) deliveries, ITV-based
deliveries with 15 rescans, uncompensated deliveries (interplay), and static deliveries.
Conventional 4D optimized deliveries are represented as circles and robust 4D optimized
deliveries are represented as triangles.
We assessed the delivery reconstructions for compliance to QUANTEC clinical dose
criteria to the lung and heart for patient 1. MP4D and static deliveries with carbon ions
satisfied the criterion of less than 13 Gy mean dose to the normal tissue of the whole lung, as
the calculated mean doses to were 5.4 Gy, 6.8 Gy, and 3.1 Gy, for static, ITV 15 rescan and
MP4D deliveries, respectively. Proton deliveries also satisfied lung dose criteria in all cases
and mean doses were 7.4 Gy, 8.1 Gy and 4.9 Gy, respectively. The heart criteria were met for
all deliveries, and V30 results were 21.4 %, 22.4 %, and 8.6 % for static, 15 rescan, and MP4D
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deliveries with carbon ions, and 20.9 %, 15.3 % and 9.1 % for static, 15 rescan, and MP4D
deliveries with protons, respectively.

Figure 6.3. Coronal and sagittal planes of dose reconstructions on a 4DCT. Deliveries with a)
carbon ions and b) protons are shown for static deliveries to a stationary target, ITV-based
deliveries with 15 rescans, and 10-phase multi-phase 4D dose deliveries (MP4D).
Carbon ion patient plans were compared with proton patient plans, for MP4D
deliveries, static deliveries, and ITV-based deliveries with 15 rescans with several DVH
metrics, including CN, V95, V107, and HI, as described in section 6.2.2. Results of these
comparisons are summarized in Table 6.1.
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Figure 6.4. Plots of the volume doses to the target volume (green lines), the heart (red
lines) and lung (blue lines) of patient 1 for 2.5 Gy, delivered with carbon ions (represented
a dashed lines) and protons (represented as solid lines) to a) static, b) 10-phase multi-phase
4D deliveries c) 15 rescans ITV, reconstructed from log files (DDD).
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Table 6.1. Table of average result values for dose volume histogram (DVH) metrics and
projected therapeutic outcomes for patients 1 and 2. Static deliveries to a static target, multiphase 4D deliveries (MP4D), and ITV-based rescanning deliveries were made with carbon
ion and proton beams.
DVH
Metric

Patient 1

Delivery
strategie
s

Static

Patient 2

MP4D

ITV rescanned

Static

MP4D

ITV
rescan
ned

Ion

Proton

Carbon

Proton

Carbon

Proton

Carbon

Proton

D95 (%)

98.2

99.4

101.4

99.0

96.2

97.3

99.4

95.5

96.1

V95 (%)

100.0

100.0

100.0

99.1

98.9

98.9

99.8

97.6

97.0

V107 (%)

0.0

0.0

2.9

42.2

0.6

1.0

0.0

0.0

3.3

CN (%)

49.6

53.3

50.8

61.7

48.6

52.4

33.7

36.9

31.7

HI (%)

2.0

1.4

2.1

6.0

3.4

3.3

1.5

3.0

4.2

Heart
NTCP
(%)

13.0
(9.1 15.6)

15.6

7.7 (6.5
- 8.5)

6.9 (6.1 11.5 (9.0
- 7.9)
- 13.5)

12.3
(9.2 15.3)

0.0 (0.0
- 0.0)

0.0 (0.0
- 0.0)

0.0
(0.0 0.0)

Lung
NTCP
(%)

0.3 (0.0 0.0 (0.0
- 0.5)
- 0.0)

0.0 (0.0
- 0.0)

0.0 (0.0
- 0.0)

0.7 (0.1
- 1.6)

0.1 (0.1 0.0 (0.0
- 0.1)
- 0.0)

0.0 (0.0
- 0.0)

0.0
(0.0 0.0)

Tumor
EUD
(GyEUBE
D)

67.1
(67.0 71.5)

68.6
(68.6 68.6)

70.8
(67.6 71.)

73.2
(71.6 75.5)

67.2
(66.8 67.4)

68.9
(68.1 69.1)

67.2
(67.167.3)

66.5
(65.6 67.5)

65.6
(65.3 66.0)

TCP
(%)

71.0
(70.8 80.3)

74.4
(74.4 74.4)

77.8
(76.9 80.4)

82.1
(80.5 82.8)

71.2
(70.1 71.6)

75.1
(74.7 75.6)

71.2
(70.8 71.6)

69.3
(67.2 71.9)

67.1
(66.2 74.1)
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6.3.1.1. NTCP and TCP Calculation Results

NTCP and TCP values were calculated for two patients: patient 1, planned with
protons and carbon ions, and patient 2, planned with protons. Results are summarized in
Table 6.1. For patient 1, 10 phase MP4D deliveries had the most favorable therapeutic
outcomes for TCP calculations and for NTCP calculations of the heart and lungs for
deliveries with proton and carbon ion beams. Notably, heart NTCP values were only 7.7 %
and 6.9 %, respectively, for the MP4D approach, while heart NTCP values were 13.0 % and
15.6 % for static deliveries. Due to the tumor location in patient 2, all delivery results showed
favorable NTCP and TCP results. Uncertainties for several parameters, including a, α/β, γ50,
td50 and tcd50 produced significant uncertainties for NTCP and TCP calculation results [192,
200, 208, 211, 213, 214]. Specifically, variations in γ50 and tcd50 values varied TCP results
for NSCLC tumors from as low as 58 % to as high as 91 % for motion compensated proton
deliveries.
6.4.

Discussion
In this study, we investigated the dosimetric quality and projected therapeutic

outcomes from two approaches to treating moving tumors: multi-phase 4D (MP4D)
deliveries and ITV-based deliveries with rescanning. We delivered patient plans using both
methods, with proton and carbon ions, and demonstrated the new, MP4D approach yielded
superior dosimetric quality compared to other delivery approaches. The major finding of this
work is that the MP4D approach can be effective at mitigating tumor motion, and potentially
reducing the risk of treatment side effects. The specific results of this study suggest that the
higher conformity of MP4D deliveries, combined with the sharper dose falloff of carbon ion
therapy can be maintained when tumor motion is effectively mitigated, resulting in greater
tissue sparing than other approaches. Further, we demonstrated that carbon ions are favorable
to protons for conformal deliveries, as carbon ions result in a steeper dose falloff; however,
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these results only impact organs directly adjacent to the tumor that are not located in the
fragmentation tail. The hotspots seen in this study for carbon ion deliveries were due to
defects in the gating system rather than limitations of the MP4D approach.
The implication of this study is that MP4D deliveries, based on 4D optimized plan
libraries, appears to be a promising approach to achieve the necessary dosimetric quality and
outcomes, compared to other motion mitigation strategies with ion beams. These pre-clinical
results are preliminary in nature and part of a larger effort to develop and validate a modular
M-DDS.
This work is the first reported implementation of a dose delivery system with
integrated capabilities for conformal, MP4D deliveries of scanned ion beams. The results of
this study are comparable to previous work in motion mitigation studies at GSI, and to
delivery results for motion mitigation at the National Institute of Radiological Science
(NIRS). At GSI, planning studies have been performed to predict the dose delivery quality of
motion mitigation strategies, including 4D rescanning (here referred to as MP4D) and beam
tracking [29]. The reported results at GSI were a V95 of 98.5 %, 72.5 %, 99.4 % and 98.5 %
for static, uncompensated, 4D rescanning and tracking plans, respectively. In comparison, we
predicted average values of V95 of 100 %, 98.9 % and 99.1 % for static deliveries, ITV-based
deliveries with 15 rescans, and MP4D deliveries, respectively. As the work by Graeff et al.
[23] was a treatment planning study, additional uncertainties, including residual motion and
noisy particle delivery rates were not factored in. At NIRS, phase-controlled rescanning is
used along with fluoroscopically gated deliveries. Typical dosimetric quality results listed by
Mori, et al. [215] were D95 > 95 %. Reported limitations included the inability to modify
delivery in response to significant changes to the tumor baseline. The NTCP and TCP
calculations used in this work are similar to Gay et al. [200] and Niemierko et al. [216]. To
our knowledge, no NTCP and TCP assessments have been performed for comparing motion
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mitigation strategies. This study has been performed with absorbed dose calculations rather
than biological dose calculations, due to the persistence of high uncertainties in α/β ratios.
Due to the high RBE for NSCLC tumors and relatively RBE in surrounding normal tissue,
carbon ion therapy is thought to be particularly beneficial for treating lung tumors.
This study has several strengths. First, the methods for assessing dosimetric quality
are commonly used at ion therapy clinics, including CNAO and NIRS [35, 87]. Further, we
considered relevant factors when designing the programs and selecting algorithms for NTCP
and TCP analysis, including using a serial NTCP model to consider the partial volumes of the
heart and a parallel model for the lungs, and factoring the fractionation scheme by performing
BED calculations. Additionally, this study uses a portable and modular device (M-DDS),
described in detail by Lis et al. [51]. This will be important to address open research
questions regarding more effective methods for tumor motion compensation. For this
purpose, the M-DDS has several motion mitigation strategies integrated into a modular unit,
including gating, ITV-based rescanning, tracking and MP4D deliveries. The M-DDS is also
available at both CNAO and at GSI for research on motion mitigation. The M-DDS is a
version of the DDS used clinically at CNAO, with modification for motion mitigation, so the
clinical safety features from the original DDS are in place. Safety and performance
assessments have been performed on the motion additions of the M-DDS [51], and the plan
libraries for MP4D deliveries described in this study have been delivered to phantoms at
CNAO. Finally, the results of this work show that the MP4D approach is versatile enough to
deliver both proton and carbon ions conformally and results in outcomes that are above the
clinical standards. This presented strategy can be extended to other ion species, including
helium ions and radioactive ion beams [217] and can be used with both synchrotrons and
cyclotrons.
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One limitation of this study is that it considered only two patients and a limited
number of treatment plans. However, this is not a serious limitation because, with the
methods and infrastructure we have now demonstrated, additional studies were initiated and
are underway to generate additional data that aim to inform the process of translating the MDDS from the laboratory to the clinic. Another limitation of this study is the simple methods
used to project therapeutic outcomes. This is not currently a serious limitation, because the
physical performance issues are the main challenges facing the continued development of the
motion mitigation strategies considered here. Much pre-clinical work remains to be done on
beam delivery, e.g., advances in gating and monitoring patient respiratory motion. Hence, the
purpose of the outcome calculations was only to provide a rudimentary context for the
observed dosimetry findings. After the M-DDS has been commissioned for clinical use, more
detailed outcome projections will become an essential part of the pre-clinical research.
Additionally, the MP4D deliveries were performed under ideal respiration, in the absence of
uncertainties due to irregular motion, such as variations in the breathing cycle patterns and an
imperfect correlation between the motion signal and the actual target motion. A more
exhaustive study on the benefits of conformal motion mitigation with carbon ions and protons
must still be performed. Another limitation was that the radiofrequency knockout extraction
gating method was not fully tuned at GSI, resulting in significant hotspots in the dose
distributions for the MP4D deliveries. Ideally, we would have delivered these plans at a
clinical facility as well, where fast magnets dump the beam entirely during a gate.
Nevertheless, the contributions of the leakage particles were quantified, and the data was
analyzed with consideration of the contributions to the dose distributions. Another limitation
was that the carbon ion plan libraries were delivered with absorbed dose calculations rather
than biological doses. This would have increased the complexity of the carbon ion deliveries,
but also would have further increased the peak to plateau ratio in comparison to proton
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deliveries. As lung is a late responding tissue, the RBE is greater for the tumor, and could
result in more favorable NTCP and TCP results. In future studies, we will investigate motion
mitigation with RBE-weighted, physically inhomogeneous doses, as must be applied in
clinical practice. Finally, though we considered subregions for the heart, we did not consider
subregions of the tumor volume, which can have an increased radio-resistance in certain
regions, resulting in decreased tumor control [218]. This is not a major limitation, as carbon
ion therapy already has been shown to be more effective in treating radioresistant tumors
[184]. Further investigation on the therapeutic gain of carbon ions for NSCLC tumors are
beyond the scope of this manuscript.
This study is part of a larger project to develop a modular, motion-synchronized dose
delivery system for clinical use. In the next stages, several of the limitations of this study,
noted above, will be addressed. For example, MP4D deliveries will be performed with
irregular motion, and the M-DDS will be expanded to correct for changes in the detected
motion trajectory (so-called “corrective tracking”) and to accept diverse forms of motion
trajectory information, including 3D displacement vectors. The M-DDS will later be
transferred to CNAO for pre-clinical testing.
6.5.

Conclusion
The results of this work support that the multi-phase 4D dose delivery (MP4D)

approach can deliver ion beam treatments with favorable treatment quality and projected
therapeutic outcomes compared to other motion mitigation approaches. The M-DDS used in
this work is modular, portable design that has a variety of motion mitigation strategies
incorporated. Compared to static deliveries and ITV-based deliveries with rescanning, the
MP4D approach is more conformal, resulting in reduced projected normal tissue
complications.
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Chapter 7. Discussion and Conclusions
This work has developed and tested a portable, modular dose delivery system for
investigating ion therapy treatment strategies, including the multi-phase 4D dose delivery
approach to motion mitigation. The motion-synchronized dose delivery system (M-DDS) was
developed as part of a framework for research in novel ion therapy solutions and for
comparing delivery strategies. This necessitated integrating the clinically certified DDS from
CNAO into a research facility, developing motion mitigation solutions, integrating a
comprehensive risk analysis strategy to verify the safety of new technologies, and developing
experiment protocols to validate performance. The major finding of this study was that the
MP4D approach can deliver conformal, motion-synchronized beams to clinically acceptable
performance, dosimetric quality and safety standards.
7.1.

Implications
The results of this study suggest that treatment outcomes for moving tumors can be

improved by delivering conformal, motion synchronized ion beams. With the delivery
strategy developed here, it is possible to consider full anatomical motion information from
4DCT images during the planning process, allowing for uniform and conformal, freebreathing treatments. This method may provide a radiotherapy method for treating tumors
such as radioresistant, late-stage NSCLC tumors and pancreatic tumors, which are often
located near critical organs and can benefit from more conformal treatments. Moreover, the
motion mitigation strategy has been implemented with a modular, portable design, which can
be utilized at multiple centers. This compatibility allows for more coherence when
performing multi-institutional studies and for performing pre-clinical testing before adopting
new treatment methods, beyond motion mitigation strategies, into clinical practice. In order
for particle therapy to expand to other treatment methods, including using radioactive ion
beams, mixed beams and Flash therapy, accelerators that are capable of providing the
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necessary beam conditions will be needed. The M-DDS has been implemented in one such
accelerator and was developed from a clinically certified DDS, allowing for testing new
delivery strategies in clinic-like conditions before translation into the clinical use (Chapter 2
and 3). Furthermore, the motion mitigation strategy was implemented into a clinically
certified delivery system, and a prospective risk analysis has been performed to confirm and
maintain the safety of the DDS and its suitability for clinical use (Chapter 4). The developed
M-DDS is not a singular solution for motion mitigation, but can be expanded to include other
motion mitigation solutions, including tumor tracking. In further studies, the M-DDS with be
expanded to include solutions for treating irregular motion.
7.2.

Coherence with Existing Literature
Though many proton and ion therapy clinics regularly use motion handling strategies

such as respiratory gating and breath holds, few integrated motion compensation strategies
have been implemented into clinical delivery systems. Therefore, it is difficult to draw direct
quantitative comparisons with other existing methods. The phase-controlled rescanning
method, used clinically at NIRS [219], synchronizes scanned ion beam delivery with tumor
motion by enabling beam delivery when the tumor is detected to be within a gating window.
Our strategy provides comparable results, as the motion compensated ellipsoid deliveries
produced 3 % homogeneities with the phase-controlled rescanning method at NIRS [38] and
5 % homogeneities with the motion-synchronized delivery approach at GSI and CNAO
(Chapter 5). Though the phase-controlled rescanning method has shown excellent dose
distributions, there is no manner to correct for changes to the respiratory motion amplitude
during delivery, and the low duty cycle of respiratory gating relies on faster delivery
methods. In contrast, our method considers the respiratory patterns measured during
acquisition of 4DCT images and delivers ion beams throughout the respiratory cycle, which
allows for inherent compensation of heterogeneous tissue motion and up to 100 % duty
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cycles. The M-DDS can also be expanded to allow for applying corrective tumor tracking
vectors to the delivery position, allowing for modifying the beam delivery to changes in the
measured breathing pattern, such as baseline drifts. Previously, the tracking method has been
studied at GSI [157]. This study determined that accuracies of up to 0.16 mm were
achievable in the lateral direction, while only a 1 mm accuracy was theoretically achievable
with longitudinal tracking. Though this strategy showed promising results, the delivery
system contained unreconcilable problems with memory capacity and delivery timing,
rendering the design unsuitable for the clinic. Additionally, delivery problems related to
differing motion between the target and entrance channel (the inverse interplay effect) and
when tumor motion was not only translational limited the performance of the tracking
method [26]. Treatment planning studies on 4D-optimized delivery [29] predicted high
treatment quality results, including a delivery uniformity of 2.2 %.
7.3.

Strengths of this Study
This study has several notable strengths. First, we designed the motion mitigation

additions of the M-DDS to be modular and portable. The M-DDS was integrated into the GSI
research facility with minimal changes to the internal software by designing an adaption layer
of interfaces between the M-DDS and the beam nozzle component interfaces. This allows for
straightforward implementation into other institutes, which can aid in performing larger,
international research studies, including multi-institutional clinical trials for light ion therapy.
Additionally, the modular design of the M-DDS is flexible and expandable, as it allows for
interchanging components for different functionalities and implementing a variety of motionmitigation techniques for comparison. We demonstrated this versatility by delivering motion
compensated and static deliveries, with and without the motion mitigation module,
respectively, at two facilities. Second, we applied well-established methods for our analyses.
More specifically, we performed a comprehensive, prospective risk analysis, based on the
145

established recommendations of the AAPM [103], and used detectors and set-ups (i.e., 2D IC
detector arrays, radiochromic films, and small-volume ICs) that are recommended by the
AAPM task group 224 report [101], as well as analysis methods commonly used in the clinic
(i.e., the homogeneity index, the gamma index analysis and the conformity index). Finally,
we performed our studies at both CNAO and at GSI at various stages. This allowed us to
verify the performance of the motion-synchronized dose delivery strategy under a variety of
delivery conditions, including higher particle intensities, two beam gating modes, two energy
modulation modes, a variety of beam nozzle elements, and in the presence of clinical
interlocks.
7.4.

Limitations of this Study
This study is not free of limitations. First, we did not perform an in-depth

characterization of the performance of each beam nozzle component implemented into the
research facility. Several components were maintained from the pilot study performed at GSI
and a subset of validation tests were performed to verify the functionality of these
components. Additionally, some peripheral components were still in development during the
course of this study. These components, such as the position monitor readout interfaces, will
be validated in a future study. A second limitation is that we did not validate the M-DDS with
irregular motion, including baseline drifts, changes to the breathing cycle amplitude and
duration, or sudden changes, such as coughs. However, the treatment quality of the M-DDS
has been validated using recorded patient breathing information, as described in Chapter 6,
and the modular design of the M-DDS will allow for expansion and implementation of
additional motion mitigation features and motion mitigation approaches. Further solutions for
mitigating irregular motion patterns, such as corrective tracking, are beyond the scope of this
study and must still be implemented and tested. Nevertheless, the current M-DDS is a
transferable product, which can be translated into the clinic. Additionally, the delivery quality
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and therapeutic outcomes of motion-synchronized deliveries have only been quantified for
two patient plans. This is not a major limitation, as the selected patients were cases that are
challenging to treat, and our finding support that MP4D delivery of 4D-optimized plan
libraries provides favorable treatment outcomes. Additionally, planning studies with 4Doptmization have been performed previously with more patient plans [29, 51]. Nevertheless,
further studies must be performed to conclusively confirm the clinical efficacy of this
approach. Moreover, we have only compared the motion compensation strategy to one
clinically approved motion handling strategy (ITV-based rescanning) at two facilities (GSI
and CNAO) and an in-depth comparison with other clinical methods, including phasecontrolled rescanning and gating, and a combination of methods should still be performed.
Finally, the dose calculations in this study were only performed with the treatment planning
system found at GSI, TRiP4D. This planning system has been used in patient treatment from
1997-2008 and has been experimentally verified under diverse conditions [26]. Nevertheless,
no independent calculations, such as Monte Carlo calculations, were performed. This is not a
major limitation, as film and 2D IC detector measurements from experiments at GSI and
CNAO compared to dose distributions simulations created from TRiP4D were in good
agreement.
7.5.

Conclusion
This work has demonstrated that a motion-synchronized approach can provide a clinical

viable and generalizable approach to motion mitigation with scanned ion beams. The M-DDS
is an example solution of a framework for integrating the development and clinical testing of
therapy methods. We have designed and implemented a modular and portable dose delivery
system with integrated motion mitigation capabilities. Our safety risk analysis has revealed
several safety risks that are unique to the M-DDS and appropriate solutions were proposed
and tested. Accordingly, the M-DDS was shown to be a safe, clinically viable solution for
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motion compensation. Additionally, we have determined that the multi-phase 4D dose
delivery strategy compensated for heterogeneous anatomical motion with minimal
degradations to the dose distributions. In conclusion, this work provides a comprehensive
pre-clinical study on the modular, motion-synchronized dose delivery system for delivering
conformal dose distributions to moving targets.
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